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The human genome consists of approximately 20-25.000 genes1, which is much less than 
first anticipated (80-140.000; [1, 2]). Even smaller than this is the number of genes 
expressed in a given cell at a given time. The differential expression of genes constitutes the 
foundation of the cellular diversity seen in higher multicellular organism. The mRNA from 
genes expressed in a cell, a tissue, an organ or an organism makes up what is referred to as 
the transcriptome [3]. As the cell goes through the cell cycle, the set of genes transcribed is 
changing continuously, both in time and amplitude. Different gene programs are turned on 
and off depending on whether the cell is proliferating or differentiating, responding to 
hormones or cytokines, whether it is secreting, engulfing or migrating, or whether it is 
entering apoptosis. 
 This fine tuned orchestration of gene expression is governed by proteins capable of 
integrating cellular signals and transmitting them to the general transcription machinery. 
These proteins are called transcription factors, and this thesis focuses on one such 
transcription factor, namely the proto-oncoprotein c-Myb.  
 
1.1 TRANSCRIPTION FACTORS 
A huge variety of proteins in the cell participates in regulating transcription. These proteins 
range from being factors residing in the cytoplasm, as the last link in a signal transduction 
pathway, to the RNA polymerase catalyzing the actual polymerization of the 
ribonucleotides. In between these two examples we find proteins capable of translocating to 
the nucleus carrying extranuclear signals and enzymes transmitting chemical signals 
through post-translation modifications. Within the nucleus there are factors involved in 
sensing and transmitting information about damaged DNA. We have the co-factors, both 
repressors and activators, which are able to modulate the activity of other transcription 
factors through protein-protein interactions or chemical modification. We find chromatin 
remodelling factors and histone modification enzymes, the general transcription machinery 
with the general transcription factors, and the mediator complex. Finally, we come to the 
sequence-specific transcription factors capable of recognizing specific DNA sequences in 
gene promoters, enhancers and silencers. Today more than 2000 human proteins have been 
classified as transcription factors. The c-Myb protein is an example of a sequence-specific 
transcription factor. However, through the introduction and the papers in this thesis, it will 





become evident that c-Myb interacts with, and is regulated by, proteins representing several 
of the above mentioned classes. 
Because of the diversity of transcription factors, attempts have been made to try to 
classify them; by structure [4], by function [4, 5] and by regulation [6]. The Myb family is a 
good example of transcription factors that have been classified based on structure. The 
evolutionary conserved DNA-binding domain (DBD; thoroughly described in chapter 
1.2.2.1) has been used to group the members of the Myb-family. Proteins having such a 
DBD are found in all eukaryotes, where they are most numerous in plants with over 100 
family members in Arabidopsis thaliana [7] (reviewed in [8-10]). Although similar in DNA-
binding properties, the different Myb proteins are not regulated in the same way, do not 
regulate the same target genes, and do not play the same biological role.  
As mentioned, gene expression is tightly regulated to meet the cells physiological 
needs. This is mainly achieved by regulating the activity and availability of different 
transcription factors. The regulatory pattern of the sequence-specific transcription factors 
has therefore been used in an attempt to categorize the them ([6]; Fig 1). This has divided 
the transcription factors into two major classes: the regulatory (conditionally) and the 
constitutively active factors. The regulatory factors are subdivided into developmentally 





   
 Figure 1 Functional classification of positive-acting transcription 
factors. Major functional groups are shown in black; specific examples 
are illustrated in grey. The list of examples is not complete, and can 
probably be applied on negative-acting transcription factors. An asterisk 
indicates that the indicated factors can be trapped in cytoplasm by 





activated upon ligand binding or post-translational modification. The last group can be 
further divided as shown in Fig 1. By categorizing the transcription factors in this way, one 
might get a better understanding of how the different factors are involved in signal 
transduction and how these pathways have evolved. However, this system also has its 
limitations, since all cell specific transcription factors by default are excluded from the 
signal dependent group. The signal-dependent transcription factors seem to be of particular 
interest in relation to carcinogenesis and thereby constitute potential therapeutic targets in 
cancer treatment. c-Myb which traditionally would have been placed in the group of 
developmental, cell specific factors, might actually belong to the class of signal-dependent 
factors, given the total body of knowledge on the significance of post-translational 
modification in regulating c-Myb activity. This will be further discussed in chapter 1.2.3. 
When an mRNA-coding gene is to be expressed, the crucial regulatory event is the 
initiation of transcription. This requires assembly of the pre-initiation complex (PIC) onto 
the core promoter (Fig 2; reviewed in [11]). The PIC is composed of properly structured 
DNA, RNA polymerase II and the general transcription factors (TFIIB, TFIID, TFIIA, 
TFIIE, TFIIF and TFIIH). When all these factors have been gathered at the promoter, TFIIH 
which contains ATP-dependent helicase activity unwind the promoter DNA around the 
transcription start site and trigger the initiation of transcription. These actions and factors 
are common to the transcriptional initiation of expression of most regulated genes in the cell.  
The specificity and level of gene expression are defined by combinatorial events 
upstream of the PIC assembly: When expressed and available, sequence-specific 
transcription factors (activators; Fig 2) can bind to their DNA recognition elements and 
recruit different co-factors. Co-factors often exert their function in larger complexes (co-
activator or co-repressor complexes) which usually contain factors with histone 
modification and nucleosome remodelling activity. These activities modulate chromatin 
dynamics which today is recognized as a fundamental way to regulate gene expression [12-
14]. By recruiting co-factor complexes DNA-binding transcription factors can poise a gene 
for transcription, or alternatively silence it. As shown in Fig 2, transcription factors bind to 
specific elements on the DNA that can be located in the proximity of the transcriptions start 
site (proximal promoter region) or to so-called distal enhancer elements. In both instances 
the transcription factors can be directly or indirectly involved in recruiting factors in the 
general transcriptional machinery, e.g. the TAFs (Fig 2). As stated above it is the balance 
between both activating and repressive events on the promoter that tunes the transcription of 




regulatory DNA-elements might be critical for the regulation of gene transcription, and 
eventually disastrous for the cell.  
The importance of transcriptional regulation can be emphasized by an interesting 
observation: At the coding nucleotide level there is approximately 99% homology between 
man and chimpanzee. Both genomes encode proteomes that differ only at single amino-acid 
positions in homologues proteins. Still the difference between these two organisms is 
conspicuous. Thus, there are strong reasons to believe that the difference resides at the level 
of gene regulation [15], even though processes like alternative splicing and posttranslational 
modifications clearly contribute. An accurately regulated genome may therefore constitute 
the major difference between monkey and man, between nature and culture, but also 
between health and disease, benignancy or malignancy. In the following chapters I will 
focus on the transcriptional regulator c-Myb. Examples will be given of how the 




Figure 2 Initiation of transcription. The RNA polymerase II is directed by transcription factors, some of 
which exert their function in multisubunit complexes (co-factors). Some of these complexes can serve as 
bridges between sequence-specific transcription factors (activators) and the RNA polymerase machinery. 
One class of co-factors, called TAFs, join with TBP (TATA-binding protein) to form the TFIID complex, 
and attach to the TATA box at the gene’s promoter. The combinatorial effect of the cells elaborate 
transcription apparatus regulates the rate of transcription. RE: Recognition Element. Illustration taken from 
the Robert Tjian lab’s homepage (www.hhmi.org/research/investigators/tjian.html). 
 
 
1.2 THE TRANSCRIPTION FACTOR c-MYB 
The first member of the myb gene family identified was the v-myb oncogene from the avian 
myeloblastosis virus, AMV (reviewed in [16]). This acutely transforming retrovirus causes 




the 80’s, and some years later the sequence of the cellular origin; c-myb [19], both gene 
products have been extensively studied. Still, many aspects of Myb-biology remain to be 
elucidated. This chapter will give a general overview of the c-Myb transcription factor, its 
structural relatives, functional domains, modifications, interaction partners and biological 
functions. 
 
1.2.1 The Myb family of transcriptions factors 
The structural characteristic of the members of the Myb family of transcription factors is the 
presence of one or more Myb domains, which make up the DNA-binding unit of these 
proteins. The Myb domain encompasses approximately 50 amino acids which contain a 
series of highly conserved residues with a characteristic spacing. This includes three 
regularly spaced Trp residues, some of which may be replaced by Phe, Ile or Tyr. Multiple 
copies of the Myb domain are frequently present as tandem repeats within a single protein 
(reviewed in [10]). The proto-oncoprotein c-Myb contains three such repeats, and in general, 
all Myb proteins found in animals contain three tandem repeats. In plants most Myb proteins 
contain two repeats, although proteins with only a single Myb domain have been found [20]. 
Three functionally distinct Myb proteins are known in vertebrates; A-Myb, B-Myb 
and c-Myb (Fig 3; [21]). c-Myb is the best characterized member in the family, and it is 
known to function as a transcriptional activator involved in regulating proliferation, 
differentiation and apoptosis in hematopoietic cells. In addition, c-Myb is also involved in 
the formation of colonic crypts through similar mechanisms. Like c-Myb, A-Myb functions 
as a transcriptional activator [22], being expressed at high levels in immature male germ 
cells, mammary gland ductal epithelium, a subset of B cells and in dividing neural precursor 
cells. In contrast to the restricted pattern of expression of A- and c-Myb, B-Myb is 
ubiquitously expressed and can be found in a variety of dividing cells. Here B-Myb 
functions as a transcriptional activator playing a general role in cellular proliferation 
(reviewed in [23]). All three vertebrate Myb proteins contain three functional domains (Fig 
3): a DNA-binding domain (DBD with three Myb repeats (R1, R2 and R3), a central acidic 
domain, which functions as a transactivation domain (TAD) in A- and c-Myb, and a 
negative regulatory domain (NRD). The DBD is the most conserved region among the Myb 
proteins. A- and c-Myb DBD share 90% identity within this region, while the homology 







Figure 3 Comparison of the vertebrate Myb family proteins, including AMV and E26 v-Myb. 
Relative to c-Myb AMV v-Myb lacks 71 and 198 amino acid residues N- and C-terminally, respectively. 
In addition it carries 10 point mutations. v-mybAMV also encodes 6 amino acids of the viral core protein 
Gag N-terminally, and 11 amino acids of the viral envelope protein Env C-terminally. E26 v-Myb is a 
Gag-Myb-Ets fusion protein, which lacks 80 and 277 amino acid residues relative to c-Myb N- and C-
terminally, respectively. In addition it carries one amino acid substitution. The oncogenic mutations are 
shown as black dots. The DNA-binding domain (DBD) is highly conserved between A-, B and c-Myb. 
Both A- and c-Myb contains a central transactivation domain (TAD), whereas the central acidic domain in 
B-Myb does not confer transcriptional activity to the protein. The C-terminal of the three Myb proteins is 
less conserved, except for the Thr- and Pro-rich region (TP/CR). NRD: negative regulatory domain, LZ: 
leucine zipper, FAETL and EVES: motifs found within the assigned regions. R1/2/3: Myb repeat 1, 2 and 3. 
 
 
In addition to the three Myb-proteins expressed normally in vertebrates, two virus-
transferred versions of c-Myb have been described, both in the chicken system; AVM and 
E26 v-Myb. AMV v-Myb, which was the first to be described [17, 18], contains a truncated 
and mutated form of chicken c-Myb. This was shown to be created by retroviral insertional 
mutagenesis, followed by recombination with the c-myb gene, and rescue by a replication 
competent helper virus [16]. AMV is an acutely transforming retrovirus which causes rapid 
and fatal monoblastic leukemia in chickens. E26, another retrovirus which causes an acute 
erythroblastic leukemia in chicken and transform multi-potent hematopoietic precursor cells 
in culture [26, 27] was found to contain another truncated version of c-Myb, termed E26 v-
Myb. Both viral Myb proteins have N- and C-terminal deletions relative to the cellular 
homologue c-Myb (Fig 3). In addition AMV v-Myb harbours 10 amino acid substituting 
mutations along with N- and C-terminally fused remnants of the viral Gag and Env proteins. 
E26 v-Myb on the other hand is part of a larger fusion protein with 272 amino acids of the 
viral gag protein fused N-terminally and 491 amino acids of the cellular protein Ets-1 fused 






1.2.2 The structural and functional domains of c-Myb 
Like most other transcription factors, the overall structure of c-Myb is modular, with 
functional domains that can act as separate units. The c-Myb protein harbours three such 
functional domains: the N-terminal DNA-binding domain (DBD), a central transcriptional 
activation domain (TAD) and a C-terminal negative regulatory domain (NRD). In this 
chapter the main features of these domains will be highlighted. 
  
1.2.2.1 The DNA-binding domain – DBD 
The c-Myb DBD consists of three conserved and closely related Myb domains, designated 
R1, R2 and R3 (Fig 4). Each repeat contains three regularly spaced tryptophan residues that 
are important for maintaining an active DNA-binding structure [28, 29]. In addition these 
domains have conserved acidic and hydrophobic regions and single position residues (Gly, 
Arg and Leu; Fig 4). 
 
 
Figure 4 Multiple sequence alignment of the three Myb domains in c-Myb DBD. R1, R2 and R3 repeat 
of human c-Myb aligned by the conserved Trp residues (black shading). Conserved acidic and hydrophobic 
residues/stretches are boxed. Conserved single residues are marked with an asterisk. The secondary 
structure elements (-helical regions) are indicated by brackets. 
 
In 1991 Gabrielsen and co-workers presented data suggesting that the R2R3 part of 
DBD built up a double helix-turn-helix (HTH) related motif [30]. This provided the first 
experimental evidence for a hypothesis put forth some years earlier [31]. Secondary 
structure predictions and mutational analyses demonstrated that the HTH motifs in both R2 
and R3 contributed to sequence-specific DNA-binding [30]. Shortly thereafter Frampton et 
al. reported a similar study [32]. The common concept was that each c-Myb repeat consisted 
of three -helices, maintained by a hydrophobic core built around the conserved 
tryptophans. Finally, NMR studies of R1R2R3, R2R3 and single repeats confirmed the 
proposed structure ([33-36]; Fig 5), even though some disagreement arose concerning the 
organization of the second repeat in solution [36, 37]. It is now thought that a distorted 
region in the R2 C-terminal, corresponding to its DNA recognition helix, becomes structured 






Figure 5 Three-dimensional structure of c-Myb R1R2R3 in complex with DNA. Myb repeats R1, R2 
and R3 are shown in red, green and blue, respectively. The recognition helices of R2 and R3 are oriented 
along the major groove, while R1 has a more peripheral localization in the complex. The picture was 
generated from the crystal structure data of Tahirov et al. [39] using RasWin v2.7.2.1.1. 
 
The c-Myb protein binds to DNA as a monomer [40, 41], and deletion studies have 
shown that the R2 and R3 repeats are required and sufficient for DNA-binding [40, 42]. The 
dispensability of R1 is demonstrated by AMV and E26 v-Myb. Both proteins have lost this 
repeat, but are still capable of binding DNA and activate transcription (Fig 3). Further NMR 
studies and crystal structure of the c-Myb:DNA complex revealed that it is the third helix in  
R2 and R3 that recognize DNA [33-36, 39]. These two recognition helices contact the major 
grove of DNA in a head-to-tail fashion (Fig 5; [35]). Furthermore, specific amino acids in 
the linker between the two repeats seem to play an important role for sequence-specific 
DNA-binding [43]. The recognition sequence of c-Myb (Myb recognition element; MRE) 
was initially determined to be YAACKG by Biedenkapp and co-workers [44] and later 
extended to YAACBGYCR and YAACKGHH by two binding site selection studies [45, 46]. 
Based on the fact that two of the Myb repeats bind DNA, the MRE can be divided into half-
sites. The folded R3 domain is involved in the recognition of the first half-site; YAAC, 




added further constraints to the binding site requirements, especially the preference for a T-
rich stretch in the second half-site [47, 48]. 
In 1996 Aasland and co-workers [49] suggested that the Myb repeats might be 
related to, and give insight to the function of, a novel protein motif termed the SANT-
domain. This ~50 amino acid long protein motif was found in several chromatin regulatory 
proteins including Swi3, Ada2, N-CoR and TFIIIB (hence the name). The Myb repeats, 
including the aromatic Trp signature residues, aligned surprisingly well with other SANT-
domains [49]. However, while the Myb-repeats bind DNA, the SANT-domains have been 
shown to bind to histone tails [50, 51]. Despite the lack of enzymatic activity, the SANT-
domains are functionally involved in histone acetylation, deacetylation, and ATP-dependent 
remodelling [50, 52]. This might be facilitated through the bipartite function of SANT, 
serving as a protein interaction domain recruiting histone modifying enzymes, while 




Figure 6 The SANT domain: a highly conserved motif that is similar to Myb DBD. Multiple sequence 
alignment of SANT- (Swi3, Ada2, N-CoR and TFIIIB) containing sequences. Columns of residues that 
show sequence similarity are coloured according to their respective properties. The secondary structures 
shown above the alignment correspond to the Iswi crystal structures. Asterisks highlight the bulky residues 
that are predicted to form the hydrophobic core of the SANT domain. Dm: Drosophila melanogaster, Hs: 
Homo sapiens, Mm: Mus musculus, Sc: Saccharomyces cerevisiae, Ada2: adaptor 2, Rsc: remodel the 
structure of chromatin, SMARCC1: SWI/SNF-related, matrix-associated, actin-dependent regulator of 
chromatin, SMRT: silencing mediator of retinoid and thyroid receptors. Adapted from [53]. 
 
For several years the function of the c-Myb SANT-domain remained elusive, and a 
direct connection between Myb domains and chromatin modification was yet to be shown. 
Then in 2005, Mo and co-workers demonstrated that c-Myb DBD also binds to the N-
terminal tail of histone H3 between amino acid residues 27-42 and facilitates acetylation of 
H3 lysines [54]. Furthermore, they could show that the leukemogenic mutations in AMV v-
Myb eliminated this interaction and consequently acetylation of H3 tails. This revealed the 
mechanism behind the lack of v-Myb induced mim-1 (Myb-induced myeloid protein 1) gene 




1.2.2.2 The transactivation domain – TAD 
The transactivation domain of c-Myb is localised near the centre of the protein (Fig 3). 
Despite the early recognition, it has been difficult to define its exact localisation. The c-Myb 
TAD was first identified in chicken c- and v-Myb [42, 55]. Both proteins can activate 
transcription on synthetic reporter constructs that contain multiple MREs [42, 55-57]. The 
initial mapping was done with various deletion constructs of c-Myb or v-Myb proteins fused 
to a heterologous DNA-binding domain (GAL4p). These mappings defined the TAD to be 
positioned between amino acid 275 and 325 in mouse and chicken c-Myb ([42, 55, 58]; 
same positions for human c-Myb; Fig 7). This region is the minimal fragment sufficient to 
activate gene expression when fused to Gal4 DBD. Nevertheless, transactivation by c-Myb 
requires both a functional DBD and TAD. The c-Myb TAD resembles other described 
transactivation domain in that is hydrophilic and slightly acidic (Fig 7). However, none of 
the acidic residues seem to be essential for transcriptional activation [59], rather several 
redundant regions seem to cooperate to achieve full transactivating ability in the full-length 




Figure 7 The minimal transactivation domain of c-Myb. Multiple sequence alignment of TADs from 
vertebrate c-Myb and AMV v-Myb, corresponding to amino acid residues 275-325 in human c-Myb. 
Hydrophobic residues are shaded in black, while acidic residues are shaded in grey. The area interacting 
with CPB/p300 is indicated with brackets above the MSA, while the Nuclear Receptor (NR) box is specified 
below. Hs: Homo sapiens, Bt: Bos Taurus, Mm: Mus musculus, Rn: Rattus norvegicus, Gg: Gallus gallus, 
Xl: Xenopus laevis Ol: Oryzias latipes. 
 
The TAD in c-Myb is able to directly recruit CBP (CREB-binding protein) and p300 
(see chapter 1.2.3.1). These closely related histone acetyl transferases (HATs) bind via their 
KIX domain to amino acids 295-309 in TAD (Figs 7 and 8). A general effect of HATs is the 
acetylation of histone lysines and consecutive de-condensation of nucleosome structure, 




there is a small LXXLL-motif called the nuclear receptor (NR) box ([61, 62]; Fig 7), which 
appears commonly in complexes formed between NRs and their co-activators. Interestingly, 
structures of the complexes between NRs and co-activators from the p160 family [63-65] 
resemble the c-Myb:KIX complex, where an amphipathic helix containing the LXXLL 
sequence is bound in a hydrophobic groove (Fig 8; [66]). Some studies indicate that the 
amphipathic helix in the CBP/p300-interacting region of c-Myb TAD stabilise upon binding 
[67, 68]. Moreover, structural and isothermal titration calorimetry data show that in contrast 
to other CBP/p300-interacting proteins, c-Myb does not need to be phosphorylated in the 

















Figure 8 The complex between CBP 
KIX and c-Myb. The CBP KIX is 
shown as a grey surface, while the 
backbone of the amphipathic helix in 
c-Myb TAD is shown as a red ribbon. 
The side-chains of c-Myb that interact 
with CBP KIX are shown in yellow. 
Taken from [66]. 
 
1.2.2.3 The negative regulatory domain – NRD 
The C-terminus of c-Myb has been termed the negative regulatory domain (NRD). 
However, the exact boundaries of the domain have been difficult to define due to conflicting 
evidence. One of the reasons for this is that the function of some of the NRD subdomains is 
still unclear. The initial idea of a carboxy-terminal NRD came from observations of the v-
Myb protein which lacks the C-terminus, while at the same time is a more potent activator 
than c-Myb. Deletion of the c-Myb C-terminus, like in the viral forms, dramatically 
increases the transactivation potential of the protein [42, 69]. The NRD encompasses three 
subdomains; FAETL, TP/CR and EVES (Fig 3). It is generally accepted that the threonine- 
and proline-rich region (termed TP/CR) and the domain containing the EVES-motif (termed 




FAETL-domain, a leucine-rich region positioned N-terminal of TP/CR, should be included 
has been a matter of debate (reviewed in [8]).  
 The leucine-rich FAETL domain is by many termed the leucine zipper region (LZ), 
due to the presence of a heptad leucine repeat (HLR) within this domain (Fig 9). It has been 
predicted to form a coiled-coil -helix structure when interacting with other HLR-
containing proteins [70]. Interestingly the HLR-containing protein p160 has been 
demonstrated to bind to this region of c-Myb [71, 72]. However, Ebneth and co-workers 
were unable to detect any -helical structure of the putative LZ domain in chicken c-Myb 
[73]. The LZ-region has been shown to promote the formation Myb-Myb dimers in vitro, 
which are unable to bind DNA [74]. However, these findings have been questioned by 
others [75]. Within the leucine-rich region there is a stretch of 10 amino acid residues which 
include the FAETL-motif that has been shown by mutational analyses to be essential for 
both transcriptional activation and oncogenic transformation by v-Myb [56, 60]. It should be 
mentioned, however, that E26 v-Myb, as opposed to AMV v-Myb, has disposed itself of 




Figure 9 The heptad leucine repeat in c-
Myb might make a leucine zipper. The 
heptad leucine region of c-Myb NRD 
represented as a helical wheel (I382-I399; 
human c-Myb numbering). Hydrophobic 
residues in beige, acidic, hydrophilic residues 
in purple and basic in green, polar residues in 
blue. Illustration made with ‘Helical wheel’ 
made by John K. Everett, CABM Structural 
Bioinformatics Laboratory (www-nmr.cabm. 
rutgers.edu). 
 
The TP/CR domain is the most conserved region of c-Myb outside the DBD and 
contains the sequence TPTPFK, found in all vertebrate A-, B-, and c-Myb proteins. This 
motif has been implicated in negative regulation of c-Myb activity [76, 77]. Nevertheless, 
several lysine residues around this sequence (K442, K445, K471, K480 and K485; human 
numbering) have been shown to be acetylated, resulting in an increase in c-Myb 




potential phosphorylation sites for proline directed kinases. Some of these sites are probably 
involved in regulating the stability of c-Myb [80]. 
The most C-terminal of the three NRD sub domains is the EVES domain. The 
EVES motif, which has given the domain its name is only found in vertebrate c-Myb 
proteins, but is well conserved within this phylum. Our group and others have reported that 
Lys503 and Lys527 (human numbering) in the NRD can be covalently modified by the 
Small Ubiquitin-related Modifier, SUMO ([81-83]; see chapter 1.2.3.2).  Both SUMO-1 and 
SUMO-2/3 modification of c-Myb result in lowered transcriptional activity [81-83]. The 
EVES domain also contains a site for proline-directed phosphorylation. Ser532 (human 
numbering) has been reported to be phosphorylated by p42mapk [84-86] which lowers the c-
Myb activity in a degradation-independent manner [87, 88] 
The mechanism behind this negative regulation by the NRD is probably 
multifaceted. However, three lines of evidence should be mentioned; recruitment of co-
repressors (I), posttranslational modifications (II) and intra-molecular interactions (III). I: 
Based on the current list of factors reported to interact with c-Myb (see chapter 1.2.3.1 and 
Table 1) there is an overrepresentation of negatively acting factors among the ones binding 
to NRD, e.g. p67/p160 [71, 72, 89] TIF1 (co-recruiting mSIN3A, N-CoR and c-Ski; [90]), 
and BS69 [91]. II: Several sites of negatively acting post-translational modifications have 
been reported. Sumoylation of Lys503 and Lys527 result in lowered transcriptional activity 
of c-Myb [81-83], while phosphorylation of several SP and TP sites lead to lowered activity 
in a degradation-dependent [80] and -independent manner [87, 88]. III: Some experiments 
have suggested that the C-terminal part of c-Myb can inhibit DNA-binding [92]. This 
reduction in DNA-avidity has been proposed to be caused by intra-molecular interactions in 
c-Myb. Specifically, the N- and C-terminus (DBD and EVES) were shown to score 
positively for protein-protein interaction in yeast two-hybrid and phage display assays [93, 
94]. However, other investigators have failed to observe this inhibition of DNA-binding by 
the NRD [75], and the data supporting the N- to C-terminal intermolecular contact have 
been difficult to reproduce (T.Ø. Andersen, unpublished results).  
 
1.2.3 Regulation of c-Myb activity  
Apart from regulating the level of c-Myb through modulating transcription of the c-myb 
gene, the cell has two main processes to implement changes in c-Myb activity: 1) interaction 
with other proteins and 2) posttranslational modifications. These processes are, as for most 




1.2.3.1 c-Myb interacting proteins 
Through the interaction with other nuclear proteins the sequence-specific transcription 
factors can increase their affinity and specificity for DNA, they can tune their 
transactivational activity, remodel chromatin, modify histones and/or in some instances 
contact the general transcriptional machinery. It has, however, become evident that 
transcription factors typically exert their function in larger protein complexes, which make 
the study of such co-factors challenging. This is also the case for c-Myb. Several proteins 
have been reported to interact with different subdomains of c-Myb and influence its activity 
(Table 1; reviewed in [95]). Still, complete multimeric complexes have so far not been 
described in greater detail, and establishing a catalogue of well documented, direct 
interaction partners of c-Myb is so far a task unfinished. In this chapter two of the best 
described co-operating factors of c-Myb; C/EBP and CBP/p300 will be highlighted. In 
addition recent data on c-Maf and MafB are included, through which a reciprocal MafB-c-
Myb repression is linked to sumoylation.  
The transcription factor C/EBP (CAAT/Enhancer Binding Protein) directly 
interacts with, and cooperates with c-Myb in activating myeloid-specific genes [39, 96, 97]. 
The crystal structure of the ternary complex with c-Myb DBD, C/EBP and DNA from the 
tom-1 promoter (see chapter 1.2.4.2) showed that the R2 repeat of c-Myb DBD, bound to 
DNA, interacted with the C-terminal part of the DNA-bound C/EBP DBD. Moreover, 
since C/EBP and c-Myb bind at a distance to the tom-1 promoter, atomic force microscopy 
demonstrated that this interaction was possible due to looping of DNA [39]. It should 
however be mentioned that looping of DNA is not required on all C/EBP and c-Myb-
responsive promoters. At the mim-1 promoter the factors bind to two adjacent sites and 
efficiently induce gene expression [96, 97]. 
 One of the best described interactions of c-Myb is the association with the acetyl 
transferase and transcriptional co-activator CREB-binding protein (CBP) and its close 
homologue; p300 [98, 99]. CBP/p300 has been shown to bind to a short motif in c-Myb 
TAD via its KIX domain (see chapter 1.2.2.2 and Fig 8). An additional interaction surface is 
found between the leucine-rich FAETL domain of c-Myb and the C/H2 domain of 
CBP/p300 [78]. The c-Myb transactivation potential is stimulated by CBP/p300, indicating 
that c-Myb is a target for the co-activator function of this protein. This finding was 
confirmed by the inhibition of Myb-dependent gene activation when lowering the 




Protein  Myb dom. Evidence References 
C/EBP DBD funct.dep, CoIP+/+, GST, X-ray [39, 100] 
Cyclin D1/D2 DBD end-CoIP+/-, Y2H, funct. dep. [101] 
c-Myb EVES DBD Y2H, yeast CoIP+/- [93] 
p100 DBD Y2H, in vitro CoIP+/-, funct. dep. [93] 
Cyp40 DBD GST, funct. dep. [102] 
Nucleolin DBD GST, end-CoIP+/-, funct. dep. [103] 
c-Maf DBD end-CoIP+/-, GST, Y2H, EMSA, funct.dep. [104, 105] 
MafB DBD GST, funct. dep. [106] 
HSF3 DBD EMSA, GST, Y2H, funct.dep. [107] 
Pim-1 DBD  [108] 
c-Ski DBD Y2H-scr, CoIP+/-, GST, funct. dep. [90] 
N-CoR DBD Y2H-scr, CoIP+/+, GST, funct. dep. [90] 
mSin3A DBD Y2H-scr, CoIP+/-, GST, funct. dep. [90] 
HIPK2 DBD end-CoIP+/-, GST, funct. dep. [109] 
NLK DBD end-CoIP+/-, GST, funct. dep. [109] 
TRAF7 DBD end-CoIP+/-, GST, funct. dep. [110] 
RAR DBD+NRD GST, Y2H [111] 
CBP/p300 TAD+NRD Y2H, funct. dep, GST, NMR, X-ray [66, 67, 78, 98, 99] 
ATBF1 TAD Y2H-scr, GST, CoIP+/-, funct. dep. [112] 
p160/Mybbp1a HLR Pull-down, funct.dep. [71, 72, 89] 
BS69 NRD Y2H-scr, in vitro CoIP, funct. dep. [91] 
TIF1 NRD Y2H-scr, CoIP+/-, GST, funct. dep. [90] 
Rcd-1 NRD Y2H-scr, GST, funct. dep. [113] 
Ubc9 NRD Y2H-scr, funct. dep. [81, 82] 
HES-1 Unknown end-CoIP +/-, funct. dep. [114] 
Pax-5 Unknown CoIP+/+, funct. dep. [115, 116] 
PML Unknown end-CoIP+/-, GST, funct. dep. [117] 
LEF-1 Unknown CoIP+/+, funct. dep. [116] 
    
Table 1 Proteins reported to interact with c-Myb. The candidates are sorted according to the c-Myb 
domain involved. Y2H: two-hybrid system, Y2H-scr: Yeast two-hybrid screening, GST: GST pull-down 
assay, CoIP: co-immunoprecipitation in vitro or in cell extracts from transfected cell lines, end-CoIP: co-
immunoprecipitation of endogenously expressed proteins, +/+: CoIP successful in both directions, +/-: only 
one-way CoIP reported/successful, funct. dep.: functional dependence, EMSA: super shift in EMSA 
(electrophoretic mobility shift assay), X-ray: X-ray diffraction, NMR: nuclear magnetic resonance. 
 
years several sequence-specific transcription factors have been shown to interact with 
CBP/p300. Some of the CBP/p300-interacting transcription factors are activated directly by 
acetylation, some rely on CBP/p300s ability to acetylate histone tails and thereby activating 
transcription, while others exploit both mechanisms. c-Myb seems to fall in the last category. 
Studies show that CBP/p300 can acetylate several Lys residues in the conserved TP domain 
of c-Myb, with different lysines as substrate (p300: K471, K480 and K485; CBP: K442, 
K445, K471, K480 and K485) [78, 79]. Acetylation of c-Myb by CBP was suggested to 
increase CBP’s affinity for c-Myb, thereby increasing the co-activation [78]. The fact that c-




and induce gene expression [54], is an example of how c-Myb utilizes the second CBP/p300 
function, namely the histone acetyl transferase activity. 
 c-Maf is an example of a protein that interacts with c-Myb to reduce its 
transcriptional activity. Expression of c-Maf in human immature myeloblastic cells inhibited 
c-Myb induced CD13/APN-driven reporter gene activity through the binding to c-Myb DBD 
[104]. This effect was dependent of the developmental stage of the cells, since formation of 
inhibitory Myb-Maf complexes changed through differentiation, with the levels being 
highest in immature myeloid cells [104]. Recently, c-Maf was also shown to downregulate 
bcl-2 expression in TCR-engaged CD4+ cells in a c-Myb dependent manner. This was 
suggested to be caused by c-Maf-c-Myb interaction disrupting the binding of c-Myb to the 
promoter [105]. Interestingly, the transcription factor MafB, a closely related Maf-family 
member also binding to c-Myb DBD, was recently shown to reciprocally inhibit 
transactivation together with c-Myb [106]. This reciprocal inhibition by the two factors was 
demonstrated to be highly dependent on sumoylation of both MafB and c-Myb (see chapter 
1.2.3.2 and 1.3).  Since MafB promotes the differentiation of myeloid progenitors towards 
the macrophage lineage, while c-Myb can maintain proliferation and block differentiation, 
these findings suggest that SUMO modification of MafB and/or c-Myb can affect the 
balance between myeloid progenitor expansion and terminal macrophage differentiation 
[106]. 
 As evident from the list in Table 1, more proteins have been reported to interact with 
c-Myb. However, both the molecular and physiological relevance of several of the reported 
interactions remain to be determined. To extend the knowledge of proteins interacting with 
c-Myb, we previously carried out a yeast two-hybrid screening in a mixed cDNA library 
(human bone marrow and human erythroleukemia cell line K562) using full-length c-Myb 
as bait [81]. Two of the interacting proteins picked up in this screening; the chromatin 
remodelling factor Mi-2 and the huge nuclear factor FLASH, reported to be essential for 
cell division, have been studied further in our group. The work on these two factors are 
included in this thesis (see PAPER I and II). Another interacting protein detected in our 
screening; the SUMO E2 conjugating enzyme Ubc9 (see chapter 1.3.2.2), which linked c-
Myb to SUMO, was reported by our group some time ago [81]. Finding that c-Myb activity 
was regulated by sumoylation, led to the initiation of the two last studies reported in this 






1.2.3.2 Post-translational modification of c-Myb 
The other main mechanism for tuning the activity of the c-Myb protein is posttranslational 
modifications, and four types of modification have been described; phosphorylation, 
acetylation, ubiquitination and sumoylation. For covalent modification of a protein to occur 
an enzymatic activity is almost always required. Thus, c-Myb is dependent on interacting 
with nuclear enzymes for these modifications to take place. Furthermore, posttranslational 
modifications of transcription factors often do not change their activity per se, but allow for, 
or exclude, interactions with other co-factors. This is also believed to be the case for c-Myb. 
Altogether, it is evident that posttranslational modifications and the repertoire of interacting 
proteins are interdependent.  
 
Phosphorylation  
The N-terminus of c-Myb has been showed to be phosphorylated by casein kinase II (CKII) 
both in vitro and in vivo on amino acid residues Ser11 and Ser12 [118], however, some 
disagreement exist about whether this phosphorylation reduces the DNA-binding and 
cooperativity with NF-M (C/EBP) or not [118-121]. Studies in our lab have shown that 
Ser116 in R2 in DBD c-Myb is phosphorylated by protein kinase A (PKA), while the 
corresponding residue in AMV v-Myb is not. This is due to mutation of the neighbouring 
residue, V117D (c-Myb numbering), in v-Myb [122]. Phosphorylation of Ser116 
destabilizes the DBD-DNA complex in vitro and prevents c-Myb-dependent activation of 
chromosomal target genes [122]. The C-terminus of c-Myb contains a number of 
phosphorylation sites for proline-directed kinases and MAP kinases [84-86]. Hyper-
phosphorylation of NRD is associated with targeted degradation of c-Myb (see chapter 
1.2.2.3) [88, 123]. This is probably caused by phosphorylation-dependent ubiquitination 
events (see Ubiquitination). 
 
Acetylation 
c-Myb can be acetylated on five lysine residues in the conserved TP domain (K442, K445, 
K471, K480 and K485) by CBP and p300 (see chapter 1.2.3.1;  [78, 79]). Acetylation of c-
Myb by CBP has been proposed to enhance the interaction between CBP and c-Myb and 
thereby increasing the co-activation by CBP [78]. Lysine to arginine mutations in these five 
sites results in a marked reduction in the transactivation potential of c-Myb. Furthermore, 
the study of Sano and Ishii indicated that acetylation of all the five seats synergistically 





The NRD has been shown to be covalently modified by polyubiquitin chains on one or more 
unidentified lysine residues, which leads to recognition and rapid degradation by the 26S 
proteasome [124, 125]. When deleting the C-terminal part of c-Myb, the protein becomes 
more stable. Determinants for degradation, or degrons, have been identified within the 
leucine-rich region and in the very C-terminus (last 87 residues; [126]). Furthermore, 
deleting amino acid residues 358-452 (covering the FAETL domain and part of the 
conserved TP region) makes human c-Myb degradation-resistant, and enhances its 
proliferative potential in hematopoietic cells [127]. These sequences may be involved in 
some aspect of the ubiquitin modification. 
 
Sumoylation 
Another ubiquitin-related protein that participates in the regulation of c-Myb through 
covalent modification is SUMO, or Small Ubiquitin-related MOdifier (see chapter 1.3). Bies 
and co-workers have shown that murine c-Myb is conjugated to SUMO-1 at K499 and 
K523 [82], while Dahle and co-workers demonstrated sumoylation of human c-Myb at 
K503 and K527 (corresponding residues), using different methods [81]. Recently it was 
shown that c-Myb also can be SUMO-2/3-modified at K503 and K527 ([83]; human c-Myb 
numbering). When c-Myb is sumoylated by either SUMO-1 or SUMO-2/3 the 
transactivational activity is reduced. Conversely, mutating the SUMO acceptor lysines 
causes a superactive phenotype [81, 83]. Through the work on SUMO-1 modification both 
groups identified the K527 as the principal sumoylation site, being much more efficiently 
sumoylated than K503, and having a much more pronounced effect on c-Myb activity [81, 
82]. Sumoylation of c-Myb is also proposed to increase the proteolytic stability of the 
protein [82]. This is not due to competition between SUMO and ubiquitin for acceptor 
lysines, but thought to be caused by some kind of shielding of ubiquitination/degradation 
related epitopes. 
Modification by SUMO-2/3 has been demonstrated to be induced by cellular stress, 
but independently of the stress-activated protein kinases of the p38/MAPK and JNK 
families [83]. Heat stress, osmotic stress and metabolic stress, but not genotoxic stress 
increases conjugation of SUMO-2/3. While the SUMO E3 ligase PIASy seem to be most 
important for SUMO-1 conjugation to c-Myb [81], PIAS3 seem to be the major ligase 




Finally, speculative data have been presented in a report indicating that TRAF7 can 
function as a SUMO E3 ligase for c-Myb, sequester sumoylated c-Myb in the cytoplasm, 
and thereby lowering c-Myb transactivational potential [110]. However, unpublished data 
from our group using c-Myb-SUMO-1 fusion constructs to mimic constitutively sumoylated 
Myb, indicate that c-Myb still translocates to the nucleus (AH. Alm-Kristiansen unpublished 
data). This makes the data on cytoplasmic retention, difficult to comprehend.  
 
1.2.4 The biology of c-Myb 
c-Myb has traditionally been described as a hematopoietic transcription factor which is 
expressed in progenitor cells in the erythroid, lymphoid and myeloid lineages [128, 129]. 
The expression of c-myb is then downregulated during terminal differentiation (Fig 10; 
[130, 131]). The hematopoietic system has for many years been the biological system in 
which c-Myb function has been studied, and it is now generally accepted that c-Myb 
contributes to the regulation of proliferation, differentiation and apoptosis in hematopoietic 
cells [132, 133]. There is, however, a growing list of other tissues in which c-myb is 
expressed, e.g. neural retina and lung epithelium [129], aortic smooth muscle cells [134], 
the thyroid gland and hair follicles [135], neural progenitor cell [136] and colonic crypts 
[137]. Still, I have chosen to focus on the hematopoietic system in the following chapters. 
  
1.2.4.1 The hematopoiesis  
The high level of c-Myb in hematopoietic progenitors clearly indicate a function in the 
development of blood cells, and c-Myb was early suggested to play a role in the choice 
between proliferation and differentiation during blood cell formation. Expression of c-myb 
is associated with proliferation and the maintenance of an immature phenotype of 
hematopoietic cells. The first clue to this came from the observation that the oncogenic v-
myb transforms hematopoietic cells with an immature phenotype [138, 139]. Furthermore, 
ectopic expression of c-myb was shown to block induced differentiation of several 
hematopoietic cell lines [140]. In contrast to the immature proliferating progenitor cells, 
mature non-proliferating hematopoietic cells do not express c-myb ([130, 141-143]; Fig 10).  
 At the molecular level c-Myb has been suggested to regulate genes associated with 
cell growth, including c-myc [144-148] , DNA topoisomerase II(TOPII; [149]) fibroblast 
growth factor 2 (FGF-2; [150]) and c-kit [151, 152]. Furthermore, c-Myb has been 
implicated as being anti-apoptotic through the activation of bcl-2 expression [148, 153-155]. 




induced by interleukin-depletion [156]. Still, opposite effects have been seen for other cell 
lines [157-159], it therefore remains unclear whether the primary role of c-Myb is to prevent 
apoptosis or simply keeping cells in a cycling mode (reviewed in [8]).  
In 1991 Mucenski and co-workers reported the homozygous c-myb null mouse, and 
showed that it develops normally up to embryonic day 13, but die on day 15 due to failure in 
the foetal liver hematopoiesis [160]. A more direct evidence for the role of c-Myb in 
hematopoietic cell proliferation comes from a series of experiments done with c-myb 
specific antisense oligonucleotides. The inhibition of c-myb expression by these 
oligonucleotides significantly reduced the proliferation of bone marrow and peripheral 
blood mononuclear cells, human myeloid cell lines and T lymphocytes (reviewed in [8, 132, 
161]. Some of these experiments have subsequently been confirmed using ribozymes 
specifically directed towards c-myb mRNA [162] and chemically modified oligonucleotides 
[163]. By employing a c-myb “knock-down allele”, expressing 5-10% on normal c-myb 
levels, Emambokus and co-workers were able to investigate the consequences of low c-Myb 





   
 
Figure 10 The hematopoiesis: c-myb expression is downregulated during terminal 
differentiation. A schematic presentation of the hematopoiesis, showing the hematopoietic stem 
cells and the eight major hematopoietic lineages generated by self-renewing multipotent 
progenitors. The Myb expression triangle is only indicative. Modified from picture in the online 





wild-type mice, but the progression towards terminal differentiation was substantially 
altered: Erythroid and lymphoid differentiation was inhibited, leading to a shift towards 
more immature cells. In contrast, macrophage and megakaryocyte differentiation seemed to 
be favoured by low c-myb levels [164]. Thus, progression through key stages of the 
hematopoiesis seems to be dependent on distinct threshold levels of c-Myb. 
Two recent screening studies in mice, where genome-wide ENU mutagenesis was 
employed to identify genes controlling specific hematopoietic processes, both hit the c-myb 
gene as the main affected locus. One study identified a point mutation in c-myb that causes 
thrombocytosis, megakaryocytosis, anaemia, lymphopenia, and lack of eosinophils [165], 
while the other study identified two point mutations that were able to rescue mice from a 
myeloproliferative syndrome with supraphysiological expansion of megakaryocytes and 
platelet production [166]. All three point mutations resulted in c-Myb proteins with lower 
transactivation potential, resembling the lower c-Myb levels in the knock-down study [164]. 
Hence a precise and stage-specific tuning of c-Myb activity and/or levels seems to be a 
prerequisite for the maintenance of the correct balance between proliferation and 
differentiation. 
 When myeloid cells are induced to differentiate either chemically or by cytokines, 
the c-myb expression is downregulated. This suggests that a reduction in the c-Myb level is 
mandatory for differentiation. In this aspect it is interesting to notice that several of the 
genes induced by c-Myb are markers of terminal differentiation (reviewed in [76]). One 
well studied example of this apparent paradox is the Myb-regulated mim-1 gene, a 
differentiation marker for chicken granulocytes, which is induced by c-Myb and NF-M 
(chicken C/EBP) in erythroids and fibroblasts [96, 97, 167].  
 In the adult thymus of homozygous null c-myb/Rag-1 chimeric mice, T cell 
development is blocked before oligopotent thymocytes mature into definitive T cell 
precursors [168]. Additional studies have suggested that c-Myb function is required for T 
lymphocyte development. In particular a transgene encoding a fusion protein of c-Myb 
DBD and the Drosophila Engrailed repressor could prevent normal thymocyte development, 
and resulted in animals with significant reduced number of T cells [169]. In addition, the T 
cells still present failed to proliferate in response to mitogen stimuli [169]. Furthermore, 
expression of the Myb-Engrailed dominant negative protein in thymocytes led to a marked 
decrease in cycling cells following -selection [170].  
 Using tissue-specific deletion to abrogate c-Myb expression at distinct stages of T 




activity is required for normal T cell development in the thymus: transition through the third 
stage of CD4-CD8- differentiation, survival of CD4+CD8+ thymocytes, and differentiation of 
CD4 thymocytes [171]. These observations are supported by the fact that c-Myb is involved 
in regulation of genes important for T cell development; e.g. CD4 [114, 172, 173], TCR  
[174, 175] and RAG-2 [176].  A similar approach has been used to abrogate c-Myb 
expression in B cells. This causes a partial block of B cell development at the pro- to pre-B 
cell transition which results in greatly reduced production of B cells in the bone marrow 
[177].  
  
1.2.4.2 Target genes 
As stated in chapter 1.2.2.1 c-Myb binds to DNA at specific Myb-recognition elements 
(MRE). Due to the rather short Myb recognition core element, YAAC[NG/GN], potential 
Myb-binding sites are found in almost any random piece of DNA  1000 bp. However, 
several of these sites are non-functional, where one reason might be lack of availability. 
Hence, the presence of such a site within a promoter does not necessarily mean that the gene 
in question is regulated by c-Myb. Through the years quite an extensive list of c-Myb target 
genes has been reported, some of which have gained better support than others. Still, the 
genes listed in Table 1 are not the complete collection. With the new and exciting global 
array techniques the assembly of a complete list of c-Myb target genes should be within 
reach, however, experimental design, technical noise, statistics, biological confounders and 
cell specific gene-expression still make this a challenge. Four global studies have been 
reported [178-181], but it is still early days if a complete and sound catalogue of genes is the 
measure.  
 Another aspect that has become evident as new techniques have been described in 
parallel with a growing list of published target genes, is the necessity of defining some 
requirements that must be met for a gene to be claimed as a direct target of c-Myb. A 
classical approach to asses the validity of a proposed Myb-target gene has been (I) to 
identify MRE sequences in the promoter, (II) analyze DNA-binding of c-Myb to these 
MREs in vitro, (III) test the promoter segment with and without the MRE(s) in a reporter 
assay, and (IV) to study whether c-Myb is able to activate the potential target gene when 
embedded in chromatin. A criterion, less often fulfilled, is (V) to confirm that the target 
gene is directly activated by c-Myb, i.e. by demonstration of a rapid induction response, or 







Activated Gene Species Function RCG References 
mim-1 chicken Chemotactic factor/acetyl transferase Yes [167] 
tom-1 chicken Membrane recruitment of clathrin Yes [182, 183] 
Lysozyme/LYG chicken Enzyme degrading bacterial cell walls Yes [184] 
A2B/ADORA2B chicken Adenosine receptor 2B, transmembrane Yes [185, 186] 
C/EBP (NF-M) chicken CCAAT-box/enhancer binding protein beta Yes [187, 188] 
Gas41 chicken Glioma-amplified sequence 41 Yes [189] 
Mcm4 chicken Mini chromosome maintenance 4 Yes [186] 
Pcd4 chicken Possible tumour suppressor Yes [190, 191] 
c-kit hu./mo. Tyrosine kinase receptor Yes [151, 152] 
c-myc hu./mo. Transcription factor, proliferation-related Yes [144-148] 
bcl2 human Anti-apoptotic regulatory protein Yes [148, 153-155]  
CD34 human Hematopoietic stem cell surface protein Yes [192, 193] 
COLIA2 human Type I collagen 2 chain, structural protein Yes [194] 
GBX2 human Transcription factor, hematopoiesis Yes [195] 
NMU human Neuromedin U Yes [196] 
RAG2 human Part of the V(J)D recombinase, lymphoid Yes [176] 
CAI mouse Carbonic anhydrase I Yes [197] 
GATA3 mouse Transcription factor Yes [198] 
H2A.Z mouse RNA Pol II histone variant Yes [199] 
IGF-I mouse Insulin-like growth factor I Yes [200, 201] 
MPO mouse Myeloperoxidase Yes [202, 203] 
ADA human Adenosine deaminase No [204] 
CD13 human Digestion-related aminopeptidase No [205] 
CD4 human Cell surface receptor No [114, 172, 173] 
cdc2 human Cell cycle-related kinase No [206] 
c-myb human See section 1.2.3 No [207] 
COX2 human Cyclooxygenase-2, prostaglandin metabolism No [208] 
Cyclin A1 human Cell-cycle regulatory molecule No [209] 
FGF-2 human Fibroblast growth factor 2 No [150] 
hChAT human Choline acetyl transferase, metabolism No [210] 
LCK type I human Lymphoid-spec. Src-family tyrosine kinase No [211] 
MAT2A human Methionine adenosyltransferase No [212] 
PRTN3 human Myeloblastin, serine protease, neutrophil No [213] 
SCF human Stem cell factor, hematopoietic No [214] 
TCR human human T cell receptor , V(D)J recombination No [174, 175] 
TCR human human T cell receptor , V(D)J recombination No [215] 
TOPII human DNA Topoisomerase No [149] 
TRHR human Thyrotropin-releasing hormone receptor No [216] 
WT1 human Transcription factor No [217] 
GATA1 mouse Transcription factor, hematopoiesis No [218] 
NE mouse Neutrophil elastase, granule protein No [219, 220] 







Repressed Gene Species Function RCG References 
c-fms hu./mo. Macrophage colony-stim. factor receptor No [222] 
c-erbB2 human Tyrosine kinase receptor No [223] 
N-ras human Small GTPase, intracellular signalling No [224] 
CD4 human Cell surface receptor No [114] 
IgGL human Ig epsilon germline, class switch recomb. No [225] 
     
Table 2 Proposed target genes of c-Myb and v-Myb. The table lists reported c-Myb and/or v-Myb target 
genes, with stronger evidence than simple detection of Myb binding sites in the promoter. The cases where 
the resident chromosomal genes (RCG) have been shown to be activated by Myb are shown in the RCG-
column. Repressed genes are listed in the lower part of the table. 
 
In a recent paper we describe and discuss two new criteria which we propose should be 
considered [226]. In order to generate a robust core collection of direct, bona fide c-Myb 
target genes these analyses should include evaluation of (VI) endogenous promoter 
occupancy of c-Myb, demonstrated by ChIP, and (VII) expression of the gene affected by 
knockdown of c-Myb. While the latter provide strong evidence for a functional link, the 
former provide evidence for a direct physical link [226]. For several of the target genes 
listed in Table 1 one or more of these criteria are not fulfilled, or they have not been tested. 
Some of the reported target genes will therefore probably end up being redefined in future 
publications, either as indirect targets or even false positives. Nevertheless, several of the 
target genes have been extensively studied, and generated important knowledge of c-Myb 
biochemistry and biology. Some of these will be described in the following sections. 
 The first identified Myb target gene, mim-1, was isolated using a temperature 
sensitive mutant of the E26 virus [167]. The mim-1 gene product has been assigned different 
functions; secretable component of promyleocyte granules, hetrophil chemotactic factor, 
and acetyl transferase [167, 227, 228]. Endogenous mim-1 can be induced by E26 v-Myb 
and c-Myb in collaboration with NF-M (C/EBP), but not by AMV v-Myb [96, 97]. This 
discrepancy has now been resolved by the findings of Mo and co-workers showing that the 
leukemogenic mutations in AMV v-Myb SANT/DBD eliminate the interaction with, and 
consequently the acetylation of, H3 tails (see section 1.2.2.1 and [54]). In contrast, the 
gastrulin brain homeobox 2 gene (GBX2) can be activated exclusively by AMV v-Myb and 
not by E26 v-Myb and c-Myb [195]. While AMV v-Myb constitutively activates GBX2 
gene expression, c-Myb requires an activated signalling pathway to induce GBX2 
expression. GBX2 is a regulator of the chicken myelomonocytic growth factor (cMGF), and 
the constitutive production of this growth factor makes AMV v-Myb able to transform cells 




 Several reports have shown that c-myc could be a target gene for c-Myb [144, 145, 
147, 148, 151, 229-231]. Even thought the results concerning the regulation of 
chromatinized c-myc have been contradictory, two studies have finally demonstrated that c-
Myb is able to regulate the expression of resident chromosomal c-myc, using a conditionally 
active Myb-ER fusion [144] or the dominant negative Myb-Engrailed fusion protein [148]. 
Expression of the MYB-ER fusion in a myeloblastic cell line rapidly restored c-myc 
expression and thereby prevented growth arrest induced by IL-6 in nearly terminally 
differentiated cells [144]. This tightens the link between c-Myb, c-Myc and cell growth. 
 A similar approach as that used for c-myc, demonstrated that the anti-apoptotic 
oncoprotein bcl-2 [148] and c-myb itself [144] are transcriptionally activated by c-Myb. 
Whether bcl-2 is activated by c-Myb in all cell systems is still not known, since the 
expression of bcl-2 seemed to be unaffected in DT40 c-myb null cells when compared to 
DT40 wild-type cells [231]. Concerning the c-myb gene, c-Myb has been show to bind to an 
MRE in the 5’ flanking region of the gene and transactivate the promoter in fibroblasts 
[207]. In contrast, negative or no regulation have been observed in T cells and a myeloid 
cell line, respectively [232]. 
 The finding of RAG-2 as a c-Myb target gene, confirmed that Myb is essential for T 
cell development [168]. Chromatin IP analysis of the RAG-2 promoter showed binding of 
endogenous c-Myb to a MRE in the proximal promoter. In addition Wang and co-workers 
showed that c-Myb was important for the activation of T cells [176]. In immature B cells 
cooperative binding of c-Myb and Pax-5 has been shown to activate the RAG-2 promoter 
[115, 116].  RAG-2 is encoding a component of the V(J)D recombinase, which is essential 
for the assembly of the antigen receptor in B and T lymphocytes. Interestingly, several other 
genes important for T cell development have been reported to be Myb-regulated (CD4, TCR 
 and -; see Table 1), although the evidences for transactivation of the chromatinized genes 
are scarce. It should be mentioned that the cell surface receptor CD4 gene is one of the few 
examples reported to be negatively regulated by c-Myb [114]. 
 Recently, Maurice at al. has shown that c-Myb is a critical downstream regulator of 
positive selection of T-helper cells, from thymocytes with intermediate avidity for antigen-
MHC complexes [198]. By biochemical and biological assays they demonstrated that 
GATA-3, a critical inducer of T-helper cell fate, is a direct target c-Myb, and that c-Myb-
induced GATA-3 expression promotes transduction of the T cell receptor signal for 




Through the regulation of its target genes one of the main functions of c-Myb is to 
participate in deciding whether the cell shall continue to proliferate or start to differentiate. 
In this context, a set of recent papers linking c-Myb to replication is intriguing. Through 
their work with c-Myb target genes the group of KH Klempnauer has discovered that three 
different Myb targets co-localizes with origins of DNA replication [186]. Using the nascent 
strand abundance assay, they have been able to shown that the MREs of the Gas41 [189], 
Mcm4 [186] and Adora2B [185] genes in chicken cells all reside within areas of DNA 
replication origin. Still, no correlation between Myb activity and replication was observed 
[186]. However, DNA replication origin is known to be decondensed during replication, 
which may support the activation of the associated genes by c-Myb. Future studies will 
hopefully reveal the basis for this association.  
 
1.2.5 c-Myb and oncogenesis  
Given the central role of c-Myb in proliferation and differentiation in the bone marrow, as 
well as in other tissues, and the fact that the discovery of the c-myb gene was done in the 
form of two activated, leukemia-causing v-myb genes, it should be no surprise that the links 
between the c-myb proto-oncogene and human cancers are increasing. The genomic locus of 
the MYB gene is frequently rearranged in several human neoplasias: acute myelogenous 
leukemias, melanomas, and breast, colon and pancreatic carcinomas [8, 132]. In some of 
these cancers this involves amplification of the MYB gene, resulting in increased expression. 
Indeed increased MYB expression has been detected in many hematopoietic malignancies, 
breast and colon cancer and cancer in the upper gastrointestinal tract [233-241].  
Until recently, no recurrent genomic involvement of the MYB locus had been 
reported in human malignancies. Then, in 2005 Sinclair and co-workers reported the 
possible involvement of MYB in a recurrent translocation, t(6;7)(q23;q32~36), coupled to 
childhood T cell acute lymphoblastic leukemia (T-ALL; [242]). This translocation, found in 
7 patients, affected the genes MYB and AHI1, which were shown to reside within the break-
point region. Still, this translocation was not correlated with changes in MYB expression 
[242]. The same translocation was earlier this year mapped in detail to t(6;7)(q23;q34), 
showing that in all cases the translocation places MYB in the vicinity of the TCRB (T cell 
receptor ) regulatory sequence [243]. Quantitative real-time PCR demonstrated that the 
TCRB-MYB translocation indeed deregulated the expression of MYB which showed 




studied having this translocation, the authors were able to define a new T-ALL subtype in 
very young children [243]. 
 In parallel with the identification of the TCRB-MYB translocation another and even 
more common perturbation of the MYB-locus was revealed. In two independent studies 
more than 11% of the T-ALL patients studied (9 of 107 cases; 13 of 84 cases) turned out to 
have a short local duplication of the MYB gene [243, 244]. The MYBdup patients like the 
TCRB-MYB patients had elevated MYB mRNA levels, but in this case it correlated with the 
duplication. In one of the studies MYBdup was shown to concur with mutations in the 
NOTCH1 gene in all cases [244]. Lahortiga and co-workers also demonstrated that 
knockdown of MYB in T-ALL MYBdup cell lines (RPMI-8402 and MOLT-4) irreversibly 
initiated T cell differentiation. Furthermore, the combined inhibition of MYB and NOTCH1 
by RNAi strongly affected proliferation and survival in a synergistic manner [244]. This 
suggests that MYB might be a therapeutic target in human T-ALL. 
 c-Myb has also been implicated in cancer of the breast [235, 236] and MYB 
expression correlates strongly with ER positive breast cancer [235]. Earlier this year 
Drabsch and co-workers showed that this is due to ER acting directly on the MYB gene to 
relieve attenuation caused by a stem-loop structure in the first MYB intron [245]. The 
investigators further showed that MYB is required for the proliferation of ER+ breast cancer 
cells, as they were able to halt cell proliferation by knocking down MYB. This demonstrates 
that c-Myb is an effector of estrogen/ER signalling and provides evidence for a functional 
role of MYB in breast cancer [245].  
Altogether the recent advances in the field of c-Myb and oncogenesis have 
strengthened the link between c-Myb aberrations, increased expression and human cancers. 
This has positioned the MYB gene as a potential cancer drug target where the aim would be 
to halt its expression or reduce its activity 2 . With its key role in hematopoiesis and 
leukemogenesis, unravelling the molecular mechanisms of the c-Myb protein is paramount. 
 





1.3 SMALL UBIQUITIN-RELATED MODIFIER - SUMO 
The small ubiquitin-related modifier, SUMO, was identified in mammalian cells in 1996, 
where it was found to be covalently linked to the GTPase activating protein RanGAP1 [246, 
247]. Since its discovery, the number of SUMO targets has grown. Moreover, SUMO 
conjugation  has been shown to be essential for cell viability [248-250]. Presumably, SUMO 
is just as important for the cell as its close relative ubiquitin, and perturbations in the SUMO 
system, as well as in the ubiquitin system, have been implicated in several different diseases 
and cancers (reviewed in [251]; see section 1.3.4). SUMO-related mechanisms are 
seemingly also an important part of c-Myb biology, and since two of the papers presented in 
this thesis deals with SUMO-regulation of c-Myb, a chapter dedicated to this nuclear protein 











Figure 11 The ubiquitin-fold. Ribbon 
diagrams highlight the similarity of the 
three-dimensional structures of SUMO-1 
and ubiquitin [252]; from N- to C-
terminus; 	Secondary structure 
elements are indicated with colour;  
sheets (green) and  helices (red). 
Modified from illustration in [253]. 
 
1.3.1 Ubiquitin-like proteins 
Since the discovery of ubiquitin in the mid-1970s, an entire family of small proteins related 
to ubiquitin has been identified and classified. Based on multiple sequence alignments, 3D 
threading, and dissection of the enzymatic mechanisms it has been possible to add about a 
dozen ubiquitin-like proteins (Ubls) to the list, e.g. ISG15, Fat10, Nedd8 and SUMO 
(reviewed in [254]). Despite sharing only medium sequence similarity, all the Ubls possess 
similar three-dimensional structure; the Ubiquitin- or the -grasp fold (;Fig 11; 
[255]).  
In general all Ubls are conjugated C-terminally to an internal lysine in the protein 
substrate, making an isopeptide bond. However, there are some exceptions [256]. The C-
terminal amino acid residue of the Ubls, in which the carboxyl group is the site of substrate 




Ubls studied (Fig 12; [253, 254]). In short, I: exposure of the C-terminal glycine by 
proteolytic cleavage, II: activation of the Ubl by an activating E1 enzyme, III: transfer of 
the Ubl to an E2 conjugating enzyme, which either IVa: forms a four protein complex with 
the Ubl, the substrate and an E3 ligase, or IVb: transfer of the Ubl to the E3 ligase, and 
finally V: conjugation of the Ubl to the substrate (see section 1.3.2.2 for details). The Ubl 
can later be cleaved off by an isopeptidase, often the same protease as in step I, and used to 





   
 Figure 12 A generalized Ubl-conjugation pathway. Precursor Ubls are processed by 
DUBs (deubiquitinating enzymes) or ULPs (Ubl-specific proteases) to expose the C-
terminal glycine in the mature Ubl. The processed Ubl is activated with ATP by E1 Ubl-
activating enzyme. This creates a thioester linkage between the Ubl and E1. The Ubl is 
transferred to the catalytic cysteine of the E2 Ubl-conjugating enzyme, and can then be 
ligated to a substrate with the aid of an E3 Ubl-protein ligase. The RING E3s catalyze 
modification by binding simultaneously the Ubl-E2 thioester complex and the substrate 
to be modified. HECT E3s catalyze substrate ligation in two steps. First, the Ubl is 
transferred to a catalytic cysteine of the HECT E3. Then, the E3-Ubl thioester complex 
transfers the Ubl to the substrate. The DUBs and ULPs can remove Ubls from substrates. 
Taken from [254]. 
 
 
Several of the Ubls function as important regulators of various cellular functions 
including transcription, DNA repair, signal transduction, autophagy, and cell cycle control 
[257-259]. Even though the Ubls are relatively small proteins (Ubiquitin: 76 aa; SUMO: 
~100 aa), a Ubl moiety may alter the biochemical properties of a substrate considerably. 




of Ubl biochemistry has been best studied for ubiquitin. In addition to being conjugated, 
ubiquitin can bind non-covalently to proteins harbouring ubiquitin-interaction/binding 
motifs (UIMs/UBMs). These motifs have been given a lot of attention the last years 
(reviewed in [260]), and reports on interaction motifs for other Ubls have now started to 
appear in the literature (see chapter 1.3.3 and [261, 262]). 
 
 
Figure 13 SUMO is highly related to ubiquitin. Multiple sequence alignment of human ubiquitin and the 
four human SUMO homologues. Identities are indicated in bold and similarities are shaded. A consensus 
motif for sumoylation present in SUMO-2, -3 and -4 is boxed in yellow, with the SUMO acceptor lysine 
boxed in red. Ubiquitin lysine 48 and 63, which serve as common sites for ubiquitin polymerization, are 
also boxed in red. The site of cleavage for production of mature proteins with C-terminal glycine-glycine 
residues is indicated with a vertical line. Modified from illustration in [253]. 
 
1.3.1.1 SUMO isoforms  
Beside ubiquitin itself, SUMO is by far the Ubl given the most attention. Today, four 
SUMO isoforms have been described in mammals; SUMO-1, -2, -3 and -4. The SUMO 
family consists of nuclear proteins of around 100 amino acids, which are ubiquitously 
expressed [253], except SUMO-4 which has a restricted pattern of expression [263]. 
SUMO-2 and -3 are highly similar, differing from one another by only three N-terminal 
residues, and have yet to be functionally differentiated [264, 265]. They form a distinct sub-
family, often referred to as SUMO-2/3, and are only 50 % identical to SUMO-1. This 
difference is actually as large as the one fond between ubiquitin and Nedd8 [254]. The 
fourth and most recently described SUMO isoform, SUMO-4, is ~ 85 % identical with 
SUMO-2/3. Due to a proline residue positioned six amino acids from the C-terminus, 
SUMO-4 cannot be matured by the SUMO specific proteases (Fig 12; see chapter 1.3.1 and 
1.3.2.2), and hence it is unlikely to be conjugated. Still, it might function as a dominant 
negative SUMO [266]. In this context it should be noted that among the tissues investigated 
the highest level of SUMO-4 expression was seen in kidney [263]. However, as evaluated 
by large-scale microarray analysis of the human transcriptome (Novartis Research 




an intron, is also highly expressed in dendritic cells, whole blood, and in hematopoietic cells 
from both the myeloid and lymphoid lineage. 
Apart from the difference in primary structure, there are other dissimilarities 
between SUMO-1 and SUMO-2/3. Virtually all SUMO-1 in the nucleus is engaged in 
conjugates, while for SUMO-2/3 there seems to exist a free pool that is incorporated into 
high molecular weight complexes when the cells are exposed to oxidative-, heat- or 
genotoxic stress [264]. The ability of ubiquitin to form polymeric chains is critical for many 
biological activities of this protein, like the interaction with the proteasome. In contrast, 
SUMO is generally thought to function as monomers. Nevertheless, SUMO-2/3 has been 
observed to form chains in vitro [265]. SUMO-2/3 and -4 harbours a consensus motif for 
sumoylation in the N-terminus (yellow box Fig 13; see section 1.3.2.1), which might 
facilitate this polymerization. Nevertheless, the functional significance of SUMO chains in 
vivo has yet to be established [265, 268-270]. It is, however, possible that SUMO 
polymerization or other post-translational modifications might add complexity to SUMO in 
mammalian cells. 
The SUMO protein is like ubiquitin evolutionary well-conserved, and homologues 
have been identified in many eukaryotes, including yeast. However, in contrast to the four 
SUMO isoforms found in mammals, yeast only expresses one, termed Smt3. Smt3p is 48 % 
and 44 % identical to human SUMO-1 and SUMO-2/3, respectively, but still has the 
ubiquitin-fold [271]. 
 
1.3.1.2 SUMO structure 
The SUMO-1 amino acid sequence shares only ~ 18 % identity with ubiquitin, still their 
three-dimensional structures are highly homologous. SUMO-1 and ubiquitin share the 
characteristic -fold, also known as ubiquitin- or the -grasp fold ([255]; Fig 11), 
and the C-terminal di-glycine motif (Fig 13) which is necessary for interaction with E2 and 
creation the isopeptide bond [272]. Unique for the SUMO peptides is the 16-20 amino acid 
long and flexible N-terminal tail (Figs. 11 and 13). In addition, the distribution of positively 
and negatively charged surface residues on SUMO is highly different from ubiquitin. These 
distinctions are probably the underlying reason for their different biological functions, as 
well as enzyme and substrate specificities (reviewed in [253]).   
 Given the difference in primary structure between SUMO-1 and SUMO-2/3, it is 
obvious that this is also reflected in three-dimensional space. All three isoforms form a 




first -helix (from the N-terminal; Figs 11 and 16). However, the basic residues are 
positioned slightly differently in the three isoforms. While the hydrophobic groove has been 
shown to be important for interaction with other proteins [273, 274] and correct positioning 
of SUMO during conjugation [275], the different positioning of the surrounding basic 
residues has been implicated in advocating specificity both in protein-protein interactions 
([276]; see chapter 1.3.3) and during selection of SUMO paralogues for conjugation [277].  
 
1.3.2 SUMO-conjugation 
The three best studied SUMO isoforms; SUMO-1, -2, and -3, are all conjugated to lysines 
positioned in a certain context. Apart from the fact that these lysines must be exposed on the 
surface of the targeted protein, several additional constraints exist, some of which have been 
deduced in the last couple of years.  
 
1.3.2.1 Consensus sequence 
Analyses of different SUMO substrates pointed to the existence of a sumoylation consensus 
motif; KXE both in mammals [278, 279] and yeast [280], where  is a hydrophobic or 
bulky residue and X is any amino acid. This sequence can bind directly to the E2 SUMO-
conjugating enzyme Ubc9 ([278, 281]; see section 1.3.2.2).  Recently, the consensus has 
been extended by Yang and co-workers showing the dependency of negatively charged 
residues located directly C-terminal of this motif [282]. The requirement of the negatively 
charged amino acids in the extended motif; NDSM (negatively charged amino acid-
dependent sumoylation motif), has also been correlated to increased affinity between the 
substrate and Ubc9 [282].  
The negatively charged amino acids can also be compensated with residues that can 
be phosphorylated, like in the PDSM (phosphorylation-dependent sumoylation motif) 
suggested by Hietakangas and co-workers [283]. This adds a potential layer of regulation to 
SUMO-conjugation: In proteins harbouring a PDSM, a phosphorylation cue might fulfil the 
requirement for negative charge in the sumoylation motif and subsequently trigger SUMO-
conjugation [283]. The SUMO-acceptor lysine K527 in human c-Myb (IK527QEVES532 
PTDKS) is part of a potential PDSM, as S532 can be phosphorylated [84-86]. But since this 
motif contains two other negatively charged glutamate residues, phosphorylation of S532 is 
not essential for sumoylation to occur (V. Matre unpublished results).  
Interestingly, there are also reports of SUMO being conjugated to sites not 




sumoylation consensus motifs have been shown to be sumoylated, as well as proteins where 
all acceptor lysines have been mutated [285-287]. Thus, there still seem to be novel 
sumoylation motifs waiting to be defined. 
 
1.3.2.2 Mechanism 
The sumoylation process is highly dynamic and reversible. By the aid of proteases, the 
SUMO protein can be deconjugated and reconjugated to substrate proteins in several 
consecutive rounds. As indicated in chapter 1.3.1 this five step process includes four 
different enzymes; a SUMO isopeptidase, a SUMO E1 activating enzyme, a SUMO E2 
conjugase and a SUMO E3 ligase. 
 
SUMO proteases 
In the first step the SUMO precursor protein has to be trimmed at the C-terminus, to expose 
the Gly-Gly motif. This is done by proteases which contain two different activities; an 
endopeptidase activity used to mature SUMO precursors, and an isopeptidase activity used 
to remove conjugated SUMO from target proteins. The SENPs (Sentrin-specific protease; 
Sentrin: original name for SUMO) constitute a family of SUMO-proteases harbouring these 
activities. Human cells express seven different SENPs (SENPs -1, -2, -3, -5, -6, -7, and -8), 
where SENP8 actually is a Nedd8 protease (reviewed in [288]). With their different tissue 
expression, different subcellular localization, and different SUMO isoform preference, these 
enzymes are thought to augment specificity in the sumoylation pathway (reviewed in [289]).  
 SENP1 and -2 constitute the best characterized SENP subfamily. SENP1 is localized 
in the nucleoplasm and deconjugates a large amount of sumoylated proteins, while SENP2 
is associated with the nuclear pore. SENP1 has a preference for SUMO-1 [290, 291], while 
SENP2 seems to have a preference for SUMO-2/3 [292]. However, they are both capable of 
processing and deconjugating all three isoforms. SENP3 and -5 on the other hand are only 
able to deconjugate SUMO-2/3. Whether or not they also can process one ore more SUMO 
isoforms is not known [289]. 
 
SUMO E1 activating enzyme 
The human SUMO E1 activating enzyme consists of a hetrodimer named SAE1/SAE2 [293, 
294]. To initiate the SUMO modification reaction SAE1/SAE2 catalyzes the formation of 
adenylated SUMO in which the C-terminal carboxyl group is covalently linked to AMP. 




the C-terminal carboxyl group of SUMO forms a thioester bond with the sulphydryl group 
of a cysteine residue in SAE2 (Fig 12). It has been shown that the adenovirus protein Gam 1 
can lower sumoylation through inhibiting the E1 activity by blocking the formation of the 
SUMO-E1 thioester complex [295]. This results in transcriptional activation of some 
promoters, and implies that the sumoylation machinery might also be a target for other 
viruses [295].  
 
SUMO E2 conjugating enzyme 
In the third step of the sumoylation cycle SUMO is transferred from E1 to a cysteine residue 
in the active site of the SUMO E2 conjugating enzyme Ubc9, forming an E2-SUMO 
thioester intermediate. This intermediate functions as a SUMO-donor in the last step where 
SUMO is transferred to the amino group of the acceptor-lysine in the target protein [296, 
297]. Ubc9 is the only Ubl E2 conjugating enzyme that directly recognizes substrate 
proteins. The conjugase can bind to the sumoylation consensus sequence 
KXE [278, 282] 
and catalyze the formation of an isopeptide bond between the C-terminal carboxyl group of 
SUMO and the -amino group of the lysine in the sumoylation motif. In addition Ubc9 
contains an N-terminal domain which binds directly to SUMO and facilitates the transfer of 
SUMO from the E1 enzyme [298]. 
While there have been reported more than 30 Ubiquitin E2 conjugases, only one is 
known for SUMO [299]. Ubc9 is therefore essential for SUMO-conjugation, and by 
knocking it out, all sumoylation is abrogated. Ubc9 null embryos progress to implantation, 
probably due to the exictence of maternal protein during preimplantation stages, but die 
after the early postimplantation period [250]. 
 
SUMO E3 ligase 
Even though SAE1/SAE2 and Ubc9 is sufficient for SUMO modification in vitro, it is rather 
inefficient, and additional components are needed to accelerate this reaction [300, 301]. The 
SUMO E3 ligases are such factors, and they promote transfer of SUMO from the E2 
conjugase to specific substrates. Several SUMO E3 ligases have been identified, most of 
which seem to employ the “IVa mechanism” described in chapter 1.3.1, forming a four 
protein complex with SUMO, Ubc9 and the substrate. This is typical for the so-called RING 
domain-containing E3s (reviewed in [259]). 
 Today, three families of SUMO E3 ligases are recognized; the PIAS (protein 




Pc2 [269, 302, 303]. In humans the PIAS proteins (PIAS1, PIASx, PIASx, PIASy and 
PIAS3; [304-306]) are characterized by a central cysteine-rich SPRING (Siz/PIAS RING) 
domain [307].  The substrate specificity of these E3 enzymes is not known, but knockout 
studies in mice suggest a certain amount of redundancy [308, 309]. In the case of c-Myb, 
PIASy has been shown to induce SUMO-1 conjugation, while PIAS3 has been shown to be 
important for stress-induced SUMO-2/3 conjugation [81, 83]. Lately, several of the PIAS 
proteins have been shown to affect the activity of transcription factors in an E3-independent 
manner [310-312].  
The nuclear pore protein RanBP2 (a.k.a. Nup-358) is not a SPRING-containing E3 
ligase, and is in general not related to the Ubl E3s. RanBP2 has been shown to accelerate the 
conjugation of SUMO-1 to Sp100 and HDAC4 [269, 313] and SUMO-2 to PML [277]. 
RanBP2 is responsible for localizing sumoylated RanGAP1 to the nuclear pore complex 
[314, 315], and the four-protein conjugation complex involving RanGAP1, RanBP2, Ubc9 
and SUMO-1 has been solved [275].  
The polycomb chromatin-modifying complex mediates transcriptional repression, 
and the Pc2 component of this complex has been shown to possess SUMO E3 ligase activity. 
Like RanBP2, Pc2 is neither a RING, nor a HECT-containing E3. Still it has the capacity to 
bind both Ubc9 and its substrate protein [316]. One of the best described substrates for Pc2-
dependent SUMO modification is the transcriptional co-repressor CtBP [302]. Ectopic 
expression of Pc2 leads to co-localization of SUMO and Ubc9 in PcG bodies, implying that 
PcG bodies might be an important site for sumoylation [302]. Recently, it has been shown 
that during DNA damage response the Pc2 E3 activity is enhanced as a result of 
phosphorylation carried out the homeodomain interacting protein kinase 2 (HIPK2). This 
leads to increased sumoylation of HIPK2, which enhances its ability to mediate 
transcriptional repression during DNA damage (reviewed in [317]). 
 
1.3.2.3 Biological consequences 
As the field of SUMO has expanded it becomes more and more evident that the small-
ubiquitin related modifiers are involved in many nuclear processes. SUMO modulates 
components involved in nuclear transport, DNA repair, chromosome organization, signal 
transduction, formation of nuclear structures, and gene expression. Here I will focus on the 



















Figure 14 Targeted by SUMO. A 
selection of identified sumoylation 
substrates, arranged by function and 
localization. Several of these proteins 
are involved in transcriptional 
regulation, organization of chromatin, 
maintaining of genome integrity, 
signal transduction and formation of 




Sumoylation has been shown to regulate the nuclear translocation of several proteins [287, 
318-320]. RanGAP1 is a good example of this function: Unmodified RanGAP1 is 
cytoplasmic, while sumoylated RanGAP1 is associated with the nuclear pores in the nuclear 
envelope [314, 315]. Interestingly several sumoylation consensus motifs have been shown 
to reside within nuclear localization signals [286, 321], and it has been suggested that most 
SUMO substrates are sumoylated when translocated to the nucleus [322]. As mentioned in 
chapter 1.2.3.2 reported data have indicated that cytoplasmic sumoylation of c-Myb by 
TRAF7 can sequester c-Myb in the cytoplasm, thereby lowering c-Myb transactivational 
potential [110]. Although exciting, we have not been able to substantiate these data using c-
Myb-SUMO fusion constructs (AH. Alm-Kristiansen unpublished data).  
 
DNA repair and chromosome organization 
Several proteins involved in DNA repair and DNA replication have been shown to be 
modified by SUMO, including PCNA (proliferating cell nuclear antigen), the RecQ-type 
helicase WRN, Topoisomerase I and II, and thymine-DNA glycosylase TDG (reviewed in 
[323]). Sumoylation of a ubiquitin-acceptor lysine has been demonstrated to counteract 
ubiquitination-dependent PCNA repair activity in undamaged cells. Furthermore, 
sumoylation of PCNA is increased during S phase, and is therefore thought to play a role in 




Dissociation of TDG from DNA after base removal is an essential step in completing the 
repair of such damages. Sumoylation of TDG has been shown to abrogate DNA-binding, 
probably mediated by conformational changes in TDG promoted by intra-molecular, non-
covalent SUMO binding (see chapter 1.3.3; [324-326]). 
SUMO plays an important role in protecting chromosome structure and function. All 
the components of the sumoylation machinery (E1, E2, E3 and SENPs) have shown genetic 
associations with the regulation of chromosome condensation, cohesion, and mitotic/meiotic 
chromosome separation [327]. Furthermore, Ubc9 knock-out mice, which die in utero post 
implantation, have severe chromosomal defects. These mice show aberrant chromosomal 
condensation and segregation, and abnormal nuclear morphology [250]. 
 
Signal transduction 
Several lines of evidence point in the direction of SUMO being involved in signal 
transduction. Moreover, SUMO conjugation itself might be controlled by intracellular 
signals. One way for the cell to transmit signals, e.g. stress signals, is through 
phosphorylation. As mentioned, a phosphorylation dependent sumoylation motif has been 
described ([283]; see section 1.3.2.1). In the same paper the transactivation capacities of the 
heat-shock factors HSF1 and HSF4b, harbouring PDSMs, were demonstrated to be 
repressed as a result of phosphorylation-dependent sumoylation [283].  
Another example of a link between sumoylation and cellular signals is the 
significant increase in SUMO-2/3 conjugation following heat-shock and oxidative stress 
[264]. Prolonged hypoxia induces CREB sumoylation [287], while DNA damage-inducing 
agents augment SUMO conjugation of the IB kinase-regulator NEMO [320]. Decreased 
phosphorylation of Promyelocytic Leukemia Protein (PML) after mitosis is necessary for 
increased sumoylation of PML and assembly of the PML nuclear bodies (PML-NBs) during 
interphase [328]. 
Some proteins are modified by sumoylation, ubiquitination and acetylation on the 
same lysine leading to different outcomes [284, 329, 330]. However, competition for the 
same acceptor lysine is probably only one aspect of this interplay. Sumoylation has been 
suggested to increase deacetylation of histone H4 [331], while several histone acetyl 
transferases (HATs) and deacetylases (HDACs) change localization and/or activity as a 
result of SUMO conjugation [313, 332, 333]. One example is HDAC-1, for which the 





Regulation of transcription 
Posttranslational modification by SUMO has diverse effects on stability, localisation and 
activity of transcriptional regulators. Proteins involved in transcription, ranging from 
sequence-specific transcriptions factors, to co-activators and co-repressors, from histone 
modifying enzymes and chromatin remodelling factors to proteins in the general 
transcription machinery, have been shown to be sumoylated [253, 334]. Sumoylation of 
DNA-binding transcriptional regulators generally leads to a repression of their 
transactivational potential. This has been demonstrated for e.g. Elk-1 [335], C/EBP [336], 
AR [337] and c-Myb [81, 82]. TCF-4 (T cell factor-4; [338]) and Ikaros [339] are some of 
the few examples suggested to be positively modulated by sumoylation. 
 In contrast to ubiquitination that mainly marks proteins for proteasomal degradation, 
sumoylation has been linked to stabilization of several proteins. This has been shown to be 
achieved either by directly competing with ubiquitin for acceptor lysines as in the case of 
IB [329], or through more independent and indirect mechanisms as reported for Smad4 
and Huntingtin [340, 341]. Ubiquitination of transcription factors has been proposed to act 
as a licensing mechanism that stimulates transcriptional activity, but at the same time targets 
the factors for proteasomal degradation [323, 342, 343]. When thinking of SUMO as an 
anti-ubiquitin, the opposite would be the case; repression and stabilisation [323]. Indeed, 
this effect has been observed in transrepression with sumoylated PPAR	 Sumoylated 
PPAR interacts with the N-CoR-HDAC3 complex and thereby blocks subsequent 
recruitment of the ubiquitination machinery responsible for clearing the promoter [344]. 
 The predominant repressive effect of sumoylation is in most cases linked to the 
recruitment of factors inhibiting transcription. Such factors include co-repressors like the 
HDAC family [332, 335] and Daxx [345, 346]. Yang and Sharrocks have observed that 
sumoylation of Elk-1 promotes its association with HDAC2, decreased histone acetylation, 
and repression of an Elk-1 target gene [335], while Lin and co-workers have shown that 
Daxx represses the transcriptional activity of sumoylated GR as well as AR, Smad4, and 
CBP [346]. With the discovery of SUMO-binding motifs in several SUMO-interacting 
proteins, including HDACs and Daxx, there are reasons to believe that co-repressors will be 
tethered even tighter to SUMO-modification (see chapter 1.3.3; [273]).    
Another interesting aspect of SUMO-conjugation is that it seems to be disrupting 
transcriptional synergy on promoters with multiple response elements. In 2000 Iniguez-




mediated “synergy control” (SC) [347]. Mutations of this site unleashed a strong synergistic 
behaviour of GR at compound promoters, but not at single response elements. Later it was 
shown that the SC motif was indeed a SUMO-conjugation site, and that the control of 
synergy was caused by sumoylation of the factor [348, 349]. This role of SUMO has been 
extended to other transcription factors, such as Ets-1 and C/EBP [347, 350]. The third 
paper presented in this thesis addresses the SC aspect in c-Myb and Myb-dependent gene 
activation (see Paper III).  
A conundrum within the field of SUMO research is the paradox of stoichiometry. 
Even though only a small fraction of a given target protein seem to be sumoylated at any 
given time, the biological consequences of abrogating SUMO-conjugation do not appear 
proportionate [259]. Here c-Myb may serve as an example: Even though as little as 5-10 % 
of the c-Myb species are conjugated to SUMO as judged from a Western analysis, mutating 
the acceptor lysines may result in a 20-fold increase in activity. Several models have been 
presented trying to account for this discrepancy [259], but till date none of them has been 
confirmed. Proposals include SUMO as a dynamic element in the transcriptional process, 
SUMO as an assembly factor, necessary only temporarily while a complex is formed, or 
SUMO as relocalization tag, changing the localization of its target protein and hence its 
activity [259]. Also the SUMO-governed synergy control and loss of this, leading to a more 
than additive effect on transcription, might be a candidate explanation. 
Concerning SUMO-dependent relocalization of transcription factors, recent work on 
the tumour suppressor PML have provided new insight into this aspect of SUMO biology. 
As stated above, the PML protein has the ability to polymerize into what is known as the 
PML nuclear bodies (Fig 15). The PML-NBs dynamically change its morphology during the 
cell cycle and in response to cellular stresses [328]. SUMO-conjugation of the PML protein 
is paramount for the bodies to nucleate [351, 352], and mutations of the SUMO-acceptor 
lysines in PML or ectopic expression of SENPs results in delocalization of PML and PML-
NB associated factors, e.g. CBP and Sp100, within the nucleus [352, 353]. Recently, it was 
demonstrated that a motif in PML, mediating non-covalent interactions with SUMO 
(SUMO-binding motif; SBM), is just as essential for PML-NB formation as SUMO-
conjugation. [354]. It is now thought that SUMO:SBM interactions are the ‘glue’ in the 
PML-NBs (Fig 15). In addition, the co-repressor Daxx, which harbours an SBM, is recruited 
to PML-NBs in an SBM-dependent manner, by binding to PML-conjugated SUMO 




SUMO-conjugation and SUMO-binding are the underlying mechanisms controlling the 





   
 Figure 15 SUMO: The glue that binds. PML forms a homodimer, with each subunit containing 
multiple SUMO modification sites (green lines) and a single SUMO-binding motif (notch). 
Intermolecular interactions, mediated by SUMO and SUMO-binding motifs, nucleate the 
formation of a PML network that is able to recruit an assortment of other SUMO-modified 
proteins and proteins with SUMO-binding motifs. Adapted from [355]. 
 
 
1.3.3 Non-covalent SUMO-binding 
As evident from the preceding chapter, non-covalent SUMO-binding has been observed for 
some nuclear factors. In 2004 Song and co-workers showed that a small hydrophobic patch; 
V/I-X-V/I-V/I, is the minimal motif needed for SUMO-interaction [273]. This only partly 
fitted with a motif proposed earlier; h-h-X-S-X-S/T-a-a-a, by Minty and co-workers ([356]; 
h: hydrophobic residue, a: acidic residue). However, with a study of SUMO-binding motifs 
in yeast (I/V-I/L-I/L-X3-D/E/Q/N-D/E-D/E; [357]) and the work of Hecker and co-workers 
[276], the suggested consensus sequences were harmonized; V/I-X-V/I-V/I-a-a-a. 
Furthermore, the motif was proven to be able to bind SUMO also when reversed; a-a-a-V/I-
V/I-X-V/I/L [274, 276]. In mammalian proteins the hydrophobic core allows for SUMO-
binding, while the negatively charged amino acids surrounding the core augments SUMO-
isoform specificity and probably also the orientation of the binding. SUMO-1 seems to be 
more dependent on such an acidic stretch for efficient binding, while SUMO-2/3 may bind 
in its absence [276]. This correlates with the basic residues positioned slightly different 
between the second -strand and the first -helix in the different SUMO isoforms [276]. As 
for the phosphorylation-dependent sumoylation motifs, phosphorylated amino acid residues 
can compensate for the lack of acidic residues in potential SBMs. Still, this only changes the 





Motifs binding non-covalently to ubiquitin have also been known for some years 
(reviewed in [260]). However, in contrast to the similarities found between ubiquitin and the 
SUMO family concerning three-dimensional structure and mechanism of conjugation, the 
non-covalent binding properties of these modifiers differ. As can be seen in figure 16, 
interacting proteins contact ubiquitin and SUMO on opposite sites of the molecules. 
Moreover, the affinities of SBMs for SUMO are in the 2-3 M range, while those of UBM 
for ubiquitin are weaker and in the range of 10-500 M [261]. Finally, only one SBM has 
been described so far, while there are more than 15 different known UBMs [260]. The 
number of SBMs might however increase with future work. 
The recognition of the SUMO-binding motifs (SBM) has provided new insight into 
the interplay between sumoylation and SUMO-binding, with the tumour suppressor PML as 
one of the best examples [354]. A question worthwhile asking is whether the SBM-SUMO 
interaction provides enough specificity in the interaction between SUMO-conjugated and 
SUMO-binding factors. If so, all sumoylated proteins could potentially interact with every 
factor holding an SBM. Most likely additional contacts between the substrate proteins are 





Figure 16 SUMO and Ubiquitin: 
same family, different binding 
sites. Comparison of the SBM-
binding site on SUMO-1 and the 
UBM-binding site on ubiquitin. The 
SBM binds to an area defined by the 
second -strand and the first -helix 
of SUMO, whereas the UBM binds 
to a group of amino acids of the third 
and fourth -strands of ubiquitin. 




1.3.4 SUMO pathology 
As the field of SUMO has evolved, several diseases have been linked to perturbations in the 
SUMO system [251]. Pathogen infections, neurodegenerative conditions and cancer have 
been associated with dysregulation of SUMO modification enzymes or disruption of 




host sumoylation apparatus during infection and replication [358]. YopJ, which codes for a 
SUMO-protease homologue, and Gam 1, which inhibits E1 activity, are two such examples 
[295, 359].  
SUMO-3 seems to be regulating the processing of amyloid precursor protein (APP) 
to amyloid  peptide (A) in hippocampal neurons. Increased production or deposition of 
A is involved in the development of Alzheimer disease (AD; [360]). Low expression of 
SUMO-3 or expression of SUMO-3 mutants, cause an increase in production of Afrom 
APP [361]. Interestingly, the SUMO-3 distribution seems to be limited to the neuronal 
cytoplasm in the AD hippocampus in contrast to non-demented brains, where SUMO-3 is 
both cytoplasmic and nuclear. The PIAS3 expression has been found to be elevated in 
several types of cancer including lung-, breast-, prostate- and brain tumours [362], while an 
increased expression of SENP1 has been demonstrated in prostatic intraepithelial neoplasia 
and prostate cancer, but not in normal prostate [363]. Moreover, since SENP1 is a strong 
activator of AR-dependent transcription, this ultimately leads to an increase in cellular 
proliferation in the prostate [363].  
The fusion protein PML-RAR, caused by translocation, cannot be sumoylated, 
hence it cannot form PML-NBs. Moreover, this translocation has been shown to induce 
acute promyelocytic leukemia (APL; [364]). Retinoic acid and arsenic trioxide treatment 
induces degradation of the PML-RAR chimera and reorganizes PML nuclear bodies by 
enhancing sumoylation of the PML moiety [365]. Thus, arsenic trioxide is used routinely in 
the treatment of APL patients [366]. These few examples illustrate the significance of a 
well-functioning SUMO-system, and indicate that SUMO-related factors might be future 
targets in treating human diseases. 
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2. AIMS OF THE STUDY 
 
As evident from the preceding chapters, c-Myb is an important player in the development 
and function of hematopoietic cells. Therefore understanding the molecular mechanisms 
governing c-Myb function and activity is highly important. Uncovering and characterizing 
the macro-molecular interactions and post-translational modifications in which c-Myb 
engages, will hopefully reveal new aspects of c-Myb biology. Moreover, knowledge about 
how c-Myb is regulated, might give a hint to how this proto-oncoprotein may be deregulated 
in hematopoietic cancers.  
When this study was initiated a successful yeast two-hybrid screening had already 
been conducted in our lab, using full-length c-Myb as bait [81]. This screening identified 
five novel c-Myb-interacting proteins. One of these was Mi-2, reported to be an integral 
component of the NuRD co-repressor complex [367], while the huge nuclear factor FLASH, 
reported to be a gene product essential for cell division [368, 369], was another. 
Furthermore, the SUMO E2 conjugating enzyme Ubc9 interacting with and promoting 
sumoylation of c-Myb was reported by our group in 2003 [81]. This had introduced us to the 
field of SUMO-biology. With new knowledge on the consequences of SUMO-conjugation, 
and lately non-covalent SUMO-binding, we were eager to get a better understanding of how 
this related to c-Myb function. Accordingly, the present work had two main objectives: 
 
1. Characterize the interaction and function of the two novel c-Myb interacting proteins 
Mi-2 and FLASH. This included: 
 
(a) Substantiate and validate the interaction. 
(b) Examining whether c-Myb is part of protein-networks already described for the 
novel interaction partners. 
(c) Investigating the functional implications for c-Myb activity. 
(d) Trying to unravel the mechanisms underlying the putative implications in c. 
 
2. Examine how c-Myb might be regulated by SUMO. This included: 
 
(a) Investigating whether c-Myb through SUMO-conjugation is subject to the 
phenomenon of synergy control, and how this might be escaped. 
(b) Exploring whether c-Myb is able to interact non-covalently with SUMO, and if 
so, what the functional consequences of this might be. 
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3. SUMMARY OF PAPERS 
 
3.1 PAPER I 
Sæther T, Berge T, Ledsaak M, Matre V, Alm-Kristiansen AH, Dahle Ø, Aubry F, 
Gabrielsen OS. (2007) The chromatin remodeling factor Mi-2 acts as a novel co-activator 
for human c-Myb. J Biol Chem, 282, 13994-14005. 
 
In the first paper we report the novel interaction between human c-Myb and the chromatin 
remodelling factor Mi-2. We identified Mi-2 as an interaction partner for human c-Myb 
in a yeast two-hybrid screening where we used full-length c-Myb as bait. This screening 
was performed in a mixed cDNA library [81]. The main interacting domains in c-Myb and 
Mi-2 were mapped to the N-terminal region of Mi-2 and the DNA-binding domain of c-
Myb using GST pull-down, with a weaker contact also detected between the FAETL 
domain of c-Myb and the C-terminal region of Mi-2. The interaction was also confirmed 
with co-immunoprecipitation and in a more functional context by mammalian two-hybrid.   
Mi-2/CHD3 and the highly related Mi-2/CHD4 belong to the CHD (chromo-
helicase-DNA binding) protein family [370]. Mi-2 and - are reported to be integral 
components of the NuRD (nucleosome remodelling and histone deacetylase) co-repressor 
complex, responsible for its chromatin remodelling activity [367]. We were therefore 
surprised when functional analyses revealed that Mi-2 enhanced c-Myb dependent reporter 
activation. This was not due to any transient transfection artefact, since Mi-2 had no effect 
on the reporter gene expression when transfected alone and had no effect on the c-Myb 
expression or stability. Furthermore, a clear co-activating function of Mi-2 was also 
observed when monitoring the gene expression from the fully chromatinized target gene 
mim-1 in HD11 cells. Consistently, knock-down of endogenous Mi-2 in c-Myb-expressing 
K562 cells led to down-regulation of the c-Myb target genes NMU and ADA. In addition, 
the Myb-Mi-2 transactivational co-operation was clearly potentiated by desumoylation of 
c-Myb, as well as co-transfection with p300.  
Finally, when wild-type and helicase-dead Mi-2were compared, the Myb-Mi-2 
co-activation appeared to be independent of Mi-2's ATPase/DNA helicase activity. The 
rationale for the unexpected co-activator function seems to lie in a dual function of Mi-
2by which this factor is able to repress transcription in a helicase-dependent, and activate 
in a helicase-independent fashion, as revealed by Gal4 tethering experiments.  
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3.2 PAPER II 
Alm-Kristiansen AH, Sæther T, Matre V, Gilfillan S, Dahle Ø, Gabrielsen OS. (2008) 
FLASH acts as a co-activator of the transcription factor c-Myb and localizes to active RNA 
polymerase II foci. Oncogene, accepted. 
 
One of the other novel interaction partners for human c-Myb found in the yeast two-hybrid 
screening was FLASH. FLASH/CASP8AP2 was first identified as a component of the Fas-
caspase-8 apoptotic pathway [368], but later reports have concluded that the main functions 
of FLASH are nuclear [371, 372]. Interestingly, a large siRNA screening in HeLa cells 
identified FLASH as one of 37 gene products essential for cell division [369]. 
We show that FLASH, like Mi-2 interacts with the DNA-binding domain of c-
Myb, and enhances c-Myb-dependent reporter activity as well as expression of endogenous 
c-Myb target genes. Interestingly, the FLASH-induced enhancement of c-Myb activity was 
comparable to the increase seen with the well-established c-Myb co-activator p300. 
Moreover, FLASH was demonstrated to bind AMV v-Myb, and to co-activate together with 
this leukemogenic version of c-Myb. siRNA knockdown of FLASH resulted in a reduction 
of the expression of the MYC and ADA genes, earlier shown to be bona fide c-Myb target 
genes [144, 204, 226]. This finding was strengthed by chromatin immunoprecipitation assay 
demonstrating that FLASH and c-Myb both associate with the MYC upstream promoter 
region, as well as with the intronic enhancer of ADA.  Furthermore, Gal4 tethering assays 
revealed that the co-activator effect is mediated through the C-terminal part of FLASH, 
which both binds c-Myb and contains a functional activation domain.  
Through immunofluorescence experiments we found FLASH to be localized in 
discrete nuclear speckles in several cell lines. Interestingly, these specles were highly co-
localized with c-Myb in active RNA polymerase II foci. Altogether, these results suggest a 
novel molecular mechanism for regulation of c-Myb activity. We propose that c-Myb 
cooperates with FLASH in foci associated with active RNA polymerase II, leading to 
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3.3 PAPER III 
Molværsmyr AK, Sæther T, Lorenzo PI, Kvaløy H, Matre V, Gabrielsen OS. (2007) 
SUMO-conjugation of the transcription factor c-Myb controls cooperative behaviour and 
induces an activator-to-repressor switch in the negative regulatory domain. Manuscript. 
 
We and others have earlier shown that c-Myb is sumoylated both by SUMO-1 [81, 82] and 
SUMO-2/3 [83] at lysines K503 and K527 in human c-Myb. Conjugation of both SUMO-
isoforms to c-Myb lowers the transactivational potential of the transcription factor. Given 
the role of SUMO as a disruptor of synergy between other transcription factors [347, 350], 
we reasoned that studying its function in synergy control of c-Myb might lead to a better 
understanding of the mechanisms by which SUMO controls c-Myb action.  
Systematic analysis of this type of behaviour required a dedicated set of reporter 
constructs with defined changes in the multiplicity of response elements. Hence we 
constructed a set of reporter plasmids with identical core promoters (from MYC P2), 
activated by one to five copies of an optimal Myb response elements (from mim-1). Using 
these reporters we were able to show that c-Myb is subject to a strong synergy control 
which is tightly linked to its level of SUMO-conjugation.  In order to be able to quantify the 
difference in synergistic behaviour between different SUMO-related mutants of c-Myb, we 
defined a relative “synergy factor” (SF). By employing this factor we showed that wild type 
c-Myb in fact display “negative synergy” (SF~0.25) while the SUMO-negative c-Myb 2KR 
show a strong “positive synergy” (SF~4). Furthermore, synergy control is clearly abolished 
in v-Myb which produced the highest SF in this study (SF=4.8).  
Based on the multiplicity of response elements and complexity of gene promoters, 
we expected the SUMO-governed synergy control to be promoter-specific. This was indeed 
the case, and we show that chromatin embedded target genes of c-Myb in hematopoietic 
cells respond differentially to SUMO-control. Finally, we show that SUMO affects the 
transactivation properties of the factor by switching off a heretofore unrecognized activation 
function in its negative regulatory domain. This contributes to the amplitude of activation 
and might explain the increase in synergy seen when removing the SUMO moieties by 
mutation or proteases. We propose a dual role for sumoylation of c-Myb in controlling both 
the transactivation properties and the synergy behaviour, ensuring a considerable dynamic 
regulation of c-Myb activity. 
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3.4 PAPER IV 
Sæther T, Alm-Kristiansen AH, Troye Pettersen LK, Gabrielsen OS. (2007) A functional 
SUMO-binding motif in the transactivation domain of c-myb regulates its activity. 
Manuscript. 
 
In the last paper we report a different kind of c-Myb-SUMO contact, namely the non-
covalent binding of SUMO to c-Myb. We recently came to realize that loss of SUMO-
conjugation sites is not the only oncogenic alteration in v-Myb that may relate to SUMO. 
Based on reports of a consensus SUMO-binding motif (SBM; aaa-V/I-V/I-X-V/I/L and V/I-
X-V/I-V/I-aaa) [273, 274, 276], we analysed the c-Myb sequence and found that it contains 
two putative SBMs; one in the R2 repeat in the DNA-binding domain (termed SBM1), and 
one in the N-terminal end of the transactivation domain (termed SBM2). Remarkably, both 
sites are mutated in v-Myb.  
GST pull-down and effector-reporter assays showed that SBM2 in the 
transactivation domain of c-Myb (V267NIV) is functional. This motif can interact non-
covalently with SUMO, and preferentially bind SUMO-2/3. Furthermore, when we mutated 
this motif and destroyed the SUMO-binding properties, a large increase in c-Myb 
transactivational activity was observed. Through different functional assays we show that 
this increase in activity was not due to impaired SUMO-conjugation, lost synergy control  or 
intramolecular interactions being broken, but rather due to lost interactions in trans. Using 
confocal imaging of PML and wild-type or SUMO-binding mutants of c-Myb we show that 
c-Myb is recruited to PML nuclear bodies (PML-NBs) in a SUMO contact-independent 
manner. The c-Myb SBM mutant (A267NAA), as well as the sumoylation-negative mutant 
(2KR) and the double mutant (ANAA 2KR), associates with the PML-NBs to the same 
extent as does c-Myb wild-type. Interestingly, the SUMO-independent recruitment of c-
Myb to PML-NBs did not correlate with functional data showing that c-Myb wild-type is 
activated by ectopic PML expression, while the SBM mutant and the sumoylation-negative 
mutant has lost some of this potential. Moreover, the double ANAA 2KR mutant is close to 
unresponsive with regard to PML-dependent activation.  
Based on these findings we hypothesize that c-Myb can be relived from negatively 
acting sumoylated and SUMO-binding factors through their sequestering in PML-NBs, and 




Transcription factor activity may be regulated in many ways; through dosage, i.e. through 
modulating the expression of the transcription factor, through posttranslational 
modifications of the factor, or through interactions with other proteins. This thesis has 
focused on two such mechanisms that regulate the activity of the proto-oncoprotein c-Myb; 
interaction with co-factors and posttranslational modification. Protein interactions and 
posttranslational modifications are often interlinked processes, and PAPER IV in the thesis 
may actually serve as an example of this. Here, a small motif able to bind the small 
ubiquitin-related modifier SUMO is identified in c-Myb. Nevertheless, I have chosen first to 
discuss the co-factor link, where the two novel c-Myb-interacting proteins Mi-2 and 
FLASH will be treated. Thereafter, I will shift focus to c-Myb and SUMO, where the 
mechanisms SUMO-conjugation, synergy control and SUMO-binding will be compared and 
discussed.  
 
4.1 CO-ACTIVATORS OF c-MYB – PROCESSES AND PLAYERS  
Several proteins have been reported to interact with different subdomains of c-Myb and 
influence its activity (see introduction; Tab 1). For some of these proteins the mechanism of 
co-regulation has been studied in great detail, C/EBP and CBP/p300 being two examples. 
Yet for others, the mechanisms are still not clear. In PAPER I and II in this thesis we report 
Mi-2 or CHD3, belonging to the chromo-helicase-DNA binding protein family, and 
FLASH, a gene product essential for cell division, as novel interacting partners for c-Myb. 
Both of these proteins function as co-activators in a c-Myb context. Through functional 
assays we have partly uncovered the mechanisms responsible for these effects. However, 
many questions still remain to be answered.  
 The co-activator principle was first coined in 1990 by Pugh and Tjian, working on 
the transcription factor Sp1 in reconstitution reactions [373]. Sp1 was shown to be unable to 
stimulate transcription at TATA-containing promoters, using purified, cloned Drosophila or 
yeast TFIID. However, in the presence of semi-purified TFIID fractions from either human 
or Drosophila cells, this became possible [373], indicating that some unknown proteins were 
able to function as molecular adaptors between transcription factors and the general 
transcription initiation machinery. With the understanding of non-DNA-binding nuclear 




was added to the field of transcription. Today, co-activators are thought to exert their 
function either through bridging of upstream transcription factors and the pre-initiation 
complex, or through the recruitment of chromatin remodelling or modification enzymes. In 
general these two mechanisms of actions might not be so different, depending on whether 
one includes indirect interactions or not. Many co-activators either have intrinsic chromatin 
remodelling or modification activity, or they recruit such enzymes to chromatin. Hence, 
modulation of chromatin dynamics is recognized as a fundamental way to regulate gene 
expression [12-14].  
 
4.1.1 Remodelling the remodeller - from NuRD to PHD 
When we identified Mi-2 as a c-Myb interacting protein (PAPER I) we expected it to exert 
its function as part of the NuRD (Nucleosome remodelling and histone deacetylase) 
complex, which possesses both chromatin remodelling and histone deacetylase activity and 
is involved in repression of gene expression [367]. Still, we found it somewhat puzzling that 
the transcriptional activator c-Myb might be involved in gene repression. Nevertheless, c-
Myb has been hypothesized to participate in establishing chromatin patterns specific for 
hematopoietic genes, due to its role as an early hematopoietic transcription factor [374]. 
This could potentially be achieved through promotion of a restricted chromatin state, 
leading to gene silencing. Yet, when we co-transfected c-Myb and Mi-2 we saw the 
opposite. Mi-2 had a co-activating effect on Myb-dependent transactivation (PAPER I). 
These data were verified on several reporters and shown to be valid also for the fully 
chromatinized c-Myb target gene mim-1. The simplest explanation for this would be that 
overexpression of Mi-2 created a dominant negative effect, by titrating out other 
components of the NuRD complex. However, we were able to show under more 
physiological conditions, that knock-down of endogenous CHD3 (Mi-2) in c-Myb 
expressing K562 cells down-regulated the expression of the bona fide c-Myb target genes 
NMU and ADA [196, 204, 226]. Removing the factor that potentially might be targeting the 
NuRD co-repressor complex to c-Myb actually lowered the expression from these 
promoters. In line with this, co-immunoprecipitation experiments using antibodies to 
precipitate NuRD subunits such as HDAC1, RbAp46 and MTA2 both in transfected cells 
and with endogenous factors only detected very weak interactions with c-Myb.  
The evidences regarding the composition of the NuRD complex are conflicting [367]. 




consensus NuRD complex consists of HDAC1 and -2, RbAp46 and -48, Mi-2 and/or - 
[375-377], one or more MTA proteins (MTA1, -2 or -3, or splice variants of these) [378], 
MBD2 or MBD3 [379], and often p66 and/or - [380]. Furthermore, the finding of a 
tripartite HEB:Mi-2:p300 complex that is able to bind to the CD4 enhancer region in T 
cells, increase histone H3 acetylation and enhance CD4 gene transcription [381], implies 
that the helicase partners in the NuRD complex might be involved in gene activation. 
p300/CBP is a well established c-Myb co-activator [78, 79, 382], and we could show that  
p300 potentiated the Myb-Mi-2 transactivational co-operation. Nevertheless, we were not 
able to detect any physical interaction between p300 and Mi-2 or c-Myb:Mi-2. Hence we 
were left with the possibility that the co-activation function of Mi-2 was coupled to its 
helicase activity. 
To our big surprise, destroying the ATPase/helicase activity by mutations did not 
eliminate Mi-2’s ability to co-activate together with c-Myb. However, when fused to 
Gal4p DBD and tethered directly to two Gal4p-responsive promoters, only the helicase-
dead mutant activated the reporter. The wild-type on the other hand repressed the reporter. 
Finally, we were able to show that the activation domain of Mi-2 seemed to reside within 
its N-terminal domain, the same domain binding to c-Myb. Thus, Mi-2 seems to harbour a 
dual function, where it is able repress transcription in a helicase-dependent and activate in a 
helicase-independent fashion. 
The functional role of the helicase activity of Mi-2 in the HEB:Mi-2:p300 
complex was not addressed by Williams and co-workers in their work on Mi-2-dependent 
activation of CD4 gene transcription [381]. It is, however, possible that also Mi-2which is 
highly homologues to Mi-2, activate the transcription of CD4 in a helicase-independent 
manner. Still, these are only speculations. Independently, in a c-Myb context Mi-2 may 
function as a classical co-activator by bridging c-Myb to other transcription-related factors. 
Which protein(s) this might be is still an open question, but the link to histone H3 is 
intriguing (Fig 17A). In 2005, the Leutz group demonstrated a SANT function for c-Myb 
[54]. The DBD/SANT of c-Myb binds to the N-terminal tail of histone H3 between amino 
acid residues 27-42 and facilitates acetylation of H3 lysines. This leads to gene activation of 
mim-1 in HD11 cells. [54]. Mi-2 is also able to bind histone H3, and has the properties of a 
histone-code reader [383]. Particularly interesting is the fact that the Mi-2PHD (Plant 
homeodomain) associates with exactly the same tail-region of histone H3 as the DBD of c-




PHD fingers, that interacts with c-Myb DBD. Hence, Mi-2 and c-Myb might meet on 
chromatin, thus strengthening the concept of c-Myb as a SANT factor (Fig 17A). 
To date, no modification-specific histone-binding has been observed for c-Myb 
SANT. In contrast, the first of Mi-2’s two PHD fingers, residing in the N-terminal region, 
show specific binding to H3 K36me3 [383]. Methylated H3K36 is found enriched in active 
chromatin where K36me3 generally accumulates toward the 3 region of transcribed genes 
[384]. Theoretically, the Mi-2 PHD might augment the specificity of the c-Myb histone-
binding: By binding to c-Myb, Mi-2 may bridge this transcription factor to a specific 
activation mark on histones. Hence it would be interesting to study how c-Myb and Mi-2 
cooperate at the chromatin level. Several questions seem relevant: Is Mi-2 stabilizing or 
destabilizing the c-Myb:histone interaction? Is Mi-2 able to bind both c-Myb and histone 
H3 at the same time, or is Mi-2 bridging c-Myb with adjacent histones? Is c-Myb capable 
of binding histone H3 and DNA at the same time or are these mutually exclusive events? 
And finally, do the interactions outlined in Figure 17 happen simultaneously or sequentially? 





Figure 17 A Myb-meeting for 
the future. A Mi-2 and c-Myb 
both binds histone H3 in the 
same region of the N-terminal 
tail (amino acid residues 27-
42). At the same time the N-
terminal domain of Mi-2 
interacts with c-Myb DBD. A 
second, much weaker 
interaction is seen between the 
C-terminal region of Mi-2 and 
c-Myb. The numbered red dots 
refer to the papers within which 
these interactions have been 
described. B Cooperative 
binding of PTMs on a single 
(cis) or two different (trans) 
histone tails. When more than 
one discrete binding contact is 
made the specificity is thought 
to increase. Most of these 
crucial interactions are 
envisioned as modification-
dependent. Modified from illu-





been shown to occur in a highly ordered fashion, where one promote the next [386, 387]. 
Furthermore, as evident from studies of several histone-code reading modules like PHD, 
Bromo, Chromo and Tudor, a given combination of modifications might facilitate binding 
of one factor and at the same time exclude others (reviewed in [385]; Fig 17B).  
The histone-code reader functions of Mi-2 might be essential for co-activation of c-
Myb. If so, simultaneous binding of DBD and histones could bring c-Myb in contact with 
more distal genomic elements. Through Mi-2-facilitated looping of chromatin, c-Myb 
might be positioned in the vicinity of other transcription factors which otherwise would be 
beyond reach, favouring synergistic gene activation. In this context it is interestingly to 
notice that Mi-2 seemed to activate better on natural promoters TRHR, RAG-2 and mim-1 
(PAPER I) than on synthetic promoters with multiple, 10 bp-spaced MREs (data not shown). 
This may indicate that when an array of c-Myb proteins is binding to the promoter, the 240 
kDa Mi-2 is prevented from interacting with DBD. Alternatively, it may allude to the fact 
that Mi-2 mainly plays a role in bridging c-Myb with other (more distal) factors, and that 
this potential already is unleashed when multiple c-Myb-species are bond at close proximity. 
In view of c-Myb as one of two piers in a transcriptional bridge, where Mi-2 is the 
bridge section, a study on Mi-2 might give a hint towards another pier candidate. Shimono 
and co-workers have shown that BRG1, a SWI/SNF component, interacts with the N-
terminal domain of Mi-2 in a co-activating fashion [388]. This corresponds to the domain 
in Mi-2 that shows the highest affinity for c-Myb, and in fact, this domain alone was 
enough to enhance the dependent reporter activation to a level comparable to that of full-
length Mi-2 (PAPER I). All in all, the results from our study, combined with previous 
reports on the co-activating functions of Mi-2 suggest that the concept of Mi-2 proteins 
being only the helicase components of a single repressive NuRD complex is too simplistic. 
 
4.1.2 Activated by a FLASH 
The second novel interaction partner of c-Myb described in this thesis is FLASH (FLICE 
associated huge; PAPER II) also known as CASP8AP2 (caspase 8 associated protein 2). In 
contrast to Mi-2 and c-Myb which both are known to be nuclear factors, FLASH was 
originally described as being cytoplasmic [368]. This suggested that the interaction between 
FLASH and c-Myb might be an artefact stemming from the yeast two-hybrid screening, 
where proteins of all subcellular localization are allowed to meet in the nucleus. In the first 




(but not shown to be) located mainly in the cytoplasm [368]. However, in another paper 
endogenous FLASH was found to be able to shuttle to the nucleus upon TNF-stimulation 
[389]. The FLASH protein harbours two putative nuclear localization signals (NLS) and one 
putative nuclear export signal [368]. Hence, the subcellular localization of this protein was 
not obvious. Therefore, we carefully studied the distribution of FLASH using both imaging 
techniques and subcellular fractionation in combination with western blotting. In all our 
experiments, we found FLASH to be localized in nucleus. Since the same patterns were 
seen when using antibodies against both the N- and C-terminal parts of FLASH, the entire 
protein must be found in the nucleus. Finally, during this work two other groups published 
evidence supporting a nuclear function for FLASH [371, 372], allowing us to continue the 
work on the c-Myb-FLASH connection. 
 Like Mi-2, FLASH co-activates together with c-Myb. This was shown using 
transient transfections in combination with effector-reporter assays as well as by monitoring 
the expression of the resident mim-1 gene in the chicken macrophage cell line HD11. 
Furthermore, knockdown of endogenous FLASH in K562 cells resulted in down-regulated 
MYC and ADA gene expression, previously shown to be responding the same way by MYB 
knock-down [226]. Moreover, through chromatin immunoprecipitation assay, we showed 
that both c-Myb and FLASH were associated with the MYC upstream promoter region as 
well as the intronic enhancer of ADA. Using Gal4 tethering assays we located a 
transactivation function in the C-terminal region of the protein, the same domain that 
interacts with c-Myb. Similar to Mi-2, FLASH interacts with the DNA-binding domain of 
c-Myb (PAPER II). Interestingly, FLASH seems to harbour a SANT-like domain in this part 
of the protein. If functional, the SANT domain may further link FLASH to chromatin and 
nuclear functions. 
Using immunofluorescence and confocal laser scanning microscopy we observed 
that both transfected and endogenous FLASH localized in nuclear speckles in several cell 
lines, with only a weak diffuse distribution in the nucleoplasm and cytoplasm (Fig 18; 
PAPER II). c-Myb was found to be co-localized with these foci, and upon co-transfection 
with FLASH observed in punctual structures in close to 100% of the c-Myb positive cells. 
The FLASH foci were demonstrated to be partly co-localized with PML nuclear bodies 
(PML-NBs; described in chapter 1.3.2.3) and Cajal bodies (CB). The CBs have been 
implicated in replication-dependent histone gene transcription and mRNA maturation, and 
assembly of the three eukaryotic RNA polymerases (pol I, pol II, and pol III) with their 




localized to these structures, we believe that the FLASH proteins form distinct “FLASH 
bodies” located in close association with both PML-NBs and CBs (PAPER II). 
 Interestingly, the nuclear protein that FLASH most often seemed to be co-localized 
with is active RNA polymerase II. Using antibodies towards RNA pol II, phosphorylated at 
Ser5 in the carboxy-terminal domain, we were able to show that both c-Myb and FLASH 
co-localized to the same active RNA polymerase II foci. These results imply a novel 
molecular mechanism of regulation of c-Myb activity. When adapting these data to a 
classical co-activator view, FLASH might be a factor able to bridge c-Myb with the general 
transcription machinery. As evident from PAPER II, we do not have any evidence for a 
direct c-Myb-FLASH-RNA pol II interaction. However, we propose that c-Myb cooperates 
with FLASH in foci associated with active RNA polymerase II, leading to enhancement of 
Myb-dependent gene activation. 
 
4.1.3 A friend in common does not imply contact 
Transcription factors typically exert their function in larger protein complexes. However, 
with a few exceptions, multimeric complexes have so far not been described in greater detail 
for c-Myb. Having reported two novel co-activators for c-Myb, both binding to c-Myb DBD, 
we were inspired to do some simple follow-up experiments aiming at disclosing any 
potential of mutual cooperation. Furthermore, since c-Myb and Mi-2 have, and FLASH 
might have an inherent affinity for histones, this could potentially strengthen the c-Myb 
chromatin link. Given a tripartite cooperation on c-Myb-responsive promoters, we expected 
no less than an additive effect on the reporter output when the three factors where co-
transfected. However, when calculating the fold-contribution of e.g. FLASH to the reporter 
activation in c-Myb/Mi-2/FLASH-transfected cells, this was exactly what we got (data not 
shown). Hence, Mi-2 and FLASH do not seem to potentiate each other in Myb-dependent 
gene expression.  
When examining the data form PAPER I and II this might be plausible. After all, 
knock-down of CHD3 (Mi-2) had an effect on ADA and NMU, but not MYC, while 
FLASH knock-down affected MYC and ADA, but not NMU. It is obvious that the c-Myb co-
activators identified in these studies have some kind of target gene preference, either 
autonomously or when bound to c-Myb. Target gene specificity based on posttranslational 
modification and repertoire of interacting co-activators or promoter-bound sequence-




latent promiscuity of c-Myb:DNA interaction this would be an obvious level to increase 
specificity. 
The nuclear distribution of the three proteins in question also indicate that c-Myb, 
FLASH and Mi-2 at best only physically interact in a small fraction of cellular time-space 
(Fig 18). Interestingly, the nuclear staining of c-Myb represents a combination of punctual 
structures and even distribution, resembling the pattern of FLASH and Mi-2, respectively. 
FLASH and c-Myb co-localize in the FLASH-foci (PAPER II), while the co-localization of 
c-Myb and Mi-2 is more difficult deduce, due to the even distribution of Mi-2 (PAPER I). 
Still, the bipartite nuclear pattern of c-Myb indicates multiple roles for this protein, which 





   
 Figure 18 A friend in common does not imply contact. Cellular 
staining of FLASH (blue), c-Myb (green) and Mi-2 (red). The 
cells depicted show a distribution pattern representative for the 
three proteins. The panels display six different cells, all transfected 
with equal amounts of the relevant expression plasmids. 
 
 
FLASH and Mi-2 have a diverging nuclear distribution. Nevertheless, only ChIP or 
better re-ChIP assays on multiple c-Myb target gene promoters will determine whether 
FLASH and Mi-2co-interact with c-Myb in Myb-dependent transcription. This also 
applies to other known c-Myb co-factors or cooperating transcription factors. We show in 
PAPER I that Mi-2 enhances c-Myb-p300 transactivational activity. Still, we were not able 
to detect any direct or indirect physical contact between p300 and Mi-2. Furthermore, the 
co-activator ability of FLASH resembles p300 (PAPER II), but their co-activation and 
interaction was not addressed. It is however possible that p300 and Mi-2 or FLASH 
cooperate on c-Myb responsive promoters without physically interacting. Other proteins 




reported to interact with c-Myb DBD, e.g. p100 and C/EBP. A large number of proteins 
have been reported to bind to this part of c-Myb, hence it would be interesting to examine 
whether some of these interactions are excluded or facilitated by FLASH and/or Mi-2. 
Since both FLASH and Mi-2 interacts with c-Myb DBD and co-activates transcription, 
DBD-binding co-repressors like c-Maf, MafB, RAR, Cyclin D1/D2, c-Ski and Cyp40 
would be candidates for mutually exclusive interacting proteins (Table 1; chapter 1.2.3.1). 
For the reported co-activators/transcription factors interacting with DBD several options are 
conceivable.   
 
 
Figure 19 The FLASH-body - a 
transcription factory? In this model, 
genes extend out of their “chromosome 
territories” to access a shared 
transcription factory. Clustered RNA 
polymerase II motor proteins (red 
spheres w/cog wheels) organize genes 
and distal regulatory elements. Rather 
than the polymerase sliding along 
chromatin, chromatin moves through 
the factory that is powered by the 
energy released during synthesis of 
RNA (green). Could FLASH (blue halo) 
be a part of such factories? Modified 
from image in [391]. 
 
4.1.4 The FLASH-body - a transcription factory? 
An intriguing aspect of our report on FLASH and c-Myb is the set of data showing that both 
c-Myb and FLASH co-localize to active RNA polymerase II foci (PAPER II). Moreover, 
when counting FLASH-positive foci as much as 75 % of these were co-localized with active 
RNA polymerase II. This suggests that these subnuclear bodies are sites of active 
transcription where all three proteins operate together to enhance gene activation. In the last 
years, the links between active transcription and nuclear structure have been strengthened 
[391]. When looking at active RNA polymerase II foci in the cell, the number of these can 
not account for the number of genes being transcribed. This has led to the prediction that 
more than one active gene is transcribed in each RNA pol II foci, which have been termed 
transcription factories [392, 393]. Furthermore, recent results show that actively 
transcribed genes that are separated by up to 40 Mb of chromosomal sequence frequently 




explain the fact that locus control regions or distal enhancers located several kb away from 
the transcription start site still regulate transcription and engage in specific higher-order, 
‘loop’ structures. The question then becomes if FLASH is part of these factories, and 
furthermore which role it plays in recruiting sequence-specific transcription factors to these 
nuclear units.  With the finding of FLASH in CBs, the latter being implicated in assembly of 
the RNA polymerases [371], and our finding of a highly frequent co-localization between 
FLASH and active RNA pol II (PAPER II), we think that the transcription factory model 
may become particular relevant for future FLASH research. With the novel finding of c-
Myb target genes residing in close proximity to origins of replication [185, 186, 189], it is 
interesting to notice that the transcription factory model also embrace replication and 
replication factories [391]. Despite being separate entities, relocation to or from 
transcription or replication factories would favour early replication and transcription in the 
same chromosomal area. 
 
4.1.5 Essential gene products and co-activation of cancer 
Although it has been known for some time that c-Myb is a gene product essential for the 
hematopoiesis [160, 164] and that AMV and E26 v-Myb cause leukemia in chicken 
(reviewed in [16]), the links to human cancers of the blood was for a long time obscure. 
However, the identification of recurrent genomic aberrations involving the MYB locus in T 
cell acute lymphoblastic leukemia (T-ALL) emphasized that c-Myb may play a role in the 
development of human leukemic disorders [242-244]. A common theme in both chicken and 
human leukemias involving c-myb/MYB anomalies is that the overall Myb-activity seems to 
be increased: I: The v-Myb proteins are stronger activators than c-Myb when tested on 
standard Myb-responsive reporters [16, 42]. II: In T-ALL the translocation, 
t(6;7)(q23;q32~36) places MYB in the vicinity of the T cell receptor B promoter, leading to 
significantly higher expressional levels of MYB than in other T-ALL patients [243], while 
III: local duplication of the MYB gene has the same effect [243, 244]. According to AM. 
Gewirtz, most human leukemias analyzed in his lab at the University of Pennsylvania show 
over-expression of c-Myb (AM. Gewirtz, 4th MYB workshop, Italy, 2007) 
 Given that increased c-Myb levels, hence activity, might be involved in the 
transformation of hematopoietic cells, one may expect that other perturbations resulting in 
increased Myb action will have the same effect. When reasoning along these lines, one type 
of candidate involved in inducing c-Myb transactivational activity is co-factors. 




neoplasias. Mi-2 was first identified as an autoantigen in the human connective tissue 
disease, dermatomyositis [394, 395]. The underlying mechanism for this is not known. Still 
several clinical studies have linked dermatomyositis as an external marker and an early 
manifestation of different forms of leukemia [396-399].  
FLASH has been found to be a promising prognostic marker in childhood acute 
lymphoblastic leukemia (ALL; [400]). In a cohort of 99 patients, low levels of FLASH 
expression predicted a lower event-free survival after chemotherapy and a higher rate of 
leukemia relapse, while high levels were associated with a greater tendency of leukemic 
lymphoblasts to undergo apoptosis. As mentioned earlier, FLASH was originally thought to 
be exclusively cytoplasmic [368]. However recent research (ours included) has shown that 
FLASH indeed has a nuclear function [371, 372, 401]. Nevertheless, FLASH can shuttle to 
the cytoplasm upon the activation of the death receptor CD95 [372]. Here it associates with 
mitochondrial caspase-8 and promote apoptosis. Regarding the clinical trial where high 
levels of FLASH were shown to be beneficial for chemotherapy treatment in an apoptosis-
dependent manner, it is most likely that this is linked to the cytoplasmic functions of 
FLASH. Recently, FLASH was found to be mutated in gastric adenocarcinomas [402]. 
Earlier, FLASH has also found to be mutated in DNA mismatch repair (MMR) defective 
colorectal cancer cell lines [403]. This was however not correlated to any biological feature 
of these cell lines. Thus, it is still an open question as to how the FLASH mutations 
contribute to the pathogenesis of these neoplasms. With the risk of overrating the 
significance of these reports, it is intriguing that FLASH function and/or deregulation has 
been linked to cancers of both blood and colon – two tissues in which c-Myb aberrations 
have been shown to be associated with cancer [8, 132, 133]. 
Finally, FLASH has also been identified as one of 37 gene product essential for cell 
division, based on the observation that FLASH mRNA knockdown caused the cells to die 
upon entry into mitosis [369]. These observations seem to contradict the notion that FLASH 
is involved in promoting apoptosis. However, this might once again highlight the multiple 
functions of this protein. Through its association with the Cajal bodies FLASH is directly 
involved in cell cycle maintenance [371]. The Cajal bodies have been shown to be essential 
for S-phase progression due to their close association with histone gene clusters, and 
FLASH have been demonstrated to positively regulate the expression of histone genes [401]. 
Hence, it is likely that it is the nuclear functions of FLASH that are indispensable for cell 
division. Even though c-Myb does not seem to be involved in the transcription of 




unpublished results), it would be interesting to assess whether FLASH affects the activation 
of other histone genes, like H2A.Z reported to be a c-Myb target [199].  
 
4.2 SUMO CONJUGATION AND BINDING - INTERPLAY OR TWO PROCESSES?  
Through the last decade, studies within the field of SUMO (Small Ubiquitin-like modifier) 
have continuously revealed new and fascinating roles for this small nuclear peptide, and the 
number of targeted proteins is constantly growing [404]. We and others have shown that c-
Myb is sumoylated both by SUMO-1 [81, 82] and SUMO-2/3 [83] at lysines K503 and 
K527 (human c-Myb numbering). The conjugation of both SUMO-isoforms to c-Myb 
lowers the transactivational potential of the transcription factor [81-83]. Even though 
sumoylation of c-Myb is established, the mechanistic explanation of how SUMO controls c-
Myb action is still lacking.  Given the role of SUMO as a disruptor of synergy between 
other transcription factors [347, 350], we reasoned that examining whether this function also 
operates on c-Myb might lead to a better understanding of SUMO and sumoylation in c-
Myb biology (PAPER III).  
In addition to suppressing the activity or synergistic potential of transcription factors, 
covalent conjugation of SUMO has been shown to alter the localization and interaction 
repertoire, or increase the stability of nuclear factors [253, 254, 258, 259]. The common 
assumption has for a long time been that most effects of SUMO have to be mediated 
through protein interactions. Therefore, the recent advances with regard to non-covalent 
binding of SUMO, and the identification of protein motifs responsible for such interactions 
has reinforced the framework within which SUMO-biology is interpreted (reviewed in 
[261]). This led us to address whether non-covalent SUMO binding also is an intrinsic 
function in c-Myb (PAPER IV). 
 
4.2.1 SUMO-conjugation of c-Myb: wrestling with synergy 
In PAPER III we show that c-Myb is indeed subject to strong SUMO-governed synergy 
control (SC). Systematic analysis of this type of behaviour required a dedicated set of 
reporter constructs with defined changes in the multiplicity of response elements. Using 
such reporters we were able to show that c-Myb wild-type activated the different reporters 
only with minor differences, while the SUMO-conjugation deficient 2KR mutant displayed 
a dramatic increase in activation with increasing amounts of MREs (PAPER III; Fig 22). 
Calculating the synergy factor (SF=RLU4×MRE/4×RLU1×MRE) showed that while c-Myb 




“positive synergy” with an SF = 3.9. Further experiments using a battery of mutants 
interfering with sumoylation of c-Myb in different ways and overexpression of the SUMO-
protease, SENP1, allowed us to conclude that the SC of c-Myb is highly dependent on the 
sumoylation status. 
 Synergy between transcription factors operating together on complex promoters is a 
well-known phenomenon. However, the link between control of the synergistic properties of 
a transcription factor and its ability to be sumoylated, was first observed in studies of the 
glucocorticoid receptor (GR; [347, 348]). Later this was extended to other factors such as 
C/EBP, SF-1 and MITF [350, 405, 406]. As for c-Myb, the SC properties of all these 
transcription factors were studied on specially designed reporters harbouring multiple 
factor-specific response elements (REs).  It is, however, obvious that only a tiny fraction of 
natural promoters has such a set-up, with evenly spaced and identical REs. Thus for these 
findings to be relevant, SC must be a mechanism that is operating also on promoters 
responding to several different factors, given that some of them are sumoylated. 
Consequently, promoters that are not subject to SC probably also exist, due to the fact that 
they only respond to transcription factors that cannot be sumoylated, or because of 
alleviative distances in time or space between the activators or REs. We therefore reasoned 
that the fold-difference in activation of resident promoters between c-Myb wild-type and 
2KR ought to differ from gene to gene. When comparing the activation of the mim-1, 
lysozyme and pdcd4 gene in chicken HD11 cells we indeed observed a difference in SUMO-
controlled gene expression. For the mim-1 gene there was a 3.3-fold difference in activation 
between 2KR and wild-type, while the same ratio for the lysozyme and pdcd4 genes were 
1.2 and ~1, respectively. 
 The mim-1 gene is co-activated by c-Myb and members of the C/EBP family, and 
these have been shown to synergize [97]. More specifically, v-Myb134 (a v-Myb version 
with c-Myb back-mutations in DBD) and a C-terminally truncated c-Myb were able to 
synergize with C/EBP in activating the mim-1 gene, while c-Myb wild-type was not [97]. 
Interestingly, we now know that neither v-Myb134 nor the C-terminally truncated c-Myb is 
sumoylated, indicating that the ability of C/EBP and c-Myb to synergize on the mim-1 
promoter probably is highly SUMO-dependent. Even more interesting are observations from 
the same study showing that C/EBP and v-Myb134 are unable to synergize on the 
lysozyme promoter [97]. Our data echoes this finding, and indicates that the lack of 




separation of c-Myb and C/EBP and not from SUMO-governed synergy control. C/EBP 
as well as other members of the C/EBP family are covalently modified by SUMO [407]. 
Hence, also the sumoylation status of C/EBP might influence the synergistic output from 
the genes studied in PAPER III. Therefore it would be interesting to study the regulation of 
the same genes when co-expressing SUMO-negative C/EBP and c-Myb, alternatively 





   
 Figure 20 A model for a SUMO-dependent promoter-switch. SUMO-conjugation of 
multiple transcription factors create an array of closely spaced SUMO-molecules that 
either recruits negatively acting co-regulators or interferes with positively acting co-
activators, keeping the promoter more or less off (negative synergy). Removing this 
array allows the transcription factors to recruit positively acting co-regulators, and the 
promoter to be turned on to high levels (positive synergy). In this model removal of 
SUMO-conjugation is a prerequisite for activation of complex promoters. One way of 
achieving this would be through controlled recruitment of SUMO-proteases. TF: 
transcription factors, S: SUMO. 
 
 
In previous papers on SUMO-governed SC, most of the focus has been on how 
SUMO might effectuate this control [347, 350]. The idea has been that the SC can be 
achieved through the recruitment of negatively acting factors, or so-called synergy control 
factors (SCF) via multivalent binding to SUMO-moieties on adjacently bound regulators 
[350]. In the light of the recent identification of motifs for non-covalent SUMO-binding 
([273, 274, 276]; see chapter 1.3.3) this theory seems plausible. Moreover, several factors 




One example here are the HDACs, where HDAC6 has the highest number (=5). Importantly, 
we did not see any increase in synergy when treating the cells with the HDAC inhibitor 
trichostatin A (PAPER III), suggesting that the SC seen with c-Myb wild-type is not 
dependent on HDAC enzymatic activity. Furthermore, the existence of an SCF at best 
explains the negative synergy seen with sumoylated transcription factors (PAPER III).  
Potential SCFs will not account for the flipside of synergy control, namely positive synergy. 
Several models have been proposed to explain the more-than-additive activity of multiple 
activators, and these may still be applicable even when a layer of SUMO-control is added. 
Some of the key concepts suggested have been multiplicity of contacts to the basal 
transcription apparatus [408, 409] promoting assembly of the pre-initiation complex [410], 
physical interactions between transcription factors [411, 412], and co-activators harbouring 
distinct domains that interact simultaneously with different factors [413]. When trying to 
explain both positive and negative synergy, multiplicity is an important aspect. One way of 
incorporating this is to assume the recruitment of a multivalent co-repressor (e.g. an SCF), 
able to interact with arrays of SUMO-conjugated factors, and multivalent recruitment of co-
activators to the non-sumoylated array.  
Even thought the concept of synergy assumes cooperativity, it is however important 
to emphasize that this not necessarily implies concurrency, i.e. simultaneous contact 
between a given co-regulator and all the transcription factors in the promoter array. Using c-
Myb as an example, one might take into consideration that when increasing the number of 
promoter-bound species from one to two or three, this will double or triple the concentration 
of a given c-Myb interaction surface at the promoter, respectively. Thermodynamically 
however, this will result in a more than additive increase in activator-co-factor complex 
formation, although the co-factor might be bound to only one c-Myb species at a time. 
Nevertheless, it is interesting to notice that when changing the helical orientation of the 
bound Myb-species by increasing the MRE-spacing to 15 bp, the level of synergy control 
becomes more relaxed, while the level of positive synergy remains unaltered (PAPER III). 
This may reflect that different mechanisms of cooperation are responsible for restricting as 
compared to promoting synergy. More precisely, a synergy control factor might be more 
dependent on multiple SUMO-contacts for efficient binding than a synergy promoting factor 
is on concurrent binding of multiple TADs.   
As seen in Figure 20 we propose a model where SUMO-modified transcription 
factors create an array of SUMO-molecules that either recruits co-repressors or interferes 




synergy). Removing this array allows the transcription factors to recruit positively acting co-
regulators, and the promoter to be turned on to high levels (positive synergy). The removal 
of SUMO-conjugates then becomes a central step in the activation of complex promoters. 
We suggest that this can be achieved by SUMO-specific proteases, i.e. SENPs. Indeed we 
have shown that activation is possible when ectopically expressing SENP1 (PAPER III). It 
is noteworthy that in mammalian cells there are as much as seven different SUMO-proteases 
plus additional splice variants [289], as compared to only one or a few enzymes in each step 
of the conjugation reaction (see chapter 1.3.2.2). A directed and controlled recruitment of 
SUMO-proteases may therefore confer specificity to the activation switch process. 
 Having found that the synergy control is operating on c-Myb in a SUMO-dependent 
manner, we continued to dissect the mechanism. As mentioned HDACs did not seem to be 
involved in conveying synergy control in our system, since TSA treatment did not alter the 
synergy factor of wild-type c-Myb. Furthermore, conjugation of SUMO to c-Myb did not 
seem to have any influence on DNA-binding properties as evaluated by EMSA (PAPER III). 
We therefore chose to pursue the idea of a more intrinsic mechanism being involved in the 
switch from negative to positive synergy.  
Since the model proposed (Fig 20) imply that the SUMO-conjugated array may 
exclude or suppress a transactivating function, we asked whether SUMO conjugated to c-
Myb might have a more specific role in controlling the TAD functions of the factor. We 
started with addressing whether the region becoming sumoylated in c-Myb by itself might 
contribute to the transactivation properties of c-Myb in a SUMO-dependent manner. There 
have been a couple of reports in the past showing that this region may display 
transactivating activity in yeast [414, 415]. When we tested c-Myb NRD in Gal4 tethering 
assays, we observed a weak repressive effect as expected. However, when abrogating 
sumoylation by mutation or when co-transfecting with SENP1, NRD displayed a strong 
activating function (PAPER III). Furthermore, we showed that SUMO-negative full-length 
c-Myb was indeed more active than c-Myb with the NRD deleted, indicating that c-Myb 
2KR is operating with two TADs (Fig 21). Finally, the SUMO-switch TAD in NRD could 
in fact rescue c-Myb transactivation when the central TAD was deleted (PAPER III). We 
therefore conclude that one aspect of the increased synergy observed for desumoylated c-
Myb appears to be the derepression of the silenced transactivation domain in NRD (Fig 21). 
The NRD-TAD switch probably makes an important contribution to the large differences 




The presence of more than one activation function within a transcription factor is 
well known from the literature. The best studied examples might be the nuclear receptors 
which harbours two such functions AF1 and AF2, where AF1 activates in a ligand-
independent fashion, while AF2 is ligand-dependent. Interestingly both AR and GR are 
SUMO-modified on lysines residing in AF1 [416]. As already mentioned, for GR this has 
been shown to impose synergy control on compound promoters [347]. The sumoylation 
sites in SF-1 also partly localise to a putative AF1 domain [417], while C/EBP is 
sumoylated in the so-called “attenuator domain”, sandwiched by two distinct transactivation 
domains [350, 418]. Hence, SUMO-switchable TAD/AFs might be a common theme in 
transcription factors subjected to synergy control. With two functional TADs operating in 
the same protein, the possibility exists that these two domains can synergize with each other, 
also in c-Myb. I fact we have data pointing in that direction. c-Myb NRD which cannot be 
sumoylated, but at the same time lacks the NRD-TAD displays a SF that is significantly 
lower than full-length c-Myb 2KR (PAPER III). However, to really show that the two TADs 
in c-Myb synergize the c-Myb-T1-2KR, with the central TAD deleted, should also be 






   
 Figure 21 c-Myb has a second TAD in the NRD controlled by SUMO-
conjugation. When c-Myb is sumoylated the transcription factor is 
operating with one TAD only. Upon desumoylation the second TAD 
becomes activated and increase both the activity and the synergistic 






4.2.2 c-Myb binds SUMO: TAD contracts a repressive neighbour 
In the last paper in this thesis we show that c-Myb harbours a motif that binds SUMO non-
covalently, preferably SUMO-2 (PAPER IV). This motif (V267NIV) is located at the very N-
terminal border of the central transactivation domain. When destroying the SUMO-binding 
motif (SBM) by alanine substitutions (V267NIVA267NAA), SUMO-binding is abrogated 
and the transactivational activity of c-Myb increases (PAPER IV). Thus, c-Myb seems to be 
repressed by SUMO-interaction at this site, and becomes derepressed when SUMO-binding 
is lost.  
The initial mapping of the c-Myb transactivation domain was done employing Gal4 
tethering assay with various Myb deletion constructs. This mapping defined the minimal 
TAD to be positioned between amino acid 275 and 325 in mouse and chicken c-Myb ([42, 
55, 58]; same positions for human c-Myb). With the characterisation of the SBM (PAPER 
IV), we have identified a repressive determinant positioned right outside the minimal 
transactivation domain of c-Myb (amino acid residues 267-272). The c-Myb TAD is by far 
the domain in c-Myb that activates transcription most efficiently when fused to a 
heterologous DBD [58]. Still, we show that this ability can be even more enhanced by 
abrogating SUMO-binding (PAPER IV). The fact that a repressive motif like the c-Myb 
SBM is located head-to-tail with the transactivation domain is not unique. In fact several 
such examples may be found in the literature: In c-Myc an important repression element lies 
between the Myc-homology Box 1 (MB1) and Box 2 (MB2) TADs. In fact a second 
repression domain overlaps MB2 TAD itself (reviewed in [419]). Furthermore, the main 
transactivation domain AF1 in the androgen receptor harbours two sumoylation sites, which 
have been shown to repress ligand-dependent transactivation (reviewed in [420]). Likewise, 
having the possibility to tune the activity of the TAD through SUMO-binding undoubtedly 
adds dynamic to c-Myb-dependent gene activation.  
In the work on synergy control we identified a second TAD in c-Myb (PAPER III; 
see chapter 4.2.1). This is another example of an activation function in c-Myb suppressed by 
SUMO, but in this instance SUMO-conjugation. In both cases obstruction of co-factor 
interaction could be part of the functional explanation. However, in the case of the SBM the 
repressive effect seems to be uncoupled from steric hindrance of the histone acetyl 
transferase p300, binding to c-Myb between amino acid residues 295-309 [66, 98, 99]. p300 
co-activated TAD wild-type just as well as TAD ANAA when evaluated in Gal4 tethering 
assays (PAPER IV). Still, further experiments are needed to unravel the potential interplay 




 Having identified a functional SBM in c-Myb, which when mutated caused 
derepression, we expected SBM to operate through the binding of a negatively acting 
sumoylated protein; either a SUMO-modified co-repressor binding in trans, or sumoylated 
NRD, binding in cis. Before we concentrated on these two non-mutually exclusive 
mechanisms, we had to rule out the possibility that the SBM somehow was involved the c-
Myb SUMO-conjugation process. If so, abrogation of SUMO-binding might lower the 
sumoylation efficiency of c-Myb, and moreover, increase the transactivational activity. 
Western blot analyses of the different SBM mutants verified that the SUMO-binding 
negative ANAA mutant still was sumoylated (PAPER IV). In a more functional context we 
asked whether loss of SUMO-binding would affect the synergistic behaviour of c-Myb. By 
using the synergy reporters from PAPER III we could now get information relevant to 
identifying what mechanism is operating through the c-Myb SBM. Interestingly, calculation 
of the synergy factor showed that even though the A267NAA mutant had the same activity as 
2KR, its SF was well below 1.0, while the 2KR mutant had a SF ~ 4 (PAPER IV). 
As shown in PAPER III, all mutations that eliminate or lower the SUMO-
conjugation of c-Myb allow the protein to escape from the SC and to activate strongly on 
composite promoters. However, changes in SC as a result of abrogated SUMO-binding had 
so far not been addressed. Interestingly, the non-covalent binding surface of SUMO was 
recently demonstrated to be essential for SUMO-governed transcriptional (and synergistic) 
control [421]. Mutating residues in the second -sheet and the following -helix of SUMO, 
three of which (K33, K35 and R50) have been implicated in SUMO-binding [273, 276, 422], 
dramatically affected the ability of both SUMO-1 and -2 to inhibit transcription [421]. 
These findings support the idea that synergy control-mediating factors may be recruited to 
sumoylated transcription factors through non-covalent SUMO-binding [347]. However, 
since the c-Myb ANAA mutant revealed a synergy factor four-fold lower than the 
sumoylation negative mutant, we have no reasons to believe that synergy control can be 
imposed by sumoylated co-regulators when binding to SBMs in transcription factors on 
composite promoters. At least this seems not to be the case for c-Myb. Furthermore, since 
the SBM mutant ANAA was able to activate transcription to the same extent as c-Myb 2KR 
(Fig 22), we think that SUMO-binding and SUMO-conjugation/synergy control are two 
independent mechanisms operating on c-Myb. Moreover, it highlights the fact that even 
though synergy obviously promotes activity, these are two different phenomenons (Fig 22). 
Based on the data presented in Figure 22 and the previous reasoning, regulation of c-Myb 




number of REs, while the potential of regulation through SUMO-conjugation and synergy 
control increases with increasing number of  REs. 
 
 
Figure 22 Activity and synergy - 
two different phenomenons. CV-
1 cells were transfected with 
reporter plasmids containing 
increasing numbers of MREs (1-
5), as indicated, and plasmids 
encoding c-Myb wild-type, 
SUMO-negative c-Myb 2KR, or 
SUMO-binding-negative c-Myb 
ANAA. The results are presented 
as relative luciferase units (RLU). 
The response curve for c-Myb 
ANAA was modelled based on 
activity measurements from 
1×MRE, 3×MRE and 4×MRE 
reporters. 
 
 Even though the SBM did not seem to promote SC, we were intrigued by the fact 
that the sumoylation negative mutant 2KR and the SUMO-binding negative mutant ANAA 
seemed to have the same transactivational phenotype on several promoters (PAPER IV). We 
therefore wondered if the two SUMO-contacts might be involved in bridging parts of c-Myb. 
Such an explanation would substantiate the hypothesis of a fold-back mechanism between 
the EVES domain and the transactivation domain in c-Myb, suggested to conceal co-
activator binding epitopes, thus lowering c-Myb activity [77, 423]. In one paper the 
transactivation domain of c-Myb was demonstrated to be activated in trans by c-Myb NRD 
when co-transfected in Gal4 tethering assays. This was in fact proposed to be caused by a 
universal cellular inhibitor, able bind both domains, being titrated out by the NRD [423]. 
Could this factor be SUMO? Peculiarly, B-Myb was not stimulated by c-Myb NRD [423].  
However, from a SUMO perspective this would fit the fact that B-Myb harbours only one 
potential SUMO-binding motif which is identical to the c-Myb SBM1, shown to be non-
functional (PAPER IV). Despite the indications of SUMO being involved, our data did not 
correspond with the activity pattern anticipated if the derepression was caused by disruption 
of an intramolecular association between the EVES domain and the SBM, bridged by 
SUMO. When introducing both the 2KR and ANAA mutations in the same construct, the 
transcriptional activity more than doubled, resulting in an extremely active phenotype 
(PAPER IV). Moreover, the ANAA mutant still had an activating effect when the NRD, 
including the SUMO-modified area of c-Myb, was deleted, and when studied in a TAD-only 




possibility of a fold-back mechanism in c-Myb not involving SUMO or not leading to 
activity changes. Given that a binding between sumoylated NRD and SBM in TAD is 
neutral regarding c-Myb transactivational activity, the trans activation of c-Myb TAD by 
NRD observed by Vorbrueggen et al. [423] might just as well be caused by displacement of 
a co-repressor binding intermolecularly to the c-Myb SBM, resembling the data we obtained 
using conjugation-deficient SUMO (PAPER IV). 
Mohan et al. recently demonstrated that SUMO conjugated to TDG (Thymine DNA 
Glycosylase) makes contact with an inherent SBM. This leads to conformational changes 
that abrogates DNA-binding [324, 326, 422]. In our study on synergy control in c-Myb we 
showed that constitutive SUMO-conjugation, mimicked by a c-Myb-SUMO fusion, did not 
alter the DNA-binding properties of the protein (PAPER III). This indicates that the c-Myb 
SUMO moieties do not act in cis, when repressing c-Myb activity.  Conversely, when DNA 
was added to the interaction buffers in the SUMO-binding study, we were still able to pull 
down c-Myb using GST-SUMO-2 (PAPER IV). Hence, DNA-binding does not seem to 
alter the SUMO binding properties of c-Myb. Taken together this further substantiates our 
conclusion that if an intramolecular SUMO-bridge does exist in c-Myb, it will most likely 
not have any impact on neither transactivation, nor DNA-binding.  
 
4.2.3 Keeping c-Myb busy: The PML-NB as a c-Myb co-factor distributor. 
Having established that c-Myb binds SUMO, most likely in the form of another sumoylated 
negatively acting protein, we chose to focus on the tumour suppressor Promyelocytic 
Leukemia (PML) protein. Several functions have been suggested for PML and the PML 
nuclear bodies (PML-NBs) [424]. However, the prevailing model is that PML functions as a 
kind of storage, sequestering nuclear proteins. Recently, both sumoylation and SUMO-
binding have been shown to regulate nucleation of the PML protein into nuclear bodies [352, 
354]. Furthermore, the presence of unoccupied SUMO-moieties and SBMs on the surface of 
the PML NBs allows for sumoylated and/or SBM-containing factors to be recruited to these 
complexes [354]. Several papers have shown that protein-protein interactions associated 
with the PML-NBs, as well as the bodies themselves, are highly dynamic [328, 425]. Thus, 
combined with the fact that these NBs also are sites for post-translational modifications 
(reviewed in [424]), the PML-NBs should be recognized as highly active protein 
distribution centres.  
We have previously shown that PML interacts with c-Myb and recruits it to PML 




Interacting protein SUMO-modified SUMO-binding 
Daxx Yes Yes 
HDAC1 Yes Yes 
HDAC2 (Yes) Yes 
HDAC3 No (Yes) 
HIPK2 Yes Yes 
N-CoR 1 Yes (Yes) 
N-CoR 2 (Yes) - 
SP100 Yes Yes 
PML Yes Yes 
TDG Yes Yes 
TOPORS Yes Yes 
ARNT Yes - 
CBP/p300 Yes - 
c-Fos Yes - 
c-Jun Yes - 
GATA2 Yes - 
Mdm2 Yes - 
p53 Yes - 
p73 Yes - 
PLZF Yes - 
pRb Yes - 
RFP Yes - 
Sin3A Yes - 
Smad 2 Yes - 
Smad 3 Yes - 
Sp 1 Yes - 
SRF Yes - 
TIF1- Yes - 
SENP2 - Yes 
c-Ski - - 
FLASH - - 
p38 MAPK - - 
   
Table 3 PML-NB interacting proteins. A selection of mammalian 
proteins reported to be recruited to PML nuclear bodies (www.gene-
profiles.org). Evidence of SUMO modification and SUMO-binding 
properties are indicated. (Yes): indirect evidence, e.g. by sequence 
homology; –: not determined.  
 
contact mutants (ANAA, 2KR and ANAA 2KR) with PML, we could see that c-Myb is 
recruited to PML-NBs in a SUMO contact-independent manner (PAPER IV). Dahle et al. 
showed that the interaction between c-Myb and PML appeared to be independent of c-Myb 
sumoylation, although a quantitative difference was not excluded [117]. Our new data 
supports this, and extend the notion of a SUMO-independent recruitment of c-Myb to PML-
NBs to include also SUMO-binding (PAPER IV). Curiously, this did not correlate with 
functional data showing that c-Myb wild-type is activated by ectopic PML expression, while 




relative PML co-activation decreased with the elimination of functional SUMO-contacts 
(PAPER IV). 
We believe that the co-activation of wild-type c-Myb might be caused by PML-NBs 
sequestering negatively acting co-factors operating through the SBM or the conjugated 
SUMO moieties. Consequently, the reduced PML co-activation seen with the SUMO-
contact mutants might be due to co-repressor interactions already being broken. A similar 
mechanism has been proposed for the glucocorticoid receptor, for which PML functions as a 
co-activator through sequestering the SUMO-binding co-repressor Daxx [346, 426]. 
Whether Daxx may function as a co-repressor also for c-Myb is not yet known. However 
thinking along these lines, we should be looking for PML/PML-NB-interacting proteins, 
known to repress transcription, that either are sumoylated or able to bind SUMO. Such 
factors would be candidates for SUMO-binding or SUMO modification-dependent 
repressors of c-Myb transactivational activity. Daxx is only one out of more than 50 proteins 
reported to interact with PML3. In table 3, I have listed some of these proteins and included 
information on SUMO-modification and SUMO-binding properties. Notably, not all the 
proteins in this table are known to function as co-repressors. However, Daxx, HDAC1-3, 
HIPK2, N-CoR, as well as SP100 and PML it self have been reported to repress 
transcription [346, 424, 427-429]. Interestingly, HIPK2, N-CoR, Sin3A and c-Ski have been 
reported to interact with c-Myb and negatively regulate Myb-dependent transactivation [90, 
109]. However, none of them have been reported to interact directly with the EVES domain 
or the SBM. In their work on SUMO-2/3 conjugation of c-Myb Sramko et al. observed a 
derepression of c-Myb activity using trichostatin A [83], indicating that we might be 
looking at an HDAC being recruited to the SUMO conjugates. Still, these are only 
speculations, and future work will hopefully identify SUMO-contact dependent co-
repressors acting on c-Myb.  
 
4.3 SUMMARY AND FUTURE PERSPECTIVES 
In the four papers included in this thesis we have described two new regulatory mechanisms 
and two novel co-activators of c-Myb. The proto-oncoprotein c-Myb is known to be an 
activator of transcription. Hence, the identification of two novel co-activators of c-Myb fits 
well with the current understanding of this protein. Still, repressive mechanisms might be 
just as central in c-Myb biology as an extensive repertoire of positively acting co-factors. In 





the end opposing mechanisms are probably integrated to ensure an accurate regulation of c-
Myb activity. 
 
4.3.1 FLASH and Mi-2 meet SUMO 
With the knowledge we have generated on both FLASH and Mi-2 action as well as 
SUMO-binding, SUMO-conjugation and synergy control, it should be possible to search for 
both interdependency and mutually exclusiveness between these mechanisms of action. Our 
study on synergy control indicated that the multiplicity of TADs on a given promoter might 
be an important aspect in promoting positive synergy (PAPER III). A natural question 
would then be if co-activators interacting with c-Myb on non-TAD surfaces, like FLASH 
and Mi-2 will provide c-Myb with a second (or even third) TAD, and thereby result in 
positive synergy. Furthermore, could such interactions compensate for the central TAD in c-
Myb if deleted? In PAPER I we presented data showing that desumoylation of c-Myb 
potentiated the Mi-2-c-Myb co-activation, alternatively, that SUMO-modification reduced 
this cooperation. It would be relevant to see if the same held true for FLASH. Moreover, 
p300 could be included in such an experiment. Another question worth asking is whether 
some of these interactions and modifications are mutually exclusive. Even though we do not 
have any observations supporting SUMO-governed intramolecular interactions in c-Myb, it 
would be interesting to examine whether sumoylated c-Myb is able to interact with FLASH 
and Mi-2	 After all, FLASH seemed to interact more strongly with the C-terminally 
deleted c-Myb[1-443] than the wild-type (PAPER II).Furthermore, will FLASH and/or Mi-
2 inhibit sumoylation of c-Myb? Notably, we have not seen such effects for the well 
established c-Myb co-activator p300, as evaluated by western blotting (data not shown).  
Some of the same questions might be relevant for SUMO-binding. Will the SBM-
mutant A267NAA have an increased affinity for Mi-2 hence lead to a better co-activation? 
What about the I267NII mutant? In PAPER II we showed that FLASH seemed to bind just as 
efficient to v-Myb (INII) as c-Myb[1-443] (VNIV), however these observations might not 
be relevant due to the mutations and deletion in v-Myb DBD and the lack of comparable 
amounts of SUMO or sumoylated proteins in the interaction reaction. Hence, further studies 
are needed. Conversely, is c-Myb able to interact with SUMO when Mi-2 or FLASH is 
bound? To answer this question employing Mi-2 or FLASH-Myb fusion proteins might be 
a strategy. Finally, several of these questions could be addressed in a more physiological 




on relevant target genes. Alternatively, the precipitated DNA from such assays could be 
cloned and sequenced to identify candidate promoters. 
 
4.3.2 SUMO-binding, SUMO-conjugation and the transforming properties of c-Myb. 
As discussed in chapter 4.1.5 it is important to keep in mind that some of the mechanisms 
unravelled in these studies may unleash the transforming potential of c-Myb when damaged 
or deregulated. The truncated and mutated AMV v-Myb causes rapid and fatal monoblastic 
leukemia in chicken (reviewed in [16]). Moreover, deregulation and duplication of MYB are 
probably involved in the development human T-ALL [242-244]. A common theme in both 
chicken and human leukemias involving c-myb/MYB anomalies is that the overall Myb-
activity seems to be increased. In PAPER III and IV we describe two SUMO-related 
mechanisms involved in dampening c-Myb activity. Interestingly, both the SUMO-binding 
motif and the SUMO-modified area of c-Myb are hit by mutations and deletions in the 
transforming v-Myb protein. Notably, v-Myb was shown to have the highest synergy factor 
(~5) among the Myb-proteins tested in PAPER III. Moreover, the combination of mutations 
abrogating both SUMO-conjugation and binding in a c-Myb background resulted in an 
extremely active phenotype (PAPER IV).  
It has been demonstrated that c-Myb with C-terminal truncations can transform avian 
yolk sac and bone marrow [69] and murine foetal liver cultures [430, 431]. This opens up 
the possibility that lost SUMO-modification and/or synergy control might be involved in the 
oncogenic activation c-Myb. Concerning SUMO-binding, the v-Myb protein seems to have 
retained this property (PAPER IV). Moreover, a linker insertion mutagenesis destroying the 
SBM in v-Myb resulted in a mutant (I202GPNII) with somewhat reduced capacity to 
transform avian yolk sack [432]. In a recent genome-wide ENU mutagenesis screening 
study, two point mutations in c-myb were identified that were able to rescue mice from a 
myeloproliferative syndrome [166]. Interestingly, these point mutations generated two 
potential SUMO-binding motifs in c-Myb and resulted in proteins with lower transactivation 
potential. This might indicate that changing the SUMO-binding properties of c-Myb may 
have biological effects. 
In recent years it has become apparent that deregulation of the sumoylation system 
as well as mutations or deletions of SUMO-acceptor sites are associated with the 
development of human diseases, including many types of cancers [251]. Therefore, we 
would like to pursue the possible link between lost SUMO regulation of c-Myb and 




research group of Prof. T.J. Gonda at the University of Queensland, where we are going to 
address the transforming properties of our different SUMO-contact mutants. Hopefully, this 
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The transcription factor c-Myb plays a key 
role in controlling gene programs during 
proliferation and differentiation of 
hematopoietic cells. Several target genes are 
activated by c-Myb in synergy with other 
transcription factors. Since the synergy 
properties of some factors are restricted by 
sumoylation (synergy control) and c-Myb is 
being sumoylated, we investigated these 
characteristics of c-Myb. By using a set of 
dedicated reporters we quantified the 
synergy behavior of c-Myb and found the 
factor to be subject to strong synergy control 
linked to SUMO-conjugation in its negative 
regulatory domain (NRD). When the ability 
of c-Myb to become sumoylated was 
modulated in various ways, its synergy 
behavior changed accordingly. Interestingly, 
AMV v-Myb appears to have escaped 
synergy control and a rather high synergy 
factor was measured for this oncogenic 
version of c-Myb. The search for a 
mechanism revealed a SUMO-controlled 
switch in the function of NRD. When NRD is 
sumoylated, it acts negatively by reducing 
the activity of c-Myb. When SUMO is 
removed, NRD switches into a 
transactivation domain (TAD), providing the 
factor with a second TAD. We propose a 
new model for c-Myb having two TADs, one 
centrally located and constitutively active 
and one in NRD being under SUMO-control. 
We also propose a new model for SUMO-
mediated synergy control in which SUMO 
restrains the number of active TADs and 
thus the available co-activator interaction 
surfaces. In this model, SUMO controls 
synergy by determining the number and 
strength of independent and active TADs 
associated with a promoter through the 
bound transcription factors. 
 Synergy between transcription factors 
operating together on complex promoters is a 
well-known phenomenon. Several models have 
been proposed to explain this more-than-
additive activity of multiple activators. Key 
concepts are multiplicity of contacts to the 
basal transcription apparatus (1,2) promoting 
assembly of the pre-initiation complex (PIC) 
(3), physical interactions between transcription 
factors (4) particularly emphasized in the 
enhanceosome model (5), co-activators 
harboring distinct domains that interact 
simultaneously with different factors (6), and 
cooperative interactions of transcription factors 
with nucleosomal DNA (7). Activators able to 
stimulate distinct steps in the transcription 
process, such as initiation and elongation, may 
also contribute to concerted action and synergy 
(8). In general terms, synergy appears to be 
intrinsic to the transcription process, being 
related to the multiplicity of interactions 
necessary to assemble an active PIC at the 
transcription start site (TSS) and unleash the 
productive elongation by RNA polymerase II. 
This makes synergy an ideal target for control 
of transcriptional output. 
 An interesting twist to the phenomenon of 
synergy was the finding of a specific negative 
control mechanism. Iniguez-Lluhi and Pearce 
identified a short protein motif in the 
glucocorticoid receptor (GR) that mediated 
“Synergy control” (SC), by acting as a 
disruptor of synergy on promoters with 
multiple response elements, but not so on 
single response elements (9). Mutations of this 
motif unleashed a strong synergistic behavior 
of GR at compound, but not at single, response 
elements. It soon became apparent that the SC 
motif was indeed a SUMO-conjugation site and 
that the disruption of synergy was caused by 
sumoylation of the factor at that site (10,11). 
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This role of SUMO (Small ubiquitin-related 
modifier) as a disruptor of synergy has been 
extended to other transcription factors such as 
Ets and C/EBP (9,12). Still, compared to the 
rapidly expanding literature on SUMO only a 
tiny fraction of papers have addressed its 
synergy-controlling properties.  
 SUMO family proteins function by 
becoming covalently linked to a variety of 
proteins, including many nuclear regulators of 
key processes such as transcription, nuclear 
transport, chromatin structure, and DNA repair 
(13-16). The modification by SUMO is a 
highly dynamic process, controlled by the 
balance between a set of conjugation enzymes, 
analogous to those of the ubiquitin pathway, 
and a set of SUMO-specific proteases. 
 c-Myb is a key transcription factor 
controlling proliferation and differentiation of 
early hematopoietic progenitor cells, as well as 
being a regulator of similar processes in other 
tissues such as colon (17,18). c-Myb becomes 
sumoylated at two sites within its negative 
regulatory domain leading to a severe drop in 
its activity (19,20). Interestingly, both SUMO-
conjugation sites are deleted in the oncogenic 
variant AMV v-Myb (19). The molecular 
mechanism by which SUMO is controlling c-
Myb activity is poorly understood. 
Interestingly, synergy is a well-documented 
aspect of c-Myb action. The factor has been 
reported to activate promoters in synergy with 
several other transcription factors such as Ets, 
C/EBP, PU.1, Pax-5 and CBF (core binding 
factor) (21-28). Consistently, many of the 
genes activated by c-Myb appear to be 
controlled by compound promoters harboring 
multiple recognition sites both for c-Myb and 
for other cooperating factors. 
 Given the role of SUMO as a disruptor of 
synergy for other transcription factors, we 
reasoned that studying its role in synergy 
control of c-Myb might lead to a better 
understanding of the mechanisms by which 
SUMO controls c-Myb action. In this work we 
show that c-Myb is subject to a strong synergy 
control, tightly linked to its level of SUMO-
conjugation, and that this synergy control is 
abolished in AMV v-Myb. This control is 
expected to be promoter-specific related to the 
multiplicity of response elements and 
complexity of the activated promoters. 
Accordingly, we show that chromatin 
embedded target genes of c-Myb respond 
differentially to SUMO-control in 
hematopoietic cells. Furthermore, we show that 
SUMO affects the transactivation properties of 
the factor by switching off an activation 
function in its negative regulatory domain, 
contributing to the amplitude of activation. We 
propose a dual role for sumoylation of c-Myb 
in controlling both the transactivation 
properties and the synergy behavior of c-Myb. 
This leads to a considerable dynamic control of 
c-Myb activity. 
EXPERIMENTAL PROCEDURES
Reporter plasmids. pGL4-1×MRE(GG)-MYC, 
pGL4-2MRE(GG)-MYC, pGL4-
3×MRE(GG)-MYC, pGL4-4×MRE(GG)-
MYC, pGL4-5×MRE(GG)-MYC were 
constructed in two steps. Oligos, containing a 
sequence from human MYC P2 core promoter, 
were first inserted into the KpnI/SmaI site of 
pGL4 basic (a designed derivative of pGL3 
Basic (E1751; Promega)) where the MCS was 
changed by oligo-insertion to contain sites for 
MluI, XhoI, KpnI, SmaI and BglII). Then oligos 
were designed to contain one, two, three, four 
or five Myb-responsive elements (MREs 
TAACGG) with a spacing of four bp (TTTT) 
giving a phasing of ten bp between the MREs 
(i.e. MREs starting in position +1, +11, +21 
etc). Duplex oligos were subcloned into 
MluI/XhoI site of the plasmid. Oligo insertions 
were verified by sequencing. In the same way, 
pGL4-4×MRE(GG)abab-MYC was constructed 
by inserting an oligo containing four MREs in 
which the phasing was 15 bp between the 
elements. The reporter pGL4-3×MRE(GG)aab-
MYC contains three MREs in which the 
phasing is 10 bp between the first two and 15 
bp between the second and third MRE. 
 The E1b driven Gal4p responsive 
luciferase reporter, pG5E1bLuc, containing 
five binding sites for the yeast transcription 
factor Gal4p upstream of an Adenovirus E1b 
TATA-box and a luciferase gene, used in the 
Gal4 tethering assays is described (29). The 
pGL3b-5GRE-SNRPN is an SNRPN-driven 
Gal4p-responsive luciferase reporter (30). 
Mammalian expression plasmids. The 
mammalian expression vectors pCIneo-hcM-
HA and pCIneo-hcM-HA-2KR (encoding wild 
type and sumoylation deficient c-Myb, 
respectively), pCIneo-hcM-HA-K503R and 
pCIneo-hcM-HA-K527R (single sumoylation 
sites mutated) have been described (19). c-Myb 
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E505/529R (abbreviated 2EA) were generated 
using the Quick Change Site-Directed 
Mutagenesis Kit (Stratagene) on a subfragment 
of human MYB, before subcloned into 
pCIneoB-hcM-HA. pCIneo-hcM-2KR-SUMO-
1 was constructed by PCR amplification and 
modification of SUMO-1 from the appropriate 
IMAGE clone, followed by subcloning in-
frame into pCIneo-hcM-HA-2KR (between 
PshAI and SalI), loosing the HA tag, but 
gaining SUMO-1 in the expressed product. 
pCIneo-hcM-VP16 was made by PCR 
amplification of the herpes simplex virus VP16 
transactivation domain from pDBD11 (31). The 
VP16-TAD region was subcloned in-frame into 
pCIneo-hcM. pCIneo-hcM-VP16–2KR has 
been described (30). 
 pCIneo-AMV encoding the (AMV v-Myb 
protein, residue 72–440 in chicken c-Myb) is 
described in (32), while the pCIneo-hcM-
NRD-HA has been described elsewhere 
(Alm-Kristiansen et al., submitted 2007).  
 The c-Myb expression constructs with the 
central TAD deleted (pCIneoB-hcM-T1-HA 
and pCIneoB-hcM-T1-HA-2KR) were made 
from a cDNA in Bluescript lacking an internal 
fragment (HpaI to SmaI) encoding human c-
Myb amino acids 229-325. The EcoRI-BglII 
fragment from pBS-SE-hcM-T1 was 
subcloned between the corresponding sites in 
pCIneoB-hcM-HA and pCIneoB-hcM-HA-
2KR, respectively. 
 The mammalian expression vectors for 
Gal4p-DBD fused to HA-tagged human c-Myb 
NRD (pCIneoB-GBD2-NRD-HA; coding for 
amino acid residue 410 to 640) were made by 
PCR amplification of the corresponding 
sequence in pCIneo-hcM-HA and subcloning 
of this fragment into pCIneoB-GBD2 
(described earlier (30)) between SalI and NotI. 
pCIneoB-GBD2-NRD-HA-2KR and -2EA 
were made by subcloning the BglII-NotI 
fragment from pCIneo-hcM-HA-2KR and -
2EA, respectively, into pCIneoB-GBD2-NRD-
HA. The Gal4p-DBD NRD-SUMO fusion 
proteins were made by the same strategy using 
pCIneo-hcM-2KR-SUMO-1 and pCIneo-hcM-
SUMO-1 (30). 
 The SENP1 expression plasmids pFlag-
CMV-SENP1 and pFlag-CMV-SENP1-mutant 
(R630L, K631M) were a kind gift from Dr. 
E.T. Yeh (33). 
 
Cell Culture, Transfection, and Luciferase 
Assays. CV-1 and COS-1 cells were grown as 
described (34). HD11 cells were grown in 
Iscove’s Modified Dulbecco’s Medium 
supplemented with 8 % heat-inactivated fetal 
bovine serum, 2 % heat-inactivated chicken 
serum and antibiotics, at 37 °C and 5 % CO2. 
All three cell lines were transiently transfected 
with the indicated plasmids (0.2 μg when 
nothing else is mentioned) using FuGENE6 
(RocheApplied Science) 24 h after seeding. For 
the luciferase assays, CV-1 cells were 
harvested 24 h after transfection and lysed in 
Passive Lysis Buffer (Promega). Luciferase 
assays were performed in triplicate (24 well 
trays; 2×104 cells/well) using Luciferase Assay 
Reagent (Promega), and data from at least three 
independent transfection experiments are 
presented.  
 For the Trichostatin A (TSA) treatment of 
CV-1 cells TSA (Sigma) was dissolved in 
EtOH and added to the culture medium, 8 h 
after transfection, at a final concentration of 
100 nM. After 14 h of incubation with TSA the 
cells were harvested and luciferase assays 
performed. 
 
Expression of Myb proteins for EMSA. COS-1 
cells were transfected as described above with 
5 μg DNA (pCIneo-hcM-HA, pCIneo-hcM-
2KR-HA or pCIneo-hcM-2KR-SUMO-1) per 
100-mm plates, seeded with 1×106 cells the day 
before. 24h after transfection the cells were 
washed twice in 1×PBS on ice before lysis in 
500 l modified Buffer F (10 mM Tris-HCl 
[pH 7.05], 50 mM NaCl, 30 mM sodium 
pyrophosphate, 50 mM NaF, 5 mM ZnCl2, 100 
mM Na3VO4, 1 % Triton X-100, 1 mM PMSF 
and 1 mM DTT) supplemented with Complete 
Protease Inhibitor™ (Roche Applied Science) 
(35). The lysates were then centrifugated for 30 
min at 4 °C, before aliquots of the supernatant 
were frozen in liquid N2 and stored at -80 °C.  
 
Electrophoretic Mobility Shift Assay. DNA 
binding was monitored by EMSA as previously 
described (36). The oligonucleotide used for 
Myb binding is based on the MRE A site in the 
mim-1 promoter (37); 5'-GCATTATAACGG-
TTTTTTAGCGC-3. The probe was labeled 
with 	-32P-ATP and purified as described in 
(38). COS-1 cell lysates (1-9 μl) with the 
different Myb proteins were adjusted to equal 
volumes with Buffer F before incubation in 
CG-buffer (20 mM Tris-HCl [pH 8.0], 0.1 mM 
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EDTA, 10 % glycerol), with final NaCl 
concentration 75 mM and 1 μg poly[dI-dC]. 5’-
	-32P-labeled MRE oligonucleotide probe (20 
fmol) were added and the binding mixture 
(total volume 20 l) was incubated for 10 min 
at room temperature before electrophoresis. 
Binding reactions were run on 6 % 0.5TBE, 5 
% glycerol PA-gels at 4 °C.  
 
Western blotting and antibodies
Cell lysates from COS-1-transfected cells were 
run on a 10 % SDS PA-gel and subjected to 
Western blotting using Hybond P membranes 
(GE Healthcare) and ECL plus kit (GE 
Healthcare) for detection. The murine Myb 
5e11 antibody (39) was used as primary 
antibody and anti-mouse IgG-HRP (NA931, 
GE Healthcare) was used as secondary 
antibody. 
 
RNA isolation and quantitative RT-PCR.  
HD11 cells were transfected as described above 
with 2 μg DNA (pCIneo-hcM-HA, pCIneo-
hcM-2KR-HA or empty pCIneo vector) in 6-
well trays (seeded with 5×105 cells per well the 
day before). 24h after transfection the cells 
were harvested and total RNA extracted with 
Trizol reagent (Invitrogen) and subsequent 
DNase treatment and purification of the RNA 
using RNeasy columns (Qiagen). 3μg of RNA 
for each sample were used for reverse 
transcription using the SuperscriptTM III system 
(Invitrogen). The cDNA obtained was 
subjected to real-time PCR analysis to 
determine the expression of three c-Myb target 
genes: mim-1, lysozyme and Pdcd4, using the 
LightCycler DNA MasterPlus SYBR Green Kit 
(Roche). A standard curve made from serial 
dilutions of cDNA was used to calculate the 
relative amount of these mRNAs in each 
sample. These values were normalized to the 
relative amount of the reference gene HPRT in 
the same samples, calculated from a standard 
curve established in the same way. The cellular 
transfections were performed in triplicate and 
the experiment was repeated three times. 
Primer sequences are available upon request.  
RESULTS
Synergy behavior of c-Myb and its relation to 
SUMO-conjugation. 
Given that c-Myb is being sumoylated and that 
its activity is significantly enhanced by removal 
of SUMO-conjugation sites (19,20), we asked 
whether c-Myb was subject to the phenomenon 
of synergy control. Systematic analysis of this 
type of behavior requires a dedicated set of 
reporter constructs with defined changes in the 
multiplicity of response elements. Hence, we 
constructed a set of reporter plasmids based on 
the pGL3 backbone with identical core 
promoters (from MYC P2), activated by one to 
five copies of an optimal MRE (Myb response 
elements) each with a phasing of ten bp (Fig. 
1A). In a systematic EMSA study of 
recombinant c-Myb binding to differently 
spaced MREs, we had observed that a phasing 
of six bp caused interference from one bound 
factor on the binding of a second, while a 
phasing of ten bp did not (data not shown). 
When reporters with one to five MREs were 
compared in effector-reporter assays in 
transfected CV-1 cells, wild type c-Myb 
activated the various reporters only with minor 
differences (Fig. 1B). In contrast, the SUMO-
conjugation negative mutant, c-Myb 2KR, 
showed a remarkable increase in activity when 
the number of MREs were augmented (Fig. 
1B). In order to be able to quantify this 
difference in synergistic behavior, we defined a 
relative “synergy factor” (SF) as the ratio of 
reporter activity with four MREs to the activity 
with one MRE, divided by four (the latter to 
obtain ratios independent on the number of 
MREs). A simple proportional increase in 
reporter activity with the number of MRE 
should then give an SF = 1, while a positive 
synergy will result in SF > 1. An SF < 1 would 
then imply a less than additive effect, which 
might be termed “negative synergy” (illustrated 
in Fig. 1C). We decided to calculate the SFs 
based on four MREs, but very similar SFs were 
obtained when we calculated ratios based on 
three or more MREs (data not shown). Using 
this simple quantification scheme, we 
compared wild type c-Myb with mutants in one 
or both SUMO-conjugation sites (Fig. 1D). 
Wild-type c-Myb displayed in fact a negative 
synergy (SF = 0.26) while the SUMO-negative 
c-Myb 2KR showed a strong positive synergy 
(SF = 3.9). Single mutants, retaining one of the 
two SUMO-conjugation sites, showed 
intermediate levels (K503R: SF = 0.98;  
K527R: SF = 0.72). These results suggest that 
the synergistic behavior of c-Myb is highly 
dependent on its ability to become sumoylated. 
 To investigate this association further, we 
asked whether the strong synergy of c-Myb 
2KR could be reduced when SUMO-1 is 
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covalently fused to the C-terminal of c-Myb 
2KR, mimicking the sumoylation of the 
protein. Figure 1E shows that this is indeed the 
case. The c-Myb-2KR-SUMO-1 fusion gave a 
strong reduction in synergy (SF = 0.95) when 
compared to the non-fused 2KR protein (SF = 
3.92). The SF value of the fusion is in fact very 
similar to the SF of the single mutants (K503R 
and K527R; Fig. 1D) also harboring one 
SUMO moiety in their conjugated state. This 
observation strongly supports a role for SUMO 
in controlling the synergy behavior of c-Myb. 
Consistent with this, ectopic expression of 
SENP1 (a SUMO-protease) enhanced the 
synergy behavior of wild type c-Myb (SF 
increased from 0.26 to 2.8) while a protease-
dead SENP1 had no effect (Fig. 2A). As 
expected, the synergy behavior of c-Myb 2KR, 
lacking functional conjugation sites, was not 




abolish SUMO-conjugation, while allowing 
other Lys-directed modifications to occur. The 
2EA mutant (E505A+E529A) severely reduced 
sumoylation of c-Myb (data not shown) and 
caused a strong increase in synergy (SF = 2.46; 
Fig. 2B). Taken together, these data suggest 
that SUMO-conjugation is the major 
determinant of synergy behavior of c-Myb as 
revealed by this MRE-multiplicity assay. 
 The oncogenic activated AMV v-Myb 
harbors both point mutations and N- and C-
terminal deletions, removing both SUMO-
conjugation sites. We expected the latter 
deletion to affect the synergy behavior of v-
Myb. The cumulative effects of the other 
mutations however were less predictable in a 
synergy assay. As shown in Fig. 3A, v-Myb 
displayed in fact the strongest synergy of all 
Myb-variants tested so far (SF = 4.78) 
suggesting that escaping synergy control might 
be an important strategy during oncogenic 
activation. 
 There have been reports on viral strategies 
to overcome the effect of the SUMO-
conjugation system (40). Since VP16 is a viral 
protein that in model systems often is fused to 
transcription factors to transform them into 
strong activators (41), we tested the synergy 
behavior of a c-Myb-VP16 fusion. As shown in 
Fig. 3B the fusion of VP16 to c-Myb clearly 
overrides the negative synergy, increasing the 
SF of c-Myb from 0.26 to 1.39. This ability of 
VP16 to confer positive synergy behavior on its 
target factor may relate to the increased number 
of TADs provided (see below).  
 In the reporters used to calculate SF 
values, the phasing of the MREs was 10 bp, 
causing the bound c-Myb activators to have the 
same helical orientation on the promoter. To 
see whether the helical orientation is of any 
importance for synergy, we designed a 4×MRE 
reporter with a phasing of 15 bp (pGL4-
4×MRE(GG)abab-MYC) to give an alternating 
helical orientation (Fig. 3C). While the SF 
values obtained with the SUMO-negative c-
Myb 2KR did not change with helical 
orientation, the lower values obtained with wild 
type c-Myb did in fact change. The level of 
“negative synergy” became more relaxed when 
the helical orientation became alternating (SF = 
0.83) compared to when all elements were 
oriented on the same side of the DNA helix (SF 
= 0.26). This may reflect a different mechanism 
responsible for cooperation generating positive 
synergy as compared to the mechanism 
restricting synergy.  
 
Relevance of SC to resident promoters 
The Myb-responsive model promoters used for 
assaying the SUMO-dependence of synergy 
were controlled by one single transcriptional 
activator. Most natural promoters on the other 
hand are more complex and often activated by 
a combination of transcription factors, several 
of which may be SUMO-conjugated. The 
activation of a natural promoter through 
desumoylation would be expected to involve 
removal of SUMO from various transcription 
factors. Unfortunately, this is not easy to mimic 
in an experimental setup. However, even 
though Myb-regulated promoters also are under 
the control of other factors, we tried to address 
the relevance of the SUMO-mediated synergy 
control of c-Myb in a more physiological 
context by comparing the activation of 
endogenous target genes by wild type c-Myb 
and c-Myb 2KR. For this purpose we used c-
Myb negative chicken macrophage HD11 cells 
since these cells express C/EBP known to 
cooperate with c-Myb in transcriptional 
activation (24,42). Activation of three different 
genes reported to be targets of c-Myb was 
monitored by real-time PCR. As shown in 
Figure 4A, co-transfection of c-Myb wild type 
or 2KR mutant resulted in a differential 
activation of mim-1, as expected if several 
MREs contribute to the activity of the 
SUMO-control of an NRD switch in c-Myb determines synergy 
 AK Molværsmyr et al 
 
6 
chromatin embedded promoter. For the 
lysozyme gene (Fig. 4B) the difference between 
c-Myb wild-type and 2KR was less 
pronounced, suggesting that fewer MREs are 
involved. Only low levels of activation and no 
obvious difference between 2KR and wild-
type, was observed with the Pdcd4 gene (Fig. 
4C). However, in this last case, the low level of 
Pdcd4 activation made it difficult to assess the 
differential activation precisely. In addition to 
the number of MREs, these promoters may 
differ is the contribution to activity from c-Myb 
versus from other factors. This may explain 
why we observe the strongest synergy effect in 
the promoter showing the strongest activation 
by c-Myb. We conclude that natural promoters 
differ significantly in their synergy behavior 
when c-Myb is compared in two states. We 
expect however that a larger difference would 
have been observed if we had been able to 
compare two or more cooperating factors in 
both SUMO-conjugated and non-conjugated 
states. 
 
In search for a mechanism 
Being confident that the synergy property of c-
Myb is controlled by SUMO, we asked what 
mechanism might be involved. We reasoned 
that at least three possibilities should be 
explored. First, SUMO-conjugation of c-Myb 
may alter its intrinsic properties, converting c-
Myb into a less potent factor with reduced 
ability to synergize with other factors. If so, 
this might be caused either by reduced specific 
DNA-binding or by impaired transactivation 
properties. In addition to these two mainly 
intrinsic mechanisms, SUMO-conjugation may, 
by adding a new interaction surface to c-Myb, 
lead to the recruitment of a repressor causing 
the transactivation output to be impaired.  
 This last possibility was addressed by 
taking into consideration reports showing that 
SUMO-conjugation in other systems lead to 
recruitment of HDAC6 (43) or HDAC-2 (44). 
If sumoylation of c-Myb leads to recruitment of 
HDACs and consequently a decrease 
transcription, then the inhibition of HDACs by 
TSA treatment should result in increase of the 
SF. We therefore measured the synergy 
behavior of c-Myb in the presence and absence 
of TSA. We observed, however, no significant 
alteration in the SF for c-Myb wild-type after 
addition of TSA (Fig. 5), suggesting that 
HDACs probably do not account for the 
phenomenon. We measured the activity of the 
SNRPN promoter under the same conditions to 
assure the efficiency of the TSA treatment. As 
shown in Fig 5B, this promoter became 
significantly activated by TSA, making us 
confident that the TSA treatment did work. We 
cannot from the TSA-insensitivity of the 
synergy behavior exclude a repressor-
recruitment model if the associated protein 
causes repression by an HDAC-independent 
mechanism. Nevertheless, we chose to proceed 
by exploring the two intrinsic mechanistic 
possibilities, modified transactivation or altered 
DNA-binding. 
 To monitor DNA-binding properties, we 
expressed in COS-1 cells the three Myb 
variants used above to calculate SFs: c-Myb 
wild type, c-Myb 2KR, and c-Myb-2KR-
SUMO1. We evaluated the amount of protein 
by Western analysis (Fig. 6 lower panel) and 
performed EMSA. With equal input of c-Myb 
proteins, the specific DNA-binding observed 
was similar for c-Myb wild type and 2KR, as 
well as for the SUMO-fusion protein (Fig. 6 
upper panel), suggesting that the SUMO moiety 
fused to the C-terminal of c-Myb had no 
significant influence on the activity of the 
DNA-binding domain localized in the N-
terminal of the protein.  
 We then proceeded to study if the intrinsic 
transactivation properties of c-Myb were 
modulated by sumoylation. SUMO may by 
itself act as a kind of general repressive domain 
as suggested by its behavior in Gal-tethering 
assays (44,45) and through its reported role in 
HDAC recruitment (43,44). We asked whether 
SUMO conjugated to c-Myb might have a more 
specific effect in controlling the TAD functions 
of the factor. First, we addressed whether the 
region becoming sumoylated in c-Myb by itself 
might contribute to the transactivation 
properties of c-Myb. A previous report showed 
that this region when tested in yeast in fact 
displays TAD activity (46).  
 The classical way of monitoring TAD-
function is by fusing the domain under 
investigation to Gal4p and monitoring the 
induced activation of a Gal4p-responsive 
reporter in transfected cells. When we tested 
the NRD region of c-Myb (amino acids 410-
640) in such a system, we saw that the wild 
type version of NRD did not activate, but rather 
had a weak repressive effect (Fig 7A). 
However, when the SUMO-conjugation sites 
were mutated (2KR) in the same domain, we 
SUMO-control of an NRD switch in c-Myb determines synergy 
 AK Molværsmyr et al 
 7
observed that the NRD was no longer acting 
negatively in this assay, but had switched into a 
positive transactivation domain (Fig 7A). To 
make sure that this remarkable observation was 
not some peculiarity related to the minimal 
E1B promoter in the pG5E1bLuc reporter used, 
we repeated the experiment with an SNRPN-
driven Gal4p-responsive luc reporter, observing 
essentially the same effect (data not shown). To 
confirm that the observed switch was indeed 
related to the elimination of SUMO-
conjugation, we tested out the E-A mutants 
instead of the K-R mutants in the same system. 
Also in this case, we observed the same change 
in the properties of the NRD becoming an 
activating domain upon reduced sumoylation 
(Fig 7A). The 2EA mutant always gave 
somewhat weaker response than 2KR, probably 
because the conjugation sites remain intact and 
the reduction in sumoylation is not totally 
abolished (data not shown). The fusion of 
SUMO-1 to the active 2KR-version of the NRD 
eliminated its TAD function totally, again 
supporting that the switch behavior is closely 
related to SUMO-conjugation. Finally, we 
analyzed the Gal-NRD fusion (wild-type) in the 
presence of overexpression of SENP1. As 
shown in Fig 7B, this SUMO-protease was able 
to induce the switch of the NRD from a weak 
repressor to a positive activator. While the wild 
type NRD changed 50-fold in activity upon 
overexpression of SENP1, the already 
derepressed 2KR version did not increase more 
than the background change. It should be 
noticed that all the Gal-responsive reporters 
used contain arrays of Gal-responsive elements 
(5GRE with 10 bp phasing), making the 
switch observed relevant for the phenomenon 
of synergy control.  
 Having found that c-Myb NRD behaved as 
a SUMO-repressed TAD when studied 
separately, we asked if this property also 
contributed to the overall transactivation 
potential of the full-length protein. The 
implicated model is that c-Myb has two TADs, 
one constitutive centrally located in the protein, 
and a second one SUMO-repressed in the NRD 
region, functioning as an internal repressor in 
the wild type protein (illustrated in Fig. 8). To 
test this model, we first compared the level of 
activity of three c-Myb constructs with 
different combinations of these two TADs. 
Consistent with earlier reports, the c-Myb-
NRD was much more active than the full-
length protein (Fig. 8). This activation by 
deletion shows the existence of a negative 
influence from the NRD region and is in fact 
the main reason for the “NRD” designation 
(47,48). Interestingly, when c-Myb 2KR was 
measured in parallel, we clearly saw that the 
elimination of SUMO-conjugation creates an 
even more active protein than c-Myb NRD, as 
expected if the silenced second TAD is 
switched on in this construct. Thus, the c-Myb 
2KR has not only lost its internal repressor 
function but behaves as a protein with two 
TADs (Fig. 8).  
 To test this model further, we reasoned that 
if the NRD contains a repressed transactivation 
domain that becomes active upon removal of 
SUMO-conjugation, we should be able to 
rescue a defect introduced in c-Myb caused by 
deletion of its constitutive central 
transactivation domain, simply by reactivating 
its silenced TAD in NRD. In Figure 9 we have 
compared c-Myb wild type, c-Myb with its 
central TAD deleted, and c-Myb with the TAD-
deletion in combination with the 2KR mutation. 
Clearly, the expected rescue is observed 
showing that also in the full-length protein the 
NRD can be activated into a second TAD 
which will contribute to the overall 
transactivation potential of the c-Myb protein. 
 
Synergy and number of TADs 
Given that SUMO-conjugation leads to 
suppression of a second TAD-function in c-
Myb, it appears quite probable that 
derepression of this TAD upon removal of 
SUMO, makes an important contribution to the 
enhanced synergy of c-Myb 2KR. An obvious 
model, combining the synergy properties of the 
c-Myb variants and the switch-property of 
NRD, would be that the efficiency of synergy 
as measured by the synergy factor, relates to 
the number and strength of independent and 
active TADs brought to a promoter through the 
bound transcription factors. If this is correct, 
we should be able to measure increasingly 
larger SFs for c-Myb variants harboring 
increasing number (and strengths) of 
independent and active TADs. To test this 
hypothesis we measured synergy factors for 
two additional c-Myb variants: c-Myb NRD 
(harboring one TAD) and c-Myb-2KR-VP16 
(harboring three TADs). These were compared 
with wild type c-Myb (harboring one partially 
repressed TAD) and c-Myb 2KR (harboring 
two TADs). As shown in Fig. 10, we observed 
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the expected SF increase when number and 
strengths of TADs increased. The deletion c-
Myb NRD with one TAD relieved from the 
repressive influence of NRD gave a higher SF 
than wild type, but still well below that of c-
Myb 2KR harboring two TADs. The c-Myb-
2KR-VP16 fusion protein, harboring three 
TADs, showed an extremely large SF of 35. 
This variant then was 140-fold more active on a 
promoter with four MREs than on a promoter 
with a single MRE. 
 We conclude that removal of SUMO-
conjugation in c-Myb unleashes the potential of 
c-Myb to synergize on compound promoters. 
One important contribution to this increased 
synergy appears to be the derepression of a 
silenced transactivation domain in the NRD of 
c-Myb becoming active upon removal of 
SUMO-conjugation. We cannot exclude that 
additional mechanism also are involved, but the 
NRD switch certainly makes an important 
contribution to the large differences observed 
between wild type and SUMO-negative c-Myb 
on complex promoters. 
DISCUSSION
Synergy is an inherent property of the 
transcription system. In contrast to the 
ribosome, no large preassembled structure 
takes care of mRNA synthesis. Rather a 
multitude of factors act together in a dynamic 
interplay to initiate transcription. The 
phenomenon of synergy appears to be a natural 
consequence of this design, being related to the 
multiplicity of interactions necessary to 
assemble an active pre-initiation complex at the 
TSS and unleash the productive elongation by 
RNA polymerase II. Since the initiation of 
transcription is the outcome of multiple weak 
interactions, any slight modulations of these 
may cause a large change in output. Thus, the 
phenomenon of synergy appears to be an ideal 
target for transcriptional control. We have in 
this work shown that c-Myb appears to be a 
rather weak activator, but with inherent 
potential to become a quite strong one. This 
property is revealed by two phenomena studied 
in this work. First we have shown that removal 
of SUMO-conjugation in c-Myb unleashes the 
potential of c-Myb to synergize on compound 
promoters. The larger the number of Myb-
responsive elements, the larger the difference in 
Myb-induced reporter activation between wild-
type c-Myb and its SUMO-conjugation 
negative mutant. All experimental modulations 
that changed the level of SUMO-conjugation 
led to the expected changes in synergy 
behavior, firmly linking the ability of c-Myb to 
synergize with its ability to become 
sumoylated. Having established this link, we 
further show that a major contribution to the 
increased synergy caused by SUMO-removal is 
the derepression of a silenced transactivation 
domain in the negative regulatory domain of c-
Myb. This domain is able to switch from acting 
as an internal repressive domain into an active 
transactivation domain upon removal of 
SUMO-conjugation. Our data suggest a new 
model for c-Myb in which the factor has two 
TADs, the established central TAD acting in a 
constitutive fashion, and a second inducible 
TAD being repressed by SUMO-conjugation. 
The latter provide c-Myb with an inherent 
potential to change from a rather weak activator 
into a potent transactivating factor harboring a 
double set of TADs. This model also implies 
that sumoylation is an important regulatory 
mechanism of the activity of c-Myb. 
 The dual TAD data shed light on an 
intriguing observation reported some time ago 
showing that the NRD region of c-Myb causes 
activation in yeast but repression in animal 
cells (46). This difference may now rather be 
linked to differences in the SUMO apparatus 
between the two biological systems, either with 
respect to SUMO-conjugation or to presence of 
SUMO-binding repressors. Because of this the 
SUMO-mediated NRD-repression mechanism 
probably does not function in yeast.  
 The link between the ability of a 
transcription factor to synergize on a complex 
promoters and it being relieved from SUMO-
conjugation, was first observed in studies of the 
glucocorticoid receptor (GR)(9,10), and later 
extended to other factors such as C/EBP, SF-1 
and MITF (12,49,50). We show in this work 
that c-Myb may be added to the growing list of 
synergy-controlled transcription factors. 
Concerning mechanisms, several possibilities, 
such as SUMO-mediated recruitment of co-
repressors, have been proposed (9,10), but none 
of the previous studies have demonstrated a 
specific mechanism explaining the 
phenomenon of synergy control. We have made 
several observations that have implications for 
how a mechanistic model may look like. 
 A mechanistic model has to take into 
account that the phenomenon of synergy is 
related to the multiplicity of interactions during 
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activation of a promoter. Therefore, SUMO-
mediated restriction of synergy would be 
expected to be caused either by a SUMO-
induced blocking of productive interactions or 
a SUMO-induced generation of repressive 
interactions. The first would be the case if 
SUMO-conjugation directly obstructed the 
association with a co-activator (illustrated in 
Fig. 11A) or indirectly induced a 
conformational change reducing the affinity for 
a co-activator. The latter would be the case if 
SUMO-conjugation of a transcription factor 
created affinity for a co-repressor (Fig. 11B). 
We reason that the synergy behavior observed, 
points to multiplicity as an important aspect that 
has to be incorporated into the mechanistic 
model. One way of incorporating this is to 
assume the recruitment of multivalent co-
repressor able to interact with arrays of SUMO-
conjugated factors. Multivalent recruitment of 
co-activators have for some time been the 
classical model for explaining synergistic 
activation of promoters (Fig. 11C). In an 
obstruction model, such multivalent co-
activator recruitment would be very efficiently 
killed if all the recruiting factors were modified 
by a blocking SUMO-peptide (Fig. 11A). In 
line with this, recruiting a SUMO-protease 
would be a way to switch on a promoter kept 
silent through sumoylation of bound 
transcription factors.  
 Our finding that the NRD region of c-Myb 
has the particular ability to switch from acting 
negatively to acting positively depending on 
sumoylation status is a novel element that may 
clarify the mechanism. Based on these switch-
properties, we propose a more specific model 
for the synergy control phenomenon operating 
on c-Myb. In this model synergy is determined 
by the number and strength of independent and 
active TADs associated with a promoter 
through the bound transcription factors. Under 
conditions of normal sumoylation, c-Myb 
contains one TAD partially repressed by NRD 
and the level of synergy is rather low (SF = 
0.26). Upon reduced sumoylation, as mimicked 
in the 2KR mutant or by ectopic expression of 
SENP1, the second TAD is turned on and the 
central TAD is relieved of its repression. Now, 
c-Myb will operate with two active TADs and 
therefore show higher synergy (SF = 3.9 and 
2.8 respectively). A similar positive synergy is 
seen in the c-Myb-VP16 fusion protein with 
two TADs, one weak and one very strong (SF = 
1.4). A factor with three independent TADs, as 
seen with c-Myb 2KR VP16 displays an 
extremely high synergy (SF = 35). In this 
model the number of TADs is a critical 
determinant of synergy. The activation 
potential of a single TAD may be enhanced by 
mutation, as seen in the case of the ANAA 
mutant in c-Myb (Sæther et al., in preparation). 
However, only a modest increase in synergy 
factor is observed with this mutant, probably 
because the number of TADs remains unaltered 
in the mutant protein.  
 A rationale for linking synergy to the 
number of TADs is that these domains most 
likely act as individual interaction domains. 
Therefore, two interaction domains would 
logically lead to more efficient co-activator 
recruitment than a single one, three even more 
so etc. A promoter-centered view is appropriate 
here. When two or three transcription factors 
cooperate, this means that they provide a 
promoter with two or three TADs resulting in a 
gradually increased efficiency of co-activator 
recruitment (Fig. 11C). A single factor 
presenting one or two TADs would in a similar 
fashion provide the promoter with one or two 
TADs each contributing to an increased 
efficiency of co-activator recruitment (Fig. 11D 
and E). From the point of view of the promoter, 
it must be the total number and strengths of the 
associated TADs that together determine its 
level of activation. With multiple TADs per 
transcription factor, efficient synergistic 
activation may be achieved with a more limited 
number of factors than if each factor is only 
carrying single TADs (illustrated in Fig. 11). 
Whether each of the TADs recruits the same 
(Fig. 11D) or different co-activators (Fig. 11E) 
remains to be determined. 
 Another aspect that remains to be clarified 
is whether the switch from negative to positive 
synergy occurs by removal of an obstructive 
effect of SUMO allowing co-activator 
recruitment (in Fig. 11 from 11A to 11D/E), or 
by a change from c-Myb being associated with 
a multivalent SUMO-binding repressor to being 
recruiting one or several co-activators (in Fig. 
11 from 11B to 11D/E). An indirect argument 
for the latter is our observation (Fig. 3C) that 
the helical arrangement of the MREs did not 
affect the positive synergy observed with c-
Myb 2KR (co-activator recruitment), but did 
affect the low level of SF observed with c-Myb 
wild-type, arguing that the repressed state of 
sumoylated c-Myb is more sensitive to 
geometrical arrangement than the non-
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sumoylated active state. This suggests an 
intermolecular mechanism for keeping c-Myb 
in a low-activity state. If our current search for 
a multivalent SUMO-binding repressor is 
successful, this may clarify the mechanism 
further.  
 We realize that v-Myb appears to be a 
counter example of our model having only one 
TAD and still displaying a strong synergy. 
However, v-Myb contains two deletions and 
several point mutations, which probably affect 
promoter activation through multiple 
mechanisms and is therefore difficult to 
evaluate relative to the current model. A more 
relevant deletion variant is c-Myb-NRD in 
which the central TAD is strengthened due to 
the NRD deletion, but where only one TAD is 
present. The synergy of this c-Myb deletion is 
significantly lower than for v-Myb (SF = 1.8 
versus 4.8 for v-Myb). 
 A question worth asking is whether this 
TAD-model is specific for c-Myb or reflecting 
a more general mechanism. This remains to be 
established. It is however worth noticing a few 
interesting parallels to nuclear receptors (NR). 
Many NRs have at least two activation 
domains, the ligand-independent activation 
function, AF-1, which resides in the N-terminal 
domain, and the ligand-dependent, AF-2, which 
is localized in the C-terminal domain. Taking 
GR as example, the AF1 region (amino acids 
108 to 317) is in fact sumoylated (K298 and 
K313) and is subjected to synergy control. 
Assuming then that AF-1 may be switched on 
or off depending sumoylation status, while AF-
2 is turned on upon ligand binding, this 
represents an interesting parallel to c-Myb with 
the potential to act with different numbers of 
TADs in a SUMO-controlled manner. 
 In this study of how SUMO-conjugation 
restricts the synergy behavior of c-Myb we 
have discovered a novel switch-property of 
NRD, providing c-Myb with a potential strong 
regulatory switch. Future studies will focus on 
how the activation potential of c-Myb is 
unleashed through desumoylation. 
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Figure 1. A SUMO-mediated synergy control (SC) is operating on c-Myb (A) Schematic picture 
of the luciferase reporters used in this study, containing different numbers of Myb responsive 
elements (MREs) upstream of a core promoter from human MYC driving the luciferase reporter 
gene. (B) CV-1 cells were transfected with reporter plasmids containing increasing numbers of 
MREs (1 - 5) as indicated and a plasmid encoding c-Myb wild-type or a SUMO-negative c-Myb 
2KR. Reporter activation is presented as relative luciferase units (RLU)±SEM. (C) Illustration of 
how we define the synergy factor, SF. (D,E) CV-1 cells were transfected with reporters containing 
one or four Myb responsive elements (1MRE(GG)-MYC or 4MRE(GG)-MYC) and plasmids 
encoding either c-Myb wild-type, c-Myb with both SUMO-conjugation sites mutated from lysine to 
arginine (2KR), single SUMO-conjugation sites mutated (K503R/K527R) or a 2KR-mutant fused to 
SUMO-1 as indicated. The results are presented as synergy factor (SF) ± SEM.
 
Figure 2. The level of synergy is highly dependent on the sumoylation status of c-Myb. CV-1 
cells were transfected with reporter plasmids containing one or four MREs (1×MRE(GG)-
MYC/4×MRE(GG)-MYC) and (A) a plasmid encoding either c-Myb wild-type or a SUMO-negative 
c-Myb 2KR, with or without the SUMO-protease SENP1 or SENP1 mutant as indicated. (B) The 
same reporter plasmids as above were co-transfected with plasmids encoding either c-Myb wild-
type, c-Myb with single SUMO-conjugation sites mutated from glutamate to alanine (E505A, 
E529A) or with both sites mutated (2EA). The results are presented as SF ± SEM. 
 
Figure 3. The level of synergy is altered in v-Myb, by fusion to virus TAD VP16 and by helical 
orientation of MREs. CV1 cells were transfected with Myb-responsive reporters containing one or 
four Myb responsive elements (1×MRE(GG)-MYC or 4×MRE(GG)-MYC) along with a construct 
encoding (A) c-Myb wild-type or the oncogenic version AMV v-Myb. (B) The same reporter 
plasmids as above were co-transfected with either c-Myb wild-type or c-Myb fused to the herpes 
simplex virus VP16 transactivation domain (amino acid residues 413-488). The results are presented 
as SF ± SEM. (C) The synergy factors were measured using wild-type c-Myb and c-Myb 2KR 
expression plasmids together with two variants of a luc reporter activated by four MRE differing in 
the helical phasing of the MREs. In the upper half the pGL4-4×MRE(GG)-MYC reporter was used 
where the MRE phasing is 10 bp while in the lower half the pGL4-4×MRE(GG)-MYC abab reporter 
was used where the MRE phasing is 15 bp. 
 
Figure 4. Different c-Myb-mediated synergy on natural chromatin-embedded promoters. 
Plasmids expressing c-Myb or the sumoylation-negative mutant c-Myb-2KR were transfected into 
HD-11 cells and total RNA isolated. Activations of the endogenous Myb-target genes mim-1, 
lysozyme and Pdcd4 were measured by quantitative real time PCR using primers specific for each 
gene, using the chicken HPRT as reference gene. The results are presented as relative expression 
normalized for the HPRT expression where the level measured with empty vector is set to 100. The 
results represent the mean ± SEM of three independent biological assays, each analyzed in triplicate 
for expression levels. 
 
Figur 5. TSA treatment does not affect SC. (A) CV1 cells were transfected with Myb-responsive 
reporters containing one or four Myb responsive elements (1×MRE(GG)-MYC or 4×MRE(GG)-
MYC) along with a construct encoding c-Myb wild-type. 8 hours after transfection, the cells were 
treated with 100 nM TSA or control (EtOH) for 14 h.  The results are presented as SF ± SEM. (B) 
Control of TSA treatment. CV1 cells were transfected with the SNRPN-luc reporter (30) and treated 
with TSA as described above where indicated. Reporter activations are presented as relative 
luciferase units (RLU) ± SEM. 
 
Figur 6. SC is not caused by weakening of the DNA-binding by SUMO. COS-1 cell lysates 
transfected with plasmids coding for c-Myb wild-type (1, 3, 9 μl, lanes 1-3), SUMO-negative c-Myb 
2KR (1, 3, 9 μl, lanes 4-6) or c-Myb 2KR fused to SUMO-1 (1, 3, 9 μl, lanes 7-9) were bound to 
1×MRE [	-32P]-labled probe (20 fmol). Complexes were incubated at 25°C for 10 min before 
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analysis with EMSA (upper panel). A western blot was also performed (lower panel). The amounts 
of lysate were adjusted to equal concentrations of proteins by western blot with anti-c-Myb (5e11) 
antibody. 
 
Figure 7. The NRD region of c-Myb can switch from being repressive to be activating. (A) CV-
1 cells were transfected with 0.2 or 0.4 g of plasmids expressing Gal4p-DBD fused to c-Myb NRD 
wt, 2KR, 2EA, SUMO-1 or 2KR-SUMO-1. The reporter output from the E1b-driven Gal4p-
responsive reporter plasmid (0.2 g) was normalized to the effect of Gal4p-DBD (0.2 or 0.4 g), 
which was set to 100. The results are presented as relative luciferase units (RLU)±SEM. (B) The 
same setup as in (A) but here with Gal-fusions co-transfected with the SUMO-protease SENP1 or a 
protease-dead SENP1 mutant. The results are presented as fold change calculated from luciferase 
units in the presence of SENP1/SENP1mut relative to the levels measured when co-transfected with 
empty vector (Fold change ± SEM). 
 
Figure 8. Evidence for two activation domains in c-Myb. CV-1 cells were transfected with a 
Myb-responsive reporter plasmid containing four MREs (4×MRE(GG)-MYC; 0.2g; upper panel) 
or a reporter plasmid containing three MREs (3×MRE(GG)aab-MYC; 0.2g; lower panel) and 0.4 
g of plasmids encoding either full-length c-Myb, its SUMO-conjugation negative mutant c-Myb-
2KR, or a deletion variant c-Myb NRD. The results are presented as relative luciferase units (RLU) 
± SEM.
 
Figure 9. Evidence for two activation domains in c-Myb. CV-1 cells were transfected with a 
Myb-responsive reporter plasmid containing three MREs (3MRE(GG)aab-MYC; 0.2g) and 
plasmids encoding full-length c-Myb, or a variant with the central transactivation domain deleted (c-
Myb-T1) or the latter also harboring the 2KR mutation abolishing SUMO-conjugation (c-Myb-
T1-2KR; 0.4g). The results are presented as relative luciferase units (RLU)±SEM. 
 
Figure 10. The importance of the number of transactivation domains for level of synergy. CV-
1 cells were transfected with reporter plasmids containing one or four MREs (1×MRE(GG)-MYC or 
4×MRE(GG)-MYC) and an effector plasmid encoding one of the following c-Myb variants: c-Myb, 
c-Myb-NRD encoding amino acids 1-443, the SUMO-conjugation negative mutant c-Myb-2KR 
and the latter fused C-terminally to VP16. The results are presented as SF ± SEM. 
 
Figure 11. A model for SUMO-mediated TAD repression and synergy control. (A) A model for 
the repressed state where SUMO-conjugation disrupts the interaction with the co-activator. (B) A 
model for the repressed state where multiple SUMO-conjugated factors recruit a multivalent co-
repressor. (C) Traditional concept of synergy mediated by joint recruitment of a multivalent co-
activator. (D) Current model for the activated state where multiple TADs (depicted as stars) per 
transcription factor lead to more efficient recruitment of a multivalent co-activator. (E) A variant of 
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AMV v-myb, an oncogenic version of c-myb, 
encodes a protein deleted both N- and C-
terminally as well as harbouring 10 point 
mutations. While the N-terminal deletion 
and mutations in the DNA-binding domain 
(DBD) influence DNA- and histone-binding, 
the C-terminal deletion removes most of the 
negative regulatory domain (NRD) and 
eliminates SUMO-conjugation. This ensures 
a high transactivational potential in v-Myb. 
Based on reports of a consensus SUMO-
binding motif (SBM) we analysed the c-Myb 
sequence and found that it contains two 
putative SBMs; one in the DBD and one in 
the transactivation domain (TAD). Remark-
ably, both SBMs are found mutated in AMV 
v-Myb. Pull-down and reporter assays 
showed that the SBM in the TAD of c-Myb 
(V267NIV; SMB2) is functional. This motif is 
necessary for c-Myb to be able to interact 
non-covalently with SUMO, preferentially 
SUMO-2/3. Destroying the SUMO-binding 
properties of c-Myb by mutation of SBM2 
resulted in a large increase in the trans-
activation potential. This enhancement was 
not due to impaired SUMO-conjugation or 
synergy control, but most probably to lost 
interaction with an unknown repressive 
partner. Analysis of combined mutations 
argued against intramolecular repression, 
caused by SUMO conjugated to c-Myb NRD, 
while activation induced by overexpression 
of conjugation-defective SUMO argued in 
favour of a sumoylated repressor being 
involved. In search for an intermolecular 
mechanism we focused on the Promyelocytic 
Leukemia (PML) protein, previously shown 
to bind c-Myb. However, confocal imaging 
of PML and c-Myb showed that c-Myb is 
recruited to PML nuclear bodies (PML-NBs) 
in a SUMO contact-independent manner. 
Most likely PML is therefore not the 
repressive partner itself. Interestingly, the 
SUMO-independent recruitment of c-Myb to 
PML-NBs did not correlate with functional 
data showing that c-Myb wild-type is 
activated by ectopic PML expression, while 
the SUMO-binding and sumoylation-
negative mutants have lost most of this 
potential. We therefore hypothesize that c-
Myb can be relieved from sumoylated and 
SUMO-binding repressive factors through 
their sequestering in PML-NBs, and that this 
loss of co-repression is mimicked by the 
SUMO contact-negative mutations. 
 
 
Through the last decade, studies within the 
field of SUMO (Small Ubiquitin-like modifier) 
have continuously revealed new and fascinating 
roles for this small nuclear peptide, and the 
number of targeted proteins is constantly 
growing. Despite the diversity of targets, there 
seems to be some common themes in functional 
effects: Covalent conjugation of SUMO to 
nuclear factors mainly suppress their activity or 
synergistic potential, alter their localization and 
interaction repertoire, or increase their stability 
[2-5]. The three best studied SUMO isoforms; 
SUMO-1, -2, and -3, are all conjugated to 
lysine in the consensus sequence KXE which 
often has additional acidic residues located 
directly C-terminally of this motif [6, 7]. 
SUMO-2 and -3, which share 98 % identity, 
exist predominantly as unconjugated proteins, 
but have been shown to be incorporated into 
high molecular weight complexes as a result of 
oxidative, heat or genotoxic stress [8]. This 
contrasts SUMO-1, which shares ~50 % 
identity with SUMO-2/3 and does not seem to 
exist in any large detectable free pool, but must 
be de-conjugated and conjugated quite rapidly 
[8]. Together with other Ubiquitin-like proteins 
such as ISG15, NEDD8, FAT10 and Ubiquitin 
itself, SUMO participates in a dynamic inter- 
play with the targeted proteins (reviewed in 
[5]). The molecular signals, however, 
determining the spatial and temporal pattern of  
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sumoylation versus de-sumoylation have yet to 
be identified. 
With the increasing number of sumoylated 
targets, and the common assumption that the 
effects of SUMO have to be mediated through 
protein interactions, the identification of a 
protein motif for non-covalent SUMO-binding 
was awaited. In 2004 Song et al. showed using 
NMR that a small hydrophobic patch, V/I-X-
V/I-V/I, was the minimal motif needed for 
SUMO-interaction [9]. This only partly fitted 
with a motif proposed earlier (h-h-X-S-X-S/T-
a-a-a) by Minty et al. [10]. However, with a 
study in yeast [11] and the work of Hecker et 
al. [12] the suggested consensus sequences 
were harmonized; V/I-X-V/I-V/I-a-a-a. 
Furthermore, the motif was demonstrated to be 
able to bind SUMO when reversed; a-a-a-V/I-
V/I-X-V/I/L [12, 13]. In mammalian proteins 
the hydrophobic core allows for SUMO-
binding, while negative charged amino acids 
surrounding the core determine the specificity 
regarding which of the SUMO-isoforms will 
bind. SUMO-1 seems to be more dependent on 
such an acidic stretch for efficient binding, 
while SUMO-2/3 can bind in its absence [12]. 
The discovery of SUMO-binding motifs 
(SBMs) has provided new insight into the 
interplay between sumoylation and SUMO-
binding, with the tumour suppressor PML as 
one of the best examples. PML contains both 
sumoylation and SUMO-binding motifs, and a 
recent paper showed how both motifs must be 
intact to form PML nuclear bodies (PML-NBs) 
[14]. Furthermore, the presence of several 
unoccupied SUMO-moieties and SBMs on the 
surface of the PML NBs allows for sumoylated 
and/or SBM-containing factors to be recruited 
to these bodies [14]. For the co-repressor Daxx 
an internal SBM has been shown to be crucial 
for targeting it to PML-NBs [15], while the 
base-excision repair enzyme Thymine DNA 
Glycosylase (TDG) has to be desumoylated to 
be able to translocate to PML-NBs, probably 
because the SUMO-moiety occludes the SBMs 
in TDG through binding [16].  
Another nuclear factor that associates with 
PML NBs is c-Myb [17]. c-Myb is a sequence-
specific transcription factor that controls 
proliferation and differentiation of early 
hematopoietic progenitor cells, as well as 
regulating similar processes in other tissues [1, 
18]. c-Myb becomes sumoylated in its negative 
regulatory domain at two sites, by both SUMO-
1 and SUMO-2/3 [19-21]. This leads to a 
severe drop in the activity of c-Myb [20, 21]. In 
a recent paper we have shown that this drop in 
activity is mainly due to enforced SUMO-
control of the synergistic potential of c-Myb 
and the silencing of a TAD-function in NRD 
[22]. When c-Myb is desumoylated at both 
conjugation sites the full synergistic potential 
of the transcription factor is unleashed and c-
Myb operates with two TADs. In v-Myb, the 
oncogenic version of c-Myb, both SUMO-
conjugation sites are deleted, hence no synergy 
control (SC) can be imposed by SUMO. A 
strategy to by-pass SUMO-conjugation and 
escape SC may be a common theme in 
oncogenic activation [22]. 
In this paper we show that the 
transactivation potential of c-Myb is modulated 
not only through SUMO-conjugation and SC, 
but also through non-covalent SUMO-binding. 
We have identified a functional SBM in the N-
terminal part of the central transactivation 
domain. This motif is necessary for non-
covalent interaction of SUMO with c-Myb, 
which preferentially binds SUMO-2/3. When 
mutated it induces an increase in c-Myb 
transactivational activity. This increase is not 
due to impaired SUMO-conjugation, lost 
synergy control or SUMO-mediated 
intramolecular interactions being broken, but 
rather lost repression in trans. Confocal 
imaging show that c-Myb is recruited to PML 
nuclear bodies in a SUMO contact-independent 
manner. At the same time co-transfection with 
PML activate c-Myb. However, when the 
SUMO-contact motifs (SUMO-binding and 
conjugation) are mutated, c-Myb looses this 
potential. This is probably due to relieve of co-
repression imposed on c-Myb by SUMO-
binding and/or sumoylated factors, being 




Plasmids - The mammalian expression 
vectors pCIneo-hcM-HA and pCIneo-hcM-HA-
2KR (encoding wild type and sumoylation-
deficient c-Myb, respectively) have been 
described [20]. The plasmids encoding the 
different SBM mutants (pCIneo-hcM-HA 
A103AEA, L106H, A267NAA and I267NII) were 
generated using the Quick Change Site-
Directed Mutagenesis Kit (Stratagene) on 
subfragments of human c-Myb. The “double 
mutant” pCIneo-hcM-HA A267NAA 2KR was 
made by subcloning the BglII-NotI fragment 
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from pCIneo-hcM-HA 2KR into pCIneo-hcM-
HA A267NAA. 
The 3×FLAG tagged human c-Myb, 
pCIneoB-3FLAG-hcM, was made by 
subcloning human c-MYB from pCIneo-hcM 
into pCIneoB-3FLAG (described earlier [23]) 
between XhoI and NotI. pCIneoB-3FLAG-
hcM[1-409], encoding human c-Myb and 
covering amino acid residues 1-409, was made 
by PCR amplification of the DBD-FAETL part 
of human c-Myb, and subcloning this fragment 
into pCIneoB-3FLAG  between SalI and NotI. 
The pCIneoB-3FLAG-hcM[1-409] A103AEA, 
L106H, A267NAA and I267NII were made by 
subcloning the XhoI-EcoRI fragment from the 
corresponding full-length construct into 
pCIneoB-3FLAG-hcM[1-409]. The pCIneoB-
3FLAG-AMV encoding a FLAG-tagged AMV 
v-Myb protein was made by subcloning the 
XhoI-NotI fragment from pCIneo-AMV 
(described earlier [24]) into pCIneoB-3FLAG-
hcM[1-409], replacing hcM[1-409]. 
The mammalian expression vectors for 
Gal4p-DBD fused to c-Myb TAD wild-type 
and A267NAA, covering amino acid residues 
259 to 337, were made by PCR amplification of 
pCIneo-hcM-HA wild-type and A267NAA and 
subcloning this fragment into pCIneoB-GBD2 
(described earlier [23]) between SalI and NotI. 
The conjugation-deficient SUMO-1 and 
SUMO-2 expression plasmids, pCIneo-
hSUMO1-1G and pCIneo-hSUMO2-1G, were 
made by PCR amplification of human SUMO-1 
(amino acid residues 1-96) and SUMO-2 
(amino acid residues 1-91) and subcloning 
these in pCIneo between XhoI and NotI. These 
plasmids encode SUMO-1 and -2 mutants that 
only retain the first C-terminal Gly of the Gly-
Gly motif. 
The TRHR reporter, pGL2b-TRHR-1250 
covering the area -1250 to +1 from the 
thyrotropin-releasing hormone receptor 
promoter has been described [25], as well as 
the SNRPN driven Gal4p-responsive luciferase 
reporter, pGL3b-5GRE-SNRPN [23]. The 
pGL4b-1×MRE(GG)-MYC, pGL4b-
3×MRE(GG)-MYC-aab and pGL4b-
4×MRE(GG)-MYC-aaaa reporters were also 
previously described [22]. All cloned fragments 
generated by PCR or by oligo-insertion were 
verified by sequencing. Primer sequences are 
available upon request. 
The p300 expressing mammalian vector 
pCMV-NHA-p300 was a kind gift from Prof. 
D. Livingston and has been described 
previously [26], while the vector expressing 
PML IVa [27] as well as the GST-SUMO 
fusion expressing plasmid pGEX-2TK-SUMO1 
[28] were kindly provided by Prof. G. Del Sal. 
The pGEX-4T3-hSUMO2 was received as a 
gift from Prof. RT. Hay and has been described 
[29], while the pCMV-T7-mPIASy vector [30] 
was a kind gift from Prof. R. Grosschedl.  
Protein expression, GST pull-down assay 
and in vitro translation – GST and GST-
SUMO fusion proteins were expressed in E. 
coli as previously described [31]. GST fusion 
proteins pre-bound to glutathione-Sepharose 
beads (GE Healthcare) were incubated over 
night at 4 ºC with 300 l total cell extract 
representing 1×106 transfected COS-1 cells 
lysed in 100 l Lysis-buffer (150 mM NaCl, 
0.6 % Triton X-100, 10 % Glycerol 50 mM 
Hepes, 1 mM EDTA, 1 mM EGTA, 25 mM 
NaF, 10 M ZnCl2, 0.1 % -Mercaptoethanol 
and Protease Inhibitor cocktail (Roche)), and 
diluted 1:2 in the same buffer without Triton X-
100, to a final concentration of 0.2 % Triton X-
100. Alternatively, proteins were in vitro 
translated and [35S]-labelled using TNT Quick 
Coupled Transcription/Translation Systems 
(Promega) and diluted in the same buffer as 
above. Beads were washed two times in 500 l 
Interaction buffer (150 mM NaCl, 0.2 % Triton 
X-100, 10 % Glycerol 50 mM Hepes, 1 mM 
EDTA, 1 mM EGTA, 25 mM NaF, 10 M 
ZnCl2, 0.1 % -Mercaptoethanol and Protease 
Inhibitor cocktail (Roche)) for 5 min at 4 ºC 
with rotation, and the proteins eluted in 75 l 
3×SDS loading buffer. Proteins were separated 
by SDS-PAGE and detected with 
immunoblotting. 
Cell culture and transfection, luciferase 
assays and immunoblotting - COS-1 and CV-1 
cells were grown as described [24]. Both cell 
lines were transiently transfected with the 
indicated plasmids using FuGENE6 (Roche). 
For the luciferase assays transfected CV-1 cells 
(24-well trays; 2×104 cells/well) were harvested 
24 hours after transfection and lysed in Passive 
Lysis Buffer (Promega). Luciferase assays 
were performed in triplicate using Luciferase 
Assay Reagent (Promega), and data from at 
least three independent transfection 
experiments are presented. In parallel 
transfected CV-1 cells were lysed in NP-40 
buffer and subjected to immunoblotting. For 
the assessment of SUMO-conjugation of c-Myb 
mutants transfected CV-1 cells (6-well trays; 
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1.2×105 cells/well) were harvested 24 hours 
after transfection, scraped in ice cold PBS, and 
lysed directly by sonication in SDS-PAGE 
sample buffer. 
Antibodies - For immunoblot detection the 
following antibodies were used; rabbit anti-HA 
antibody (H 6908 Sigma), mouse anti-FLAG 
M2 monoclonal antibody (F3165, Sigma), anti-
mouse IgG-HRP (NA931, GE Healthcare) and 
anti-rabbit IgG-HRP (NA934, GE Healthcare). 
As immunofluorescence antibodies we used 
rabbit anti-HA (H 6908 Sigma) and mouse anti-
PML (sc-966 Santa Cruz). Alexa Fluor 488 
goat anti-rabbit IgG(H+L) and Alexa Fluor 633 
goat anti-mouse IgG1 (	1) (Molecular Probes) 
were used as secondary antibodies.  
Immunofluorescence and confocal laser 
scanning microscopy - 1.8×104 CV-1 cells were 
plated out in 24-well trays containing cover-
slips and transfected 24 hours later with the 
indicated plasmids at a total of 0.6 
g DNA. 24 
hours after transfection cells were washed in 
PBS. Cells were fixed and permeabilized with 
4 % formaldehyde for 10 min and ice cold 
methanol for 2 min. Samples were washed 
three times for 5 min in PBS containing 0.1 % 
Tween 20 and then blocked for 30 min with 2 
% BSA in PBS with 0.1 % Tween 20, followed 
by incubation with primary antibodies diluted 
1:50 in the blocking solution for 45 min. The 
samples were then washed three times as 
described above, and incubated with secondary 
antibodies diluted 1:100 in 2 % BSA in PBS 
with 0.1 % Tween 20 for 30 min. Samples were 
washed three times again and incubated with 
Hoechst 33258 (Sigma-Aldrich) for 20 min to 
visualize DNA. After three washes the cover-
slips were placed on microscope slides using 
mounting medium (Dako). Cells were 
examined using a FluoView laser scanning 
system from Olympus. Images from the 
different channels were collected sequentially 




c-Myb contains two putative SUMO binding 
motifs which are both mutated in AMV v-Myb 
The C-terminal deletion in AMV v-Myb, an 
oncogenic version of c-Myb, eliminates the 
negative regulatory domain (NRD), making 
AMV v-Myb behave like an activated form of 
c-Myb in transactivation assays. Lost SUMO-
conjugation plays a key role here [20]. We 
recently came to realize that loss of SUMO-
conjugation sites is not the only oncogenic 
alteration in v-Myb that may relate to SUMO-
biology. Based on reports of a consensus 
SUMO-binding motif (SBM; aaa-V/I-V/I-X-
V/I/L and V/I-X-V/I-V/I-aaa) [9, 12, 13], we 
analysed the c-Myb sequence and found that it 
contains two putative SBMs; one in the R2 
repeat in the DNA-binding domain (termed 
SBM1), and one in the N-terminal end of the 
transactivation domain (termed SBM2; Fig 1A 
and B). Remarkably, both sites are mutated in 
v-Myb, as illustrated in Fig 1B. In fact, three of 
the ten oncogenic mutations in v-Myb are 
localized to the putative SBMs. Hecker et al. 
have shown that the specificity of non-covalent 
SUMO-1 versus SUMO-2 binding lies in a 
stretch of negatively charged residues located 
directly N- or C-terminally of the core SBM 
motif [12]. The fact that only SBM1 has such 
neighbouring residues implies that if 
functional, the c-Myb SBM1 would be a 
SUMO-1 binding motif, while SBM2 mainly 
would bind SUMO-2/3. 
 
Mutating the SBM in c-Myb TAD derepress c-
Myb and makes it super active. 
To investigate whether mutations in these 
potential SMBs would influence c-Myb activity 
and thereby give a hint to whether or not these 
sites are of functional importance, we made a 
set of mutants aiming to abrogate SUMO-
binding (outlined in Fig 1C). The mutants 
L106H and I267NII were made to mimic the 
mutations found in v-Myb SBM1 and SBM2, 
respectively. It may be noticed that the 
sequence change in SBM2 introduced in AMV 
v-Myb is not expected to abolish SUMO-
binding. Hence, since only the L106H mutation 
seemed to represent a deviation from the SBM 
consensus, the mutations A103AEA (wild type: 
V103IEL) and A267NAA (wild type: V267NIV) 
were made to ensure a complete elimination of 
any binding of SUMO to the SBMs, given that 
one or both of the SBMs were functional.   
We then performed effector-reporter assays 
in CV-1 cells using the c-Myb responsive 
3×MRE(GG)-MYC luciferase reporter [22]. As 
can be seen in Fig 2A, the SBM1 mutant 
L106H apparently had no effect in this system, 
while the A103AEA appeared to have a slight 
negative influence on c-Myb-mediated 
transactivation. On the other hand the A267NAA 
SBM2 mutant had a dramatic effect and 
activated, i.e. derepressed, c-Myb more than 
13-fold. The activity of this mutant closely 
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resembled that of the SUMO-conjugation 
negative 2KR mutant [20], which we included 
as a positive control (Fig 2A). The v-Myb 
mimicking mutation I267NII had no such 
derepression effect; it rather lowered the c-Myb 
activity slightly. These results were also 
verified on another reporter harbouring the c-
Myb responsive TRHR promoter (data not 
shown). As can be seen in Fig 2B, none of 
these effects can be attributed to mutation-
induced changes in expressional levels or 
protein stability. It therefore appears that that 
the V267NIV motif in c-Myb TAD has a strong 
repressive function, possibly mediated through 
the binding of SUMO, and that the A267NAA 
mutant abrogates this repression. 
 
Human c-Myb binds SUMO 
If c-Myb contains a functional SBM, the 
protein must show some affinity for SUMO. 
However, since SUMO in general binds to 
SBMs with affinities in the micromolar range 
[12], demonstrating interactions may be 
technically difficult. To examine whether c-
Myb is able to bind SUMO, we tried to pull out 
c-Myb from COS-1 lysates using GST-SUMO-
1 and SUMO-2. Until date this is one of the 
most stringent ways of detecting SUMO-
binding, allowing both endogenous SUMO and 
SUMO-binding factors to compete for epitopes.  
To avoid the potential problem of SUMO 
conjugated to c-Myb interfering with any 
SUMO binding sites we used a shorter version 
of human c-Myb (spanning amino acid residues 
1-409) where the NRD (harbouring the SUMO-
conjugation motifs) had been deleted. As can 
be seen in Fig 3A, c-Myb did interact with 
SUMO under these conditions, although 
weakly as expected. Furthermore, c-Myb 
seemed to bind more efficiently to SUMO-2 
than to SUMO-1 (Fig 3A). 
Knowing that the shorter version of c-Myb 
was able to bind SUMO, we then tested if the 
same held true for full-length c-Myb. Using the 
same experimental setup as above, we found 
that GST-SUMO-2 was able to interact with 
full-length c-Myb as well (Fig 3B). The two 
lower bands seen with full-length c-Myb are 
the result of some unspecific C-terminal 
degradation. Nevertheless, this shows that c-
Myb binds to SUMO-2, and that the interacting 
motif is exposed and available when full-length 




Only the putative SBM in c-Myb TAD (SBM2) 
is functional and mediates SUMO-binding. 
In order to determine whether c-Myb binds 
SUMO via the putative SBMs and to identify 
which of the SBMs might be responsible for 
the non-covalent binding of SUMO, we 
carefully evaluated the different mutants using 
GST-SUMO pull-down in COS-1 lysates. 
When comparing c-Myb wild-type with the 
SBM1 mutants (L106H and A103AEA) we were 
not able to see any difference in the ability to 
interact with SUMO (Fig 4A), and both 
proteins showed similar binding to SUMO-2 as 
the wild type. In contrast, an obvious difference 
was observed when comparing the SBM2 
mutants (A267NAA and I267NII) with the wild-
type. While the I267NII mutant seemed to have 
retained the ability of c-Myb to bind SUMO, 
the A267NAA mutant had lost this property, and 
only very weak background bands were 
detected (Fig 4B). 
In general the same pattern emerged when 
using in vitro translated, [35S]-labelled c-Myb 
as prey (spanning amino acid residues 89-337) 
in GST pull-down assays. In Fig 4C we show 
the quantified and normalized average of two 
independent experiments. In this system the 
INII mutant bound more strongly to SUMO 
than the wild-type, consistent with its negative 
influence on the activity of c-Myb (Fig. 2A). 
However, no preference for SUMO-2 was 
apparent and the binding of c-Myb to SUMO-1 
seemed as strong as to SUMO-2. Consistent 
with the binding studies in COS-lysates, the 
ANAA mutant once again showed significantly 
reduced binding and was not retained on GST-
SUMO more than the background seen in the 
GST control. We therefore conclude that c-
Myb binds SUMO, with a preference for 
SUMO-2 under stringent conditions, through 
the TAD-localized SBM2, and that this 
interaction correlates with suppressed 
transactivational activity of c-Myb. 
To test whether the binding of DNA to c-
Myb would affect the SUMO-binding 
properties, we conducted some of these 
experiments in the presence or absence of 
ethidium bromide or DNA (1×GG-MRE (mim-
1A)) [22]. However, none of these experiments 
indicated that the presence of Myb-responsive 
DNA changed the interaction between c-Myb 
and SUMO (data not shown). We therefore 
concluded that DNA does not have any 
influence on the non-covalent binding of 
SUMO to c-Myb. 
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AMV v-Myb still binds SUMO 
Although intriguing, the mutations found in the 
v-Myb SBMs (L106H and I267NII; c-Myb 
numbering) had not proved to cause any major 
change in the SUMO-binding properties of c-
Myb (Fig 4). Still, the other oncogenic 
alterations in AMV v-Myb, made us consider 
the possibility that the SMB-mutations might 
have an effect in a v-Myb context. We 
therefore carefully compared c-Myb[1-409] 
and AMV v-Myb in the same experiment. As 
seen in Fig 5, v-Myb showed the same SUMO-
binding characteristics as c-Myb, including the 
preferred binding to SUMO-2. From these 
experiments, and the mutation studies, we 
conclude that AMV v-Myb still binds SUMO-2 
with an affinity comparable to that of c-Myb. 
 
Mutating the SBM does not affect the 
sumoylation of c-Myb 
Having found evidence for a physical, non-
covalent interaction between c-Myb and 
SUMO, and observed a derepression of c-Myb 
activity with the SBM2 A267NAA mutant that 
resembled the effect of the SUMO-conjugation 
disrupting 2KR mutations, we then asked 
whether their similar derepressions might 
simply be caused by SUMO-conjugation being 
dependent on a functional SBM2. The two 
SBM2 mutants (A267NAA and I267NII) were 
expressed in CV-1 cells and the sumoylation 
patterns were compared with those of c-Myb 
wild-type and 2KR. As can be seen in Fig 6A, 
neither the INII, nor the ANAA mutation 
changed the sumoylation pattern of c-Myb. 
This contrasts the 2KR mutant, where SUMO-
conjugation is lost in both sites (K503 and 
K527). 
Another strategy for assessing whether 
non-covalent SUMO-binding affects covalent 
SUMO-conjugation to c-Myb would be to 
study the synergistic properties of the SBM 
mutants. In a recent work we showed that c-
Myb is subject to a strong synergy control, 
which is tightly linked to the sumoylation level 
of c-Myb [22]. By studying the SBM mutants 
in this context one might also get information 
relevant to identifying what mechanism is 
operating through this motif. We therefore 
carefully measured the output from our 
dedicated synergy reporters, only differing in 
the number of Myb-responsive elements. The 
synergy factor (SF) calculated from the relative 
luciferase expression from the 1×MRE and 
4×MRE-containing MYC-reporters showed that 
even though the A267NAA mutant had the same 
activity as 2KR (Fig 2A), its SF was well below 
1.0 (Fig 6B). This was also the case for I267NII 
and wild-type c-Myb, while the 2KR mutant 
had a SF ~ 4 (Fig 6B). 
Altogether, these data show that mutating 
the SBM has no influence on the sumoylation 
of c-Myb. Hence, SUMO-binding and SUMO-
conjugation are two independent events, 
controlled by separate mechanisms. 
Furthermore, destroying SUMO-binding has 
only minor effect on the synergy behaviour of 
c-Myb, in contrast to the large change in 
synergy seen after abrogating SUMO-
conjugation. Thus loss of synergy control can 
not explain the high transactivation of the 
ANAA mutant. 
 
The SBM is not controlling c-Myb activity 
through binding in cis to SUMO-conjugated 
NRD.  
In the mid-nineties data were presented 
showing that there might exist intramolecular 
interactions between the EVES domain and the 
N-terminal region in c-Myb [32]. Moreover, 
others have speculated that there might be an 
indirect contact between the NRD and the TAD 
[33, 34]. With sumoylation of c-Myb being 
well documented [20, 21] and the present 
identification of a functional SBM in c-Myb 
TAD, we asked whether SUMO-conjugates in 
the NRD and the SUMO-binding motif in the 
start of TAD might be involved in bridging 
these parts of c-Myb. We reasoned that if 
SUMO-conjugation and SUMO-binding were 
part of the same mechanism in c-Myb, 
destroying one or both of these functions would 
lead to the same transactivational phenotype. 
As shown in Figures 2A and 7A c-Myb 
A267NAA and c-Myb 2KR is almost identical 
with regard to activity, however, when both 
these mutations were introduced in the same 
construct (c-Myb ANAA 2KR) an additive 
increase in activity was observed (Fig 7A). 
Even when deleting the entire NRD, the 
A267NAA mutation still increased the activity 
of c-Myb (Fig 7B). Taken together this argues 
against the hypothesis of a SUMO-governed 
bridging of the EVES and TAD domain and 
further supports the notion that that the 
transactivation potential unleashed with the 
SBM mutation in full-length c-Myb is 
disconnected from the SUMO-conjugation in 
the EVES domain. 
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Finally, we asked whether the SBM was a 
determinant of the strength of the neighbouring 
TAD. Given that c-Myb binds SUMO in TAD, 
elimination of this interaction by mutation 
might simply increase the likelihood of c-Myb 
interacting with the well-established co-
activator p300. We therefore fused TAD wild-
type and TAD ANAA to the yeast Gal4p DNA-
binding domain and studied their activity in the 
absence or presence of p300. As can be seen in 
Fig 7C the ANAA mutation induced an 
increase in the transactivational activity of the 
isolated TAD. Moreover, both TAD wild-type 
and the SBM mutant seemed to respond equally 
well to co-expression of p300. From this we 
conclude that the c-Myb SUMO-binding motif 
is functional in a TAD-only context, and that 
the suppression of c-Myb activity seen with a 
functional SBM is a property of c-Myb that 
appears to be uncoupled from steric hindrance 
of p300. 
 
c-Myb is binding SUMO in trans in a SBM-
dependent fashion 
Since our data obtained with double mutations 
or NRD-deletions did not support the 
hypothesis of an intramolecular repressive 
binding of SUMO, i.e. SUMO-moieties 
conjugated to the NRD, we assumed that the 
SBM had to bind SUMO in trans. 
Consequently, the repressive effect of the 
functional SBM had to be attributed to the 
recruitment of one or more sumoylated, 
negatively acting co-factors. If so, it should be 
possible to titrate out this co-repressor with an 
excess of free SUMO, and thereby increase 
Myb activity. To test this we expressed 
increasing amounts of non-conjugatable 
SUMO-1 and -2 (mono-Gly in C-terminal) in 
the presence of c-Myb wild-type and compared 
this with SUMO-binding and SUMO-
conjugation negative c-Myb mutants. As can be 
seen in Fig 8A, co-expression of SUMO-1-1G 
in the presence of c-Myb wild-type led to an 
increase in c-Myb activity, while no significant 
change in activity was seen for c-Myb ANAA 
2KR. The derepression of wild-type c-Myb was 
even more pronounced when titrating in 
increasing amounts of SUMO-2-1G (Fig 8B), 
consistent with the observed preference for 
SUMO-2. Interestingly, a reduced 
responsiveness was observed for c-Myb ANAA 
as well as for c-Myb 2KR, even though both 
proteins experienced a slight induction in 
transcriptional activity. The slight induction 
observed with c-Myb ANAA might have been 
caused by a weak inhibitory effect of the 
SUMO-1Gs on conjugation. Still there is a 
clear difference between the SBM mutant and 
wild-type c-Myb. Altogether, we conclude that 
c-Myb binds SUMO in trans. This interaction, 
which probably involves a negatively acting 
sumoylated protein, may be titrated out with 
increasing amounts of free SUMO, in which 
case SUMO-2 is the most efficient competitor. 
This last observation fits well with our 
interaction data showing that the SBM in c-
Myb TAD preferably binds SUMO-2. 
 
Co-activation of c-Myb by PML is lost when 
the SUMO-binding and conjugation properties 
of c-Myb is abrogated 
Having established that c-Myb binds SUMO, 
most likely in the form of another sumoylated 
protein, we wanted to identify such a factor. 
Since a functional SBM in c-Myb seems to 
suppress c-Myb transactivation, the sumoylated 
factor(s) that is recruited to the c-Myb SBM 
probably acts as a traditional co-repressor, 
alternatively keeps c-Myb away from active 
transcription by sequestering. One such factor 
that might fulfil these criteria is PML. We have 
previously shown that PML interacts with c-
Myb and recruits it to PML nuclear bodies 
(PML-NBs) [17]. To investigate whether the 
SUMO-related mutations in c-Myb influence 
the ability of PML to modulate c-Myb 
transactivation, c-Myb wild-type, ANAA, 2KR 
and the double mutant ANAA 2KR were 
transfected alone or together with PML IVa in 
CV-1 cells. As seen before this co-transfection 
led to an increase in activity for c-Myb wild-
type (Fig 9; [17]).  Curiously, the relative 
increase in activity decreased with the removal 
of functional SUMO-contacts; wild-type > 
ANAA  2KR > ANAA 2KR, where the 
double mutant, ANAA 2KR, was near 
unresponsive. We therefore conclude that PML 
co-activates c-Myb-dependent transcription, 
and that its ability to co-activate is dependent 
on functional SUMO-binding and SUMO-
conjugation properties in c-Myb. 
 
PML and c-Myb co-localizes in a SUMO-
contact independent manner 
Trying to relate the PML-induced activity 
alterations to PML-NB recruitment, we 
performed co-localization studies with PML 
IVa and the different c-Myb mutants. We first 
evaluated the distribution of the ANAA, 2KR 
and the ANAA 2KR when transfected 
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individually, and compared that to the wild-
type distribution. c-Myb stains mainly 
uniformly in the nucleus except nucleoli, but is 
also found in punctual structures [17, 35]. This 
pattern was also seen with the ANAA, 2KR and 
the ANAA 2KR mutants (Fig 10A). Hence, 
abrogating c-Myb-SUMO contact does not 
seem to affect the general distribution of the 
protein within the cell. When we then looked at 
cells were both c-Myb and PML were 
ectopically expressed, the PML NBs were 
clearly visible with their characteristic 
doughnut-like, hollow spheres [36]. As shown 
earlier c-Myb wild-type co-localizes to these 
structures (Fig 10B; [17]). To our surprise 
neither loss of SUMO-binding nor SUMO-
conjugation properties in c-Myb affected the 
recruitment to PML-NBs. Both the ANAA and 
the 2KR mutant, as well as the double mutant, 
ANAA 2KR, co-localized with PML (Fig 10C, 
D and E). 
From this we conclude that c-Myb is 
recruited to PML nuclear bodies in a SUMO 
contact-independent manner, and that the 
lowered co-activating function of PML seen 
with lost c-Myb SUMO-binding and/or SUMO-





In this work we have identified a novel SUMO-
link in human c-Myb in the form of a 
functional SUMO-binding motif (V/I-X-V/I-
V/I; V267NIV) located in the N-terminal part of 
its transactivation domain. The functionality of 
this motif was assessed by two criteria: (1) c-
Myb should show detectable binding affinity 
for SUMO, dependent on an intact SBM; and 
(2) removal of SBM by mutation should cause 
a change in the activity of c-Myb. The first 
criterion was assessed by GST pull-down 
assays with different SUMO isoforms and 
showed that c-Myb binds SUMO in an SBM-
dependent fashion, with a clear preference for 
SUMO-2/3 (Fig 3). The second functionality 
test demonstrated that c-Myb with the SBM 
inactivated had become derepressed and 
increased its transactivation potential 
significantly (Fig 2). 
Using the reported SUMO-binding 
consensus motifs [12, 13] we identified two 
putative SBM sites in c-Myb; one in DBD and 
the other in TAD. The potential SBM in the 
DBD was found to be positioned in the middle 
of the first -helix in the second Myb-repeat 
(SBM1; Fig 1A). This was in itself a reason for 
rejection, since the SBMs reported so far seem 
to reside within short linear protein motifs 
found in unstructured regions [9]. Still, data on 
the structure of Myb R2 in solution has been 
conflicting [37, 38], even though it is now 
generally accepted that only the third helix in 
R2 is dependent on DNA-binding for its 
structuring [38-40]. The putative SMB in TAD 
(SBM2; Fig1A) on the other hand seemed to be 
in an unstructured region, based on a GlobPlot 
analysis. Nevertheless, since both putative 
SBMs turned out to be mutated in AMV v-
Myb, we chose to examine both of them. 
Effector-reporter assays and GST pull-down 
with both in vitro translated and COS-1-
expressed c-Myb showed that only mutations in 
the TAD-localized SBM had an effect on c-
Myb activity and SUMO-binding. When 
destroying the potential SBMs by classical 
alanine substitutions (V/I/LA) only the 
V267NIVA267NAA mutation both derepressed 
c-Myb transactivational activity (Fig 2A) and 
abrogated SUMO-binding (Figs 4BC). We 
therefore conclude that only the SBM2 met our 
criteria for being functional. If SBM1 also 
contributes to SUMO-binding, it probably 
plays a minor role.  
Recently, the determinant for SUMO 
isoform specificity in SBMs was shown to lie 
in a stretch of negatively charged residues 
located directly N- or C-terminally of the SBM 
[12]. Hecker et al. have demonstrated that 
SBMs that lack the acidic stretch tend to 
interact with SUMO-2/3 [12]. Since the SBM2 
only consisted of a hydrophobic core (closest 
acidic residue: +14), we reasoned that if 
functional, SBM2 would be a SUMO-2/3 
binding motif, and indeed this was the case: In 
all the different interaction assays we 
performed with c-Myb expressed in vivo, a 
preference for SUMO-2 binding was observed 
(Figs 3, 4AB and 5). When using in vitro 
translated protein, SUMO-1 seemed to interact 
as strongly with c-Myb as SUMO-2 (Fig 4C). 
Whether this difference is an effect of changes 
in c-Myb topology or interaction milieu; e.g. 
lack of factors competing for epitopes or 
promoting interaction, is not known. More 
important, when conjugated to the right factor 
the SUMO-moiety might bind more efficiently 
to c-Myb than seen in the GST pull-down 
assays in this study, due to additional 
interaction surfaces [41]. 
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When taking a closer look at the c-Myb 
SBM and the nearby residues, it becomes 
evident that it displays a kind of symmetry; 
V267NIVNV (Fig 1A). Song et al. has shown 
that SUMO is able to bind SBMs also in the 
reverse direction; V/I-V/I-X-V/I/L [13]. For 
SUMO-1 binding however, the context 
sequence, i.e. the localization of the acidic 
cluster, probably directs the orientation [12, 
13]. SUMO-2/3 on the other hand, which is not 
dependent on these negative charges, could 
theoretically bind in both directions at semi-
palindromic SBMs. For c-Myb and other 
SUMO-2/3 binding proteins with symmetric 
SBMs this might increase the flexibility of the 
interaction, and moreover, thermodynamically 
strengthen the binding. In this context it is 
interesting to notice that even though the 
functional significance of semi-palindromic 
SBMs in SUMO-2/3 binding still has not been 
established, such SBMs are found in many 
SUMO-binding factors. 12 out of 22 SBMs 
listed in [12] displays symmetry. This includes 
SBMs in Sp100, PIAS1, -2 and -3, and 
RanBP2. In addition the SBM in PML [9, 14], 
in Daxx [15], and one of the two in TDG [16] 
are symmetric. 
The fact that both of the putative c-Myb 
SMBs are mutated in AMV v-Myb, motivated 
the initiation of this study. The finding of 
evolutionary conserved motifs with a 
designated function that is mutated in the 
leukemogenic v-Myb, immediately suggested a 
possible association. Still, only the SBM in 
DBD (SBM1), were mutated away from the 
consensus (V103IELVV103IEHV). Moreover, 
when ruling out that SBM1 was functional 
(Figs 2 and 4A), it became clear that AMV v-
Myb has not disposed it self of SUMO-binding. 
The I267NII motif still supports binding of 
SUMO-2/3, both in a c-Myb (Fig. 4BC) and v-
Myb background (Fig 5). Some of our 
experiments even suggested a slightly enhanced 
binding caused by the INII substitution (Fig 
4C). Furthermore, v-Myb is probably still 
subjected to negative regulation via this motif 
(Figs 2A and 7B). One might ask why loss of 
SUMO binding is not found in v-Myb, since it 
would be expected to relieve it from negative 
control.  Given the significant derepression 
seen with SBM2 mutated, its associated 
phenotype might not be selected for. Regarding 
mutational activation of essential gene products 
like c-Myb, there obviously exists a threshold 
limit, beyond which additional aberrations 
becomes lethal. Hence, subtle phenotypes may 
be more likely to accumulate. On the other 
hand, neutral mutations may occur as a natural 
consequence of the mutation-driven evolution. 
Therefore it is possible that some mutations, 
also in v-Myb, do not alter the phenotype.  
Further evidence for a functional SUMO-
binding, also in AMV v-Myb, comes from an 
older report using linker insertion mutagenesis 
in AMV v-myb. In an effort trying to link 
transactivation and transformation by v-Myb, 
Lane et al. in fact generated one insertion 
mutant interfering with the SBM2 element 
defined in this work (v-Myb 752; 
I202NIII202NGPII) [42]. Interestingly, this 
mutant were able to activate transcription 25-
fold more efficiently than AMV v-Myb in QT6 
cells [43], suggesting that this might be due to 
loss of interaction with a unknown cellular 
inhibitor. In light of the present work, their data 
supports the functionality of SBM2, and 
consequently that v-Myb is negatively 
regulated by SUMO-binding.  
Having identified a functional SBM in c-
Myb, we sought to dissect its mechanism of 
action. As given for a SUMO-binding domain, 
we expected SBM2 to act through the binding 
of a sumoylated protein. Furthermore, since 
mutation of SBM2 caused derepression, we 
expected the unknown sumoylated partner to 
exert a repressive effect on c-Myb. Two 
different types of binding partners could 
potentially fulfil these requirements. The most 
plausible would be an intermolecular 
mechanism, where a SUMO-modified co-
repressor binds to SBM2, resulting in lowered 
c-Myb transactivational activity. An alternative 
hypothesis might be that SBM2 interacts 
intramolecularly with sumoylated NRD, 
leading to a repressed conformation of c-Myb.  
Before we addressed the inter- and 
intramolecular hypothesis, we had to exclude a 
rather trivial explanation, assuming that the 
SBM might be required for binding of SUMO 
as part of the c-Myb SUMO-conjugation 
process. Loss of SUMO-binding would then 
lead to reduced SUMO-conjugation and 
thereby increased activity. Non-covalent 
binding of SUMO has been indicated to be an 
important property in orientating SUMO for 
optimal conjugation [44, 45]. However, as 
evident from western blots of the different 
SMB mutants, neither the A267NAA, nor the 
I267NII mutation had any effect on the 
sumoylation of c-Myb (Fig 6A). We have 
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recently shown that the “synergy control (SC) 
phenomenon” is strongly operating on c-Myb, 
and that this is tightly linked to sumoylation 
[22]. Therefore, the observation that c-Myb 
ANAA still displayed SC, with a synergy factor 
below 1.0 (Fig 6B), functionally supports our 
conclusion that the SBM do not contribute to 
the sumoylation of c-Myb. 
The first candidate mechanism we 
addressed was the intramolecular one where 
SUMO conjugated to the NRD of c-Myb might 
act as the binding partner of SBM2. Such an 
explanation would potentially substantiate the 
hypothesis of a fold-back mechanism between 
the EVES domain and the N-terminal region in 
c-Myb [32, 46] or the transactivation domain 
[33, 34]. Such intramolecular interactions have 
been hypothesized to conceal co-activator 
binding epitopes, thus lowering c-Myb activity. 
Furthermore, the transactivation domain of c-
Myb was demonstrated to be activated in trans 
by c-Myb NRD when co-transfected in Gal4 
tethering assays. This was in fact suggested to 
be caused by a universal cellular inhibitor, able 
bind both domains, being titrated out by the 
NRD [33]. The comparable activities of c-Myb 
2KR and ANAA seen in our study (Figs 2A and 
7A) suggested a common mechanism, given 
that these mutants represented two separate 
ways of destroying the same intramolecular 
bridge. However, when introducing both the 
2KR and ANAA mutations in the same 
construct, the transcriptional activity more than 
doubled, resulting in an extremely active 
phenotype (Fig 7A). Moreover, the ANAA 
mutant still had an activating effect when the 
NRD, including the SUMO-modified area of c-
Myb, was deleted (fig 7B). Finally, destroying 
the SUMO-binding properties of c-Myb even 
had an effect when studied in a TAD-only 
context (Fig 7C). Thus, these data do not fit the 
activity pattern anticipated if the derepression 
was caused by disruption of an intramolecular 
association between a SUMO-conjugated 
EVES domain and SBM2. Still these 
experiments do not formally exclude the 
possibility of a fold-back mechanism in c-Myb 
not involving SUMO or not leading to activity 
changes. 
Having excluded altered SUMO-
conjugation or broken intramolecular 
interactions as explanations to the increased 
transactivational potential of the SBM mutant, 
we addressed the possibility of intermolecular 
mechanisms. We reasoned that if a sumoylated, 
negatively acting factor was able to bind to the 
c-Myb SBM, it should be possible to interfere 
with this binding by overexpressing non-
conjugatable SUMO. By co-transfecting c-Myb 
and increasing amounts of SUMO-1-1G and 
SUMO-2-1G we were able to increase the c-
Myb activity, most likely by titrating out both 
SUMO-binding repressors (Fig 8: wt vs. 
ANAA) and SUMO-conjugation of c-Myb by 
interference with the sumoylation apparatus 
(Fig 8: wt vs. 2KR). This suggests that c-Myb 
is repressed in trans via SBM2, as well as via 
the SUMO moieties in EVES.  
In principle, intermolecular mechanisms 
may explain our observed derepression directly 
or indirectly. Either, a binding partner of SBM 
may lead to obstruction of co-activator 
interaction, or it may itself act as an active co-
repressor. A clear candidate for an obstructive 
mechanism would be interference with binding 
of the co-activator p300 to c-Myb TAD 
(binding between amino acid residues 295-309; 
[47-49]). However, the repressive effect seems 
to be uncoupled from steric hindrance of the 
histone acetyltransferase, since we observed 
that p300 co-activated TAD wild-type just as 
well as TAD ANAA (Fig 7C). Interestingly, 
p300 has been shown to be sumoylated, leading 
to the recruitment of HDAC6 and repression of 
p300-dependent transcription [50]. Given the 
close proximity of the SBM and the p300-
interacting region in c-Myb it would be 
interesting to examine whether sumoylated 
p300 can bind both motifs. 
One obvious candidate for an SBM-partner 
acting in trans and thus regulating c-Myb 
transactivation is the Promyelocytic Leukemia 
(PML) protein. Recently, both sumoylation and 
SUMO-binding have been shown to regulate 
nucleation of the PML protein into nuclear 
bodies (PML-NBs; [14, 51]). Furthermore, the 
sequestering of nuclear factors into the PML-
NBs is also mediated through SUMO-contacts 
[15, 52]. As shown earlier c-Myb wild-type co-
localizes with these structures [17]. When 
comparing this pattern (Fig 10B) with the co-
localization of PML and the SUMO-contact 
mutants (ANAA, 2KR and ANAA 2KR) 
employing immunofluorescence, no detectable 
changes in localization was observed (Fig 10C-
E). Dahle et al. showed that the interaction 
between c-Myb and PML appeared to be 
independent of c-Myb sumoylation, although a 
quantitative difference was not excluded [17]. 
Our new data supports this, and extend the 
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notion of a SUMO-independent recruitment of 
c-Myb to PML-NBs to include also SUMO-
binding. PML and PML-NBs have been given a 
particular attention because of their role in 
human Acute Promyelocytic Leukemia (APL; 
[53]). Accordingly, dissecting the link between 
c-Myb and PML, both being implicated in 
leukemic disorders, is of importance. 
Interestingly, and in contrast to the co-
localization of c-Myb and PML, the co-
activating function of PML was reduced as the 
SUMO-binding motif and the SUMO-acceptor 
lysines in c-Myb were mutated (Fig 9). We 
believe that this co-activation might be caused 
by PML-NBs sequestering negatively acting 
co-factors acting on c-Myb through the SBM or 
conjugated SUMO moieties, and furthermore, 
that the reduced PML co-activation seen with 
the SUMO-contact mutants is due to co-
repressor interactions already being broken.  
Indeed, PML has been shown to function as a 
co-activator for the glucocorticoid receptor 
through sequestering the SUMO-binding co-
repressor Daxx to PML-NBs [15, 54].  In their 
work on SUMO-2/3 conjugation of c-Myb 
Sramko et al. observed a derepression of c-
Myb activity using tricostatin A [21]. This 
indicates that we might be looking at an HDAC 
being recruited to the SUMO conjugates. 
Concerning what negative-acting factor(s) that 
binds to the c-Myb SBM, a follow-up study of 
the linker insertion mutagenesis hitting the 
SBM in v-Myb might give some directions. 
When the v-Myb I202GPNII mutant was tested 
in yeast cells, it only induced transcription 
about two-fold more than v-Myb, as compared 
to 25-fold more than v-Myb in quail fibroblasts 
[43]. This narrows the candidates down to 
vertebrate-specific proteins. Still, it might just 
indicate that the yeast SUMO homologue, 
Smt3p, is unable to interact with the c-Myb 
SBM. However, the affinity of Smt3p for the 
SBM in PIAS2 (V467DVIDL) is similar to that 
of human SUMO [12, 13] 
In conclusion, we have identified a site in 
c-Myb being important for the ability of the 
factor to associate with SUMO. The mutation 
of this motif causes a significant derepression 
of the activity of c-Myb. Our observations 
point in the direction of an intermolecular 
rather than an intramolecular mechanism. 
However, the identity of the assumed SBM-
binding repressor remains to be determined. 
Therefore, identifying SUMO-contact 
dependent co-repressors acting on c-Myb is an 
important task for future work.  
 
 
Acknowledgements - We thank Marit Ledsaak 
for excellent technical assistance and Profes-
sors D. Livingston, G. Del Sal, RT. Hay and R. 






1. Oh, I.H. & Reddy, E.P. (1999) The myb gene family 
in cell growth, differentiation and apoptosis. 
Oncogene 18, 3017-33. 
2. Gill, G. (2004) SUMO and ubiquitin in the nucleus: 
different functions, similar mechanisms? Genes Dev 
18, 2046-59. 
3. Gill, G. (2005) Something about SUMO inhibits 
transcription. Curr Opin Genet Dev 15, 536-41. 
4. Hay, R.T. (2005) SUMO: a history of modification. 
Mol Cell 18, 1-12. 
5. Kerscher, O., Felberbaum, R. & Hochstrasser, M. 
(2006) Modification of Proteins by Ubiquitin and 
Ubiquitin-Like Proteins. Annu Rev Cell Dev Biol. 
6. Hietakangas, V., Anckar, J., Blomster, H.A., 
Fujimoto, M., Palvimo, J.J., Nakai, A. & Sistonen, L. 
(2006) PDSM, a motif for phosphorylation-
dependent SUMO modification. Proc Natl Acad Sci 
U S A 103, 45-50. 
7. Yang, S.H., Galanis, A., Witty, J. & Sharrocks, A.D. 
(2006) An extended consensus motif enhances the 
specificity of substrate modification by SUMO. 
EMBO J 25, 5083-93. 
8. Saitoh, H. & Hinchey, J. (2000) Functional 
heterogeneity of small ubiquitin-related protein 
modifiers SUMO-1 versus SUMO-2/3. J Biol Chem 
275, 6252-8. 
9. Song, J., Durrin, L.K., Wilkinson, T.A., Krontiris, 
T.G. & Chen, Y. (2004) Identification of a SUMO-
binding motif that recognizes SUMO-modified 
proteins. Proc Natl Acad Sci U S A 101, 14373-8. 
10. Minty, A., Dumont, X., Kaghad, M. & Caput, D. 
(2000) Covalent Modification of p73alpha by 
SUMO-1. Two-hybrid screening with p73 identifies 
novel SUMO-1-interacting proteins and a SUMO-1 
interaction motif. J Biol Chem 275, 36316-36323. 
11. Hannich, J.T., Lewis, A., Kroetz, M.B., Li, S.J., 
Heide, H., Emili, A. & Hochstrasser, M. (2005) 
Defining the SUMO-modified proteome by multiple 
approaches in Saccharomyces cerevisiae. J Biol 
Chem 280, 4102-10. 
12. Hecker, C.M., Rabiller, M., Haglund, K., Bayer, P. & 
Dikic, I. (2006) Specification of SUMO1- and 
SUMO2-interacting motifs. J Biol Chem 281, 16117-
27. 
13. Song, J., Zhang, Z., Hu, W. & Chen, Y. (2005) Small 
ubiquitin-like modifier (SUMO) recognition of a 
SUMO binding motif: a reversal of the bound 
orientation. J Biol Chem 280, 40122-9. 
14. Shen, T.H., Lin, H.K., Scaglioni, P.P., Yung, T.M. & 
Pandolfi, P.P. (2006) The mechanisms of PML-
nuclear body formation. Mol Cell 24, 331-9. 
Non-covalent binding of SUMO to c-Myb 
T Sæther et al 
 
12 
15. Lin, D.Y. et al. (2006) Role of SUMO-interacting 
motif in Daxx SUMO modification, subnuclear 
localization, and repression of sumoylated 
transcription factors. Mol Cell 24, 341-54. 
16. Mohan, R.D., Rao, A., Gagliardi, J. & Tini, M. 
(2007) SUMO-1-dependent allosteric regulation of 
thymine DNA glycosylase alters subnuclear 
localization and CBP/p300 recruitment. Mol Cell 
Biol 27, 229-43. 
17. Dahle, O., Bakke, O. & Gabrielsen, O.S. (2004) c-
Myb associates with PML in nuclear bodies in 
hematopoietic cells. Exp Cell Res 297, 118-26. 
18. Ramsay, R.G. (2005) c-Myb a stem-progenitor cell 
regulator in multiple tissue compartments. Growth 
Factors 23, 253-61. 
19. Bies, J., Markus, J. & Wolff, L. (2002) Covalent 
attachment of the SUMO-1 protein to the negative 
regulatory domain of the c-Myb transcription factor 
modifies its stability and transactivation capacity. J 
Biol Chem 277, 8999-9009. 
20. Dahle, O., Andersen, T.O., Nordgard, O., Matre, V., 
Del Sal, G. & Gabrielsen, O.S. (2003) 
Transactivation properties of c-Myb are critically 
dependent on two SUMO-1 acceptor sites that are 
conjugated in a PIASy enhanced manner. Eur J 
Biochem 270, 1338-48. 
21. Sramko, M., Markus, J., Kabat, J., Wolff, L. & Bies, 
J. (2006) Stress-induced inactivation of the c-Myb 
transcription factor through conjugation of SUMO-
2/3 proteins. J Biol Chem 281, 40065-75. 
22. Molvaersmyr, A.K., Saether, T., Lorenzo, P., 
Kvaloey, H., Matre, V. & Gabrielsen, O.S. (2007) 
SUMO-conjugation of the transcription factor c-Myb 
controls cooperative behaviour and induces an 
activator-to-repressor switch in the negative 
regulatory domain. Manuscript. 
23. Saether, T., Berge, T., Ledsaak, M., Matre, V., Alm-
Kristiansen, A.H., Dahle, O., Aubry, F. & 
Gabrielsen, O.S. (2007) The chromatin remodeling 
factor Mi-2alpha acts as a novel co-activator for 
human c-Myb. J Biol Chem 282, 13994-4005. 
24. Andersson, K.B., Kowenz-Leutz, E., Brendeford, 
E.M., Tygsett, A.H., Leutz, A. & Gabrielsen, O.S. 
(2003) Phosphorylation-dependent Down-regulation 
of c-Myb DNA Binding Is Abrogated by a Point 
Mutation in the v-myb Oncogene. J Biol Chem 278, 
3816-24. 
25. Matre, V., Hovring, P.I., Fjeldheim, A.K., Helgeland, 
L., Orvain, C., Andersson, K.B., Gautvik, K.M. & 
Gabrielsen, O.S. (2003) The human neuroendocrine 
thyrotropin-releasing hormone receptor promoter is 
activated by the haematopoietic transcription factor 
c-Myb. Biochem J 372, 851-9. 
26. Eckner, R., Ewen, M.E., Newsome, D., Gerdes, M., 
DeCaprio, J.A., Lawrence, J.B. & Livingston, D.M. 
(1994) Molecular cloning and functional analysis of 
the adenovirus E1A-associated 300-kD protein 
(p300) reveals a protein with properties of a 
transcriptional adaptor. Genes Dev 8, 869-84. 
27. Fogal, V., Gostissa, M., Sandy, P., Zacchi, P., 
Sternsdorf, T., Jensen, K., Pandolfi, P.P., Will, H., 
Schneider, C. & Del Sal, G. (2000) Regulation of 
p53 activity in nuclear bodies by a specific PML 
isoform. EMBO J 19, 6185-95. 
28. Kadoya, T., Yamamoto, H., Suzuki, T., Yukita, A., 
Fukui, A., Michiue, T., Asahara, T., Tanaka, K., 
Asashima, M. & Kikuchi, A. (2002) Desumoylation 
activity of Axam, a novel Axin-binding protein, is 
involved in downregulation of beta-catenin. Mol Cell 
Biol 22, 3803-19. 
29. Tatham, M.H., Jaffray, E., Vaughan, O.A., Desterro, 
J.M., Botting, C.H., Naismith, J.H. & Hay, R.T. 
(2001) Polymeric chains of SUMO-2 and SUMO-3 
are conjugated to protein substrates by SAE1/SAE2 
and Ubc9. J Biol Chem 276, 35368-74. 
30. Sachdev, S., Bruhn, L., Sieber, H., Pichler, A., 
Melchior, F. & Grosschedl, R. (2001) PIASy, a 
nuclear matrix-associated SUMO E3 ligase, 
represses LEF1 activity by sequestration into nuclear 
bodies. Genes Dev 15, 3088-103. 
31. Gabrielsen, O.S., Sentenac, A. & Fromageot, P. 
(1991) Specific DNA binding by c-Myb: evidence 
for a double helix-turn-helix- related motif. Science 
253, 1140-3. 
32. Dash, A.B., Orrico, F.C. & Ness, S.A. (1996) The 
EVES motif mediates both intermolecular and 
intramolecular regulation of c-Myb. Genes Dev 10, 
1858-69. 
33. Vorbrueggen, G., Kalkbrenner, F., Guehmann, S. & 
Moelling, K. (1994) The carboxyterminus of human 
c-myb protein stimulates activated transcription in 
trans. Nucleic Acids Res 22, 2466-75. 
34. Dubendorff, J.W., Whittaker, L.J., Eltman, J.T. & 
Lipsick, J.S. (1992) Carboxy-terminal elements of c-
Myb negatively regulate transcriptional activation in 
cis and in trans. Genes Dev 6, 2524-35. 
35. Alm-Kristiansen, A.H., Saether, T., Matre, V., 
Gilfillan, S., Dahle, O. & Gabrielsen, O.S. (2007) 
FLASH acts as a co-activator of the transcription 
factor c-Myb and localizes to active RNA 
polymerase II foci. Submitted to Oncogene. 
36. Janderova-Rossmeislova, L., Novakova, Z., 
Vlasakova, J., Philimonenko, V., Hozak, P. & 
Hodny, Z. (2007) PML protein association with 
specific nucleolar structures differs in normal, tumor 
and senescent human cells. J Struct Biol 159, 56-70. 
37. Ogata, K., Morikawa, S., Nakamura, H., Hojo, H., 
Yoshimura, S., Zhang, R., Aimoto, S., Ametani, Y., 
Hirata, Z. & Sarai, A. (1995) Comparison of the free 
and DNA-complexed forms of the DNA-binding 
domain from c-Myb. Nat Struct Biol 2, 309-20. 
38. Carr, M.D., Wollborn, U., McIntosh, P.B., Frenkiel, 
T.A., McCormick, J.E., Bauer, C.J., Klempnauer, 
K.H. & Feeney, J. (1996) Structure of the B-Myb 
DNA-binding domain in solution and evidence for 
multiple conformations in the region of repeat-2 
involved in DNA binding: implications for sequence-
specific DNA binding by Myb proteins. Eur J 
Biochem 235, 721-35. 
39. Jamin, N., Gabrielsen, O.S., Gilles, N., Lirsac, P.N. 
& Toma, F. (1993) Secondary structure of the DNA-
binding domain of the c-Myb oncoprotein in 
solution. A multidimensional double and triple 
heteronuclear NMR study. Eur J Biochem 216, 147-
54. 
40. Myrset, A.H., Bostad, A., Jamin, N., Lirsac, P.N., 
Toma, F. & Gabrielsen, O.S. (1993) DNA and redox 
state induced conformational changes in the DNA-
binding domain of the Myb oncoprotein. EMBO J 
12, 4625-33. 
41. Geiss-Friedlander, R. & Melchior, F. (2007) 
Concepts in sumoylation: a decade on. Nat Rev Mol 
Cell Biol 8, 947-56. 
Non-covalent binding of SUMO to c-Myb 
T Sæther et al 
13 
42. Lane, T., Ibanez, C., Garcia, A., Graf, T. & Lipsick, 
J. (1990) Transformation by v-myb correlates with 
trans-activation of gene expression. Mol Cell Biol 10, 
2591-8. 
43. Chen, R.H. & Lipsick, J.S. (1993) Differential 
transcriptional activation by v-myb and c-myb in 
animal cells and Saccharomyces cerevisiae. Mol Cell 
Biol 13, 4423-31. 
44. Reverter, D. & Lima, C.D. (2005) Insights into E3 
ligase activity revealed by a SUMO-RanGAP1-
Ubc9-Nup358 complex. Nature 435, 687-92. 
45. Tatham, M.H., Kim, S., Jaffray, E., Song, J., Chen, 
Y. & Hay, R.T. (2005) Unique binding interactions 
among Ubc9, SUMO and RanBP2 reveal a 
mechanism for SUMO paralog selection. Nat Struct 
Mol Biol 12, 67-74. 
46. Karafiat, V., Dvorakova, M., Pajer, P., Kralova, J., 
Horejsi, Z., Cermak, V., Bartunek, P., Zenke, M. & 
Dvorak, M. (2001) The leucine zipper region of Myb 
oncoprotein regulates the commitment of 
hematopoietic progenitors. Blood 98, 3668-76. 
47. Dai, P., Akimaru, H., Tanaka, Y., Hou, D.X., 
Yasukawa, T., Kanei-Ishii, C., Takahashi, T. & Ishii, 
S. (1996) CBP as a transcriptional coactivator of c-
Myb. Genes Dev 10, 528-40. 
48. Oelgeschlager, M., Janknecht, R., Krieg, J., Schreek, 
S. & Luscher, B. (1996) Interaction of the co-
activator CBP with Myb proteins: effects on Myb-
specific transactivation and on the cooperativity with 
NF-M. Embo J 15, 2771-80. 
49. Zor, T., De Guzman, R.N., Dyson, H.J. & Wright, 
P.E. (2004) Solution structure of the KIX domain of 
CBP bound to the transactivation domain of c-Myb. 
J Mol Biol 337, 521-34. 
50. Girdwood, D., Bumpass, D., Vaughan, O.A., Thain, 
A., Anderson, L.A., Snowden, A.W., Garcia-Wilson, 
E., Perkins, N.D. & Hay, R.T. (2003) P300 
transcriptional repression is mediated by SUMO 
modification. Mol Cell 11, 1043-54. 
51. Zhong, S., Muller, S., Ronchetti, S., Freemont, P.S., 
Dejean, A. & Pandolfi, P.P. (2000) Role of SUMO-
1-modified PML in nuclear body formation. Blood 
95, 2748-52. 
52. Best, J.L., Ganiatsas, S., Agarwal, S., Changou, A., 
Salomoni, P., Shirihai, O., Meluh, P.B., Pandolfi, 
P.P. & Zon, L.I. (2002) SUMO-1 protease-1 
regulates gene transcription through PML. Mol Cell 
10, 843-55. 
53. Salomoni, P. & Pandolfi, P.P. (2002) The role of 
PML in tumor suppression. Cell 108, 165-70. 
54. Lin, D.Y., Lai, M.Z., Ann, D.K. & Shih, H.M. 
(2003) Promyelocytic leukemia protein (PML) 
functions as a glucocorticoid receptor co-activator by 
sequestering Daxx to the PML oncogenic domains 
(PODs) to enhance its transactivation potential. J 




Non-covalent binding of SUMO to c-Myb 





Figure 1 c-Myb contains two putative SUMO-binding motifs which are both mutated in AMV 
v-Myb. A, Schematic presentation of human c-Myb with its two potential SUMO-binding motifs, 
one residing in the R2 repeat of DBD and the other in the N-terminal part of TAD. DBD: DNA-
binding domain, TAD: transactivation domain, NRD: negative regulatory domain, R1, -2, -3: Myb 
repeat 1, 2 and 3, TP/CR: Thr- and Pro-rich conserved region, FAETL and EVES: motifs found 
within the assigned regions, LZ: putative leucine zipper. B, Multiple sequence alignment of the areas 
harbouring the SUMO-binding motifs (boxed), using different mammalian c-Mybs. The acidic 
streches close to the SBMs are indicated by a solid line. AMV v-Myb is included for comparison. 
The consensus SUMO-binding motifs suggested by Song et al. 2005 and Hecker et al. 2006 are 
included for clarity. C, The SBM mutants used in this work. No change in amino acid residue is 
marked with “-“.  
 
Figure 2 Mutating the SBM in c-Myb TAD derepress c-Myb and makes it super active. 
 A, CV-1 cells were transfected with a Myb-responsive 3×MRE(GG)-MYC reporter plasmid (0.2 g) 
and plasmids encoding full-length c-Myb wt, 2KR, AAEA, L106H, ANAA or INII in increasing 
amounts (0.2-0.4 g).  The results are presented as relative luciferase units (RLU). The results 
represent the mean RLU±SEM of at least three independent assays performed in triplicates. B, CV-1 
cells were transfected with plasmids encoding c-Myb-HA wt, 2KR, AAEA, L106H, ANAA or INII 
(0.2 g). Cell lysates were subjected to SDS-PAGE and immunoblot analysis was performed using 
an anti-HA antibody. 
 
Figure 3 Human c-Myb binds SUMO. In vitro binding assays were performed in lysates from 
COS-1 cells transfected with A, pCIneoB-3FLAG-hcM[1-409] or B, pCIneoB-3FLAG-hcM[1-409] 
and pCIneoB-3FLAG-hcM. The lysate was incubated with comparable amounts of GST-SUMO-1 
and -SUMO-2 fusion proteins. The bound proteins were analyzed by SDS-PAGE and immunoblot 
analysis using an anti-FLAG antibody. 5 % of the input (total cell extract) used for the pull-down 
was loaded as reference. The amount of GST and GST fusion proteins was evaluated with Ponceau 
S red staining of the membrane after immunoblotting. 
 
Figure 4 Only the putative SBM in c-Myb TAD (SBM2) is functional and mediates SUMO-
binding. In vitro binding assays were performed in lysates from COS-1 cells transfected with A, 
pCIneoB-3FLAG-hcM[1-409] wt and the SBM1 mutants AAEA and L106H and B, pCIneoB-
3FLAG-hcM[1-409] wt and the SBM2 mutants ANAA and INII. The lysates were incubated with 
comparable amounts of GST-SUMO-1 and SUMO-2 fusion proteins. The bound proteins were 
analyzed by SDS-PAGE and immunoblot analysis was performed using an anti-FLAG antibody. 5 
% of the input (total cell extract) used for the pull-down was loaded as reference. The amount of 
GST and GST fusion proteins was evaluated with Ponceau S red staining of the membrane after 
immunoblotting. C, In vitro binding assays were performed with in vitro translated, [35S]-Methionine 
labeled human c-Myb R2-TAD (amino acid residues 89-337) wt and the SBM2 mutants ANAA and 
INII. The proteins were incubated with comparable amounts of GST-SUMO-1 and SUMO-2 fusion 
proteins. The bound proteins were analyzed by SDS-PAGE and the amount of GST and GST fusion 
proteins was evaluated with Comassie Brilliant Blue staining of the gel before the [35S]-signals were 
read with a Typhon phoshoimager (GE Healthcare). The signals from the input controls (loaded as 
reference) were used to normalize the data acquired with ImageQuant TL v2003.02 (GE Healthcare). 
The results represent the mean % retention of the total in vitro translated protein ± SD of two 
independent assays. 
 
Figure 5 AMV v-Myb still binds SUMO. In vitro binding assays were performed in lysates from 
COS-1 cells transfected with pCIneoB-3FLAG-hcM[1-409] wt and pCIneoB-3FLAG-AMV. The 
lysates were incubated with comparable amounts of GST-SUMO-1 and SUMO-2 fusion proteins. 
The bound proteins were analyzed by SDS-PAGE and immunoblot analysis using an anti-FLAG 
antibody. 5 % of the input (total cell extract) used for the pull-down was loaded as reference. The 
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amount of GST and GST fusion proteins was evaluated with Ponceau S red staining of the 
membrane after immunoblotting. 
 
Figure 6 Mutating the SBM does not affect the sumoylation of c-Myb. A, CV-1 cells were 
transfected with plasmids encoding c-Myb-HA wt, ANAA, INII or 2KR (1.0 g) in combination 
with a small input of PIASy expression plasmid (0.25 g). Cells were scraped in cold PBS and lysed 
directly by sonication in SDS loading-buffer. The lysates were subjected to SDS-PAGE and 
immunoblot analysis using an anti-HA antibody. B, CV-1 cells were transfected with the c-Myb 
responsive 1×MRE(GG)-MYC or 4×MRE(GG)-MYC reporter plasmids (0.2 g) and plasmids 
encoding full-length c-Myb wt, ANAA, INII or 2KR (0.2 g) The results are presented as Synergy 
Factor (SF) calculated from the relative luciferase units (SF=RLU4×MRE/(4×RLU1×MRE) [22]. The 
results represent the mean SF±SEM of at least three independent assays performed in triplicates. 
 
Figure 7 The SBM is not controlling c-Myb activity through binding in cis to SUMO-
conjugated NRD. A, CV-1 cells were transfected with a Myb-responsive 3×MRE(GG)-MYC 
reporter plasmid (0.2 g) and plasmids encoding full-length c-Myb wt, 2KR, ANAA or ANAA 2KR 
(0.4 g). B, CV-1 cells were transfected with a Myb-responsive 3×MRE(GG)-MYC reporter plasmid 
(0.2 g) and plasmids encoding  c-Myb[1-409] wt, AAEA, L106H, ANAA or INII in increasing 
amounts (0.2-0.4 g). C, CV-1 cells were transfected with 2.5 ng (grey bars) or 5.0 ng (black bars) 
of a plasmid expressing Gal4p-DBD fused to c-Myb TAD wt or ANAA (amino acid residues 259-
337) in the absence or presence (0.1 g) of a p300 expression plasmid. The reporter output from the 
SNRPN-driven Gal4p-responsive reporter plasmid (0.2 g) was normalized to the effect of Gal4p-
DBD, which was set to 100. The results are presented as relative luciferase units (RLU). The results 
represent the mean RLU±SEM of at least three independent assays performed in triplicates. 
 
Figure 8 c-Myb is binding SUMO in trans in a SBM-dependent fashion.  CV-1 cells were 
transfected with a Myb-responsive 3×MRE(GG)-MYC reporter plasmid (0.2 g) and plasmids 
encoding full-length c-Myb wild-type, ANAA, 2KR or ANAA 2KR (0.2 g), in combination with 
increasing amounts (0-0.4 g) of A, SUMO-1-1G or B, SUMO-2-1G (conjugation-deficient 
mutants). Increasing amounts of SUMO-1-1G or SUMO-2-1G (0–0.4 μg) were also transfected 
singularly together with the reporter. The results are presented as fold-induction of relative luciferase 
units (RLU), and the activities of the different c-Myb proteins in the absence of SUMO is set to 1.0. 
The results represent the mean RLU±SEM of at least three independent assays performed in 
triplicates. 
 
Figure 9 Co-activation of c-Myb by PML is lost when the SUMO-binding and conjugation 
properties of c-Myb is abrogated. CV-1 cells were transfected with a Myb-responsive 
3×MRE(GG)-MYC reporter plasmid (0.2 g) and plasmids encoding full-length c-Myb wt, 2KR, 
ANAA or ANAA 2KR (0.2 g), alone or together with PML IVa (0.2 g). The results are presented 
as fold-induction of relative luciferase units (RLU), and the activities of the different c-Myb proteins 
in the absence of PML is set to 1.0. The results represent the mean RLU±SEM of at least three 
independent assays performed in triplicates. 
 
Figure 10 PML and c-Myb co-localizes in a SUMO-contact independent manner. A, CV-1 cells 
were transfected with plasmids encoding HA-tagged c-Myb wild-type, c-Myb ANAA, c-Myb 2KR 
or c-Myb ANAA 2KR (0.3 g) as indicated in the figure and analyzed by indirect 
immunofluorescence and confocal microscopy. The c-Myb proteins were detected with rabbit anti-
HA antibody and Alexa Fluor 488 goat anti-rabbit IgG(H+L). B-E, CV-1 cells were transfected with 
plasmids encoding PML IVa (0.15 g) and HA-tagged c-Myb wild type (B), c-Myb ANAA (C), c-
Myb 2KR (D) or c-Myb ANAA 2KR (E) (0.3 g) and analyzed as above. The c-Myb proteins were 
detected as in A (green signal) and PML was detected with mouse anti-PML antibody and Alexa 
Fluor 633 goat anti-mouse IgG1 (red signal). Co-localization is visualized as yellow colour when 
merging the images (right panel). DNA was labelled by Hoechst 33258 (blue signal). 
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